Evaluation of Three Risk Factors for Sporadic Alzheimer's Disease in Human and in Immune-Challenged Wild Type Mice by Notter, Tina
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2015
Evaluation of Three Risk Factors for Sporadic Alzheimer’s Disease in
Human and in Immune-Challenged Wild Type Mice
Notter, Tina
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-113404
Dissertation
Published Version
Originally published at:
Notter, Tina. Evaluation of Three Risk Factors for Sporadic Alzheimer’s Disease in Human and in
Immune-Challenged Wild Type Mice. 2015, University of Zurich, Faculty of Science.
 Evaluation of Three Risk Factors for Sporadic 
Alzheimer’s Disease in Human and in Immune-
Challenged Wild Type Mice 
 
 
Dissertation 
 
zur 
Erlangung der naturwissenschaftlichen Doktorwürde 
(Dr. sc. nat.) 
vorgelegt der 
Mathematisch-naturwissenschaftlichen Fakultät 
der 
Universität Zürich 
 
 
von 
Tina Fabia Notter 
 
von 
Baden, AG 
 
Promotionskomitee: 
Prof. Dr. Jean-Marc Fritschy (Vorsitz) 
PD Dr. Irene Knuesel 
Prof. Dr. Stephan Neuhauss 
Prof. Dr. Roland Martin 
 
 
Zürich, 2015 
 	
	
	
	
	
	
	
I 
ACKNOWLEDGEMENTS 
During my dissertation I had the opportunity to be guided by two main supervisors. Both gave 
me tremendous support to successfully accomplishing my PhD thesis. 
 
I hereby would like to sincerely thank Prof. Dr. Jean-Marc Fritschy. He allowed me to perform 
my PhD thesis in his lab and also made it possible for me to continue the project after Irene 
Knuesel has left the Institute. Jean-Marc, you adopted me without hesitation and supported me 
with your excellent knowledge and expertise. I would have not been able to wrap up my project 
and write the thesis in the time I managed to do so. I would like to thank you for your 
discussions related to the project as well as carrier planning and life. I am very grateful for your 
tremendous support in the application processes that had to be managed during the already 
intense time of writing. It was a true pleasure to work with you and in your well-equipped and 
organized lab. Thank you. 
 
I especially thank PD. Dr. Irene Knuesel for giving me the opportunity to start my PhD in the 
fantastic “Reelin group”. Working with you and being a member of your group for almost three 
years was a great experience. Thank you for introducing me into the fascinating as well as 
complex world of Alzheimer’s disease. The excellent atmosphere in our group motivated us all 
in doing the best research we could. 
 
I would further like to express my gratitude to the members of my thesis committee, Prof. Dr. 
Stephan Neuhauss and Prof. Dr. Roland Martin for their guidance, scientific inputs and 
discussions about my project. 
 
At this point I would like to thank our technicians Tatjana Haenggi (for her patience and 
endurance in the stereological counting), Christina Koester (for her help with the behavioral 
experiments), Cornelia Schwerdel and Giovanna Bosshard providing me technical support and 
knowledge. Special thanks go to Romy Gisler for all your efforts in organizing the lab. I owe my 
profound gratitude to all the animal care takers, particularly Carmen Brazerol and Dennis 
Boadum who did an excellent work in taking care of my aging mice cohorts. Big thanks go to 
Nicole Wildner for your incredible organization skills, all your help with the microscopes, and 
your good mood and jokes. 
Very special and warm thanks go to Karen Haenraets and Sandra Pfister. Karen and Sandra, you 
have become close friends and your support both work and private related are of tremendous 
II 
value to me. Sandra, it was the greatest pleasure to work with you in the Reelin group. Thank 
you so much for everything (including the formatting of this thesis)! Karen, I am very grateful to 
have been able to share the same office for almost 3 years. You were always there and took your 
time independent on your own stress level. Thank you so much for all the proof reading you did 
during the three years including big parts of this thesis. Special thanks go to Dimi Krstic, who 
became our mentor once Irene has left the Institute. Thank you for introducing me to the 
biochemical analyses. Especially thank you for all the great discussions and your skill to always 
find the appropriate words in any given situation. You are a master of motivation. I hereby would 
like to thank my co-PhDs of our current group Tilo Gschwind and Mariana Zaichuk. It was 
fantastic working with you and I am very grateful to having met you and spending the last two 
years working with you. I would like to thank Mimi I could not have imagined a better master 
student. Thank you for working one year with me. In addition I would like to thank both Dr. 
Claire de Groot and PD Dr. Dietmar Benke for their help in biochemical analyses. 
 
I would like to thank my collaborators. I owe my sincere gratitude to Charlotte Burger from the 
Institute of Anatomy UZH for introducing me to paraffin sectioning of human brain blocks and 
providing me with her excellent hematoxylin according to Ehrlich protocol and solution. I would 
like to thank Lutz Slomianka from the Institute of Anatomy UZH, who introduced me to and 
supported me during, stereological analyses of human brain sections giving me full access to 
their systems. Especially, I would like to thank him for taking his time in answering all my 
questions. Special thanks go to PD Dr. Stefanie Kraemer from the Animal Imaging Center of 
ETH Hoenggerberg for giving me the opportunity to perform the FDG-PET imaging 
measurements in her facility. I would like to sincerely thank PD Dr. Dr. Matthias Wyss who 
introduced me to FDG-PET imaging in mice. Matthias, it was a great pleasure working with you. 
Your skill to introduce me into this novel field of research was remarkable. The two intensive 
weeks and following analyses were a fantastic experience. Not only were they very inspiring on 
a scientific level but very amusing. I had a great time! In particular, thank you for your patience 
in the analysis and your time. I would like to express my gratitude to Claudia Keller, the 
technician from the animal imaging center. Your expertise and organization skills of PET 
imaging are incredible. It was a great pleasure working with both of you. We were a great team! 
In addition I would like to thank Philipp Maechler who taught me how to place a catheter into 
tail vein of mice. 
 
III 
I sincerely thank Prof. Dr. Urs Meyer from the Institute for Veterinary Pharmacology and 
Toxicology UZH for his unlimited support during the final phase of my PhD. Urs, your expertise 
and great help in the prenatal immune challenge model were invaluable. Thank you for your 
generosity and support. In particular thank you for answering all my questions and introducing 
me into the field of prenatal developmental models from a different point of view. I hereby owe 
my gratitude to Dr. Stéphanie Vuillérmot, who performed the cytokine measurements in the third 
study. Very special thanks go to Dr. Sandra Giovanoli. Without hesitation you took your time 
and introduced me to, helped me performing and analyzing the Y-maze experiments. It was a 
fantastic experience working with all of you from the Schwerzenbach Lab. You rock! 
 
I would like to thank my past and present colleagues from the “Fritschy group” and also the 
members of the “Zeilhofer group” and “Weber group” for the unforgettable and inspiring time I 
spent with you inside and outside the lab. Special thanks go to Louis Scheurer. It was always a 
pleasure meeting you in the coffee room or corridors. Again thank you all! I would have never 
been able to finish my dissertation without having such wonderful and helpful people around me. 
 
Big time thanks go to my present (Karen, Rebecca, Sabine, Monika and Sereina) and former 
(Sandra, Dimi, Mimi, Fabia, Patrick) office mates for the warm, supportive and joyful 
atmosphere. I would also like to thank all of you who came and drank coffee here, especially 
Caro and Laeti. Thanks to all “Jogging ladies” for the enjoyable discussions during running. 
 
I would hereby like to thank Rebecca Das Gupta and Carolin von Schoultz for proofreading the 
abstract and the “Zusammenfassung”. I thank Francine Deprez for her help in formatting this 
thesis. In addition I thank André Bodmer from Bodmer & Rahn, Zurich. Thank you for your 
financial support during the start of my PhD. Your donation allowed us to buy the highly 
valuable human tissue for the first study as well as additional essential lab equipment for 
biochemical analysis. 
 
Finally, I am deeply thankful to my parents Christian and Kathrin, my elder sister Alexandra and 
my younger brother Niklaus Notter and all friends (in particular Lisa Basler, Stefania Koller, and 
Stefanie Fischer) and family (special thanks go to my aunt May Boller for proof reading major 
parts of this thesis and to my grandmother Ruth Boller for all her motivation and great 
conversation). Your help and support in all different stages of my life is of indescribable value. I 
IV 
would have never managed to achieve this without you. Last but not least I thank Max Lutz one 
of my dearest and best friends. You are always here when I need you. Thank you!  
 
V 
TABLE OF CONTENTS 
 
ZUSAMMENFASSUNG .......................................................................................................................... VII 
ABSTRACT ............................................................................................................................................. XI 
I.  GENERAL INTRODUCTION ............................................................................................ 1 
Dementia, Alzheimer’s Disease and the Worldwide Burden ............................................................................... 1 
Alzheimer’s Disease ............................................................................................................................................ 1 
Two Histopathological Hallmarks ....................................................................................................................... 2 
Acetylcholine Hypothesis .................................................................................................................................... 4 
APP, PSEN1 and PSEN2 – “Amyloid Cascade Hypothesis” ............................................................................... 5 
ApoE4 - the Strongest Genetic Risk Factor in Sporadic AD ............................................................................... 5 
The “Inflammation Hypothesis” and Axonopathy in Sporadic AD ..................................................................... 7 
Reelin ................................................................................................................................................................... 9 
Prenatal Exposure to Inflammatory Insults and Its Long-Term Effect on Basal Brain Functions ..................... 12 
“Double Hit” Model – Wild Type Mouse Model for Sporadic AD ................................................................... 15 
The Noradrenergic System in AD...................................................................................................................... 17 
Impaired Glucose Metabolism, Bioenergetic Insufficiency ............................................................................... 20 
II.  AIM OF THE THESIS ....................................................................................................... 23 
III.  RESULTS ............................................................................................................................. 25 
STUDY I: REELIN IMMUNOREACTIVITY IN NEURITIC VARICOSITIES IN THE HUMAN HIPPOCAMPAL 
FORMATION OF NON-DEMENTED SUBJECTS AND ALZHEIMER’S DISEASE PATIENTS ....................... 25 
Abstract .............................................................................................................................................................. 27 
Introduction ....................................................................................................................................................... 29 
Materials and Methods....................................................................................................................................... 31 
Results ............................................................................................................................................................... 37 
Discussion .......................................................................................................................................................... 45 
Conclusion ......................................................................................................................................................... 49 
Additional Files ................................................................................................................................................. 51 
Acknowledgements ............................................................................................................................................ 55 
STUDY II:  EFFECTS OF ACUTE AND CHRONIC NORADRENERGIC AXON DEPLETION IN A WILD 
TYPE MOUSE MODEL FOR SPORADIC ALZHEIMER’S DISEASE ............................................................ 57 
Abstract .............................................................................................................................................................. 59 
Introduction ....................................................................................................................................................... 61 
Materials and Methods....................................................................................................................................... 63 
Results ............................................................................................................................................................... 73 
VI 
Discussion .......................................................................................................................................................... 93 
Supplementary Results ..................................................................................................................................... 101 
Acknowledgements .......................................................................................................................................... 107 
STUDY III:  ACUTE PERIPHERAL IMMUNE RESPONSE IN PRO-INFLAMMATORY CYTOKINE 
LEVELS UPON SYSTEMIC POLYI:C INJECTIONS DO NOT DIFFER BETWEEN C57BL/6JOLA AND 
C57BL/6JN MICE ................................................................................................................................ 109 
Abstract ............................................................................................................................................................ 110 
Introduction ...................................................................................................................................................... 111 
Results and Discussion ..................................................................................................................................... 113 
Materials and Methods ..................................................................................................................................... 117 
Acknowledgements .......................................................................................................................................... 118 
IV.  GENERAL DISCUSSION ............................................................................................... 119 
Corpora Amylacea - Ageing Associated Disturbances of Basic Cell Functioning? ......................................... 120 
PolyI:C Effect on the Regeneration Capacity of Noradrenergic Axons ........................................................... 123 
Genetic Background and -Synuclein – Reason for the Lack of PolyI:C-Induced Phenotype? ...................... 126 
REFERENCES ....................................................................................................................................... 129 
ABBREVIATIONS .................................................................................................................................. 147 
CURRICULUM VITAE .......................................................................................................................... 151 
PUBLICATIONS .................................................................................................................................... 153 
APPENDIX ............................................................................................................................................ 155 
 
 
 
 
 
 
VII 
ZUSAMMENFASSUNG 
Die sporadische Alzheimer Krankheit (AD, Englisch: Alzheimer’s disease) ist die häufigste 
altersabhängige Demenz. Sie ist durch eine schnell fortschreitende Abnahme kognitiver 
Fähigkeiten und durch Neurodegeneration gekennzeichnet. Histopathologisch wird sie durch das 
Vorhandensein von amyloiden Plaques und neurofibrillären Bündeln, wie auch Entzündungen im 
Gehirngewebe definiert. Bei Krankheitsbeginn werden typischerweise sowohl Veränderungen im 
Glukosehaushalt und der Energiezufuhr des Gehirns, als auch Störungen in zentralen cholinergen 
und monoaminergen Neuronen festgestellt. Im Gegensatz zur sehr seltenen, familiären Form – 
die durch eine einzelne, dominant vererbbare Mutation ausgelöst wird – stellt die sporadische 
Form eine multifaktorielle Erkrankung dar, bei der mehrere synergistisch wirkende 
Mechanismen zum Ausbruch der Krankheit führen können. In den letzten Jahrzehnten wurden 
eine grosse Anzahl genetischer wie auch umweltbedingter Faktoren identifiziert, die das Risiko, 
an AD zu erkranken, erhöhen und/oder das Fortschreiten der Krankheit beschleunigen können. 
Der Fokus dieser Arbeit lag auf drei spezifischen Systemen, die mit einem solchen erhöhten 
Risiko in Verbindung gebracht werden konnten. Alle drei zeigen altersbedingte Veränderungen, 
die sich in frühen Stadien von AD stark verschlimmern. Diese beinhalten die Signalwege von 
Reelin, chronische, zentrale und periphere Entzündungsreaktionen und das zentrale, 
noradrenerge (NA) System. In jedem dieser drei Systeme wurden genetische Polymorphismen 
identifiziert, welche mit einem erhöhten Risiko für AD assoziiert wurden. Diese 
Polymorphismen befinden sich insbesondere in Genen, welche Bestandteile des angeborenen 
Immunsystems, Reelin, DBH (Dopamin--Hydroxylase – das essenzielle Enzym der 
Noradrenalin (NA) Synthese) und den -adrenergen Rezeptoren kodieren. In Übereinstimmung 
mit diesen genetischen Faktoren haben Studien mit transgenen Mausmodellen für AD gezeigt, 
dass mittels systemischer Immunstimulation, Beeinträchtigung von NA Transmission, und 
Reduktion von Reelin Expression der Phänotyp dieser AD-transgenen Mäuse stark 
verschlimmert werden kann. 
Darüber hinaus hat unser Labor kürzlich gezeigt, dass Wildtypmäuse bei zweifacher, prä- und 
postnataler Behandlung (“double hit” Mausmodell) mit dem viralen Imitator polyriboinosinic-
polyribocytidilic acid (PolyI:C), welcher eine starke Entzündungsreaktion verursacht, im Alter 
einen AD-ähnlichen Phänotyp entwickeln. Diese Ergebnisse unterstützen das Konzept, dass 
chronische Entzündungen eine Schlüsselrolle in der AD Pathogenese spielen. Eine einmalige 
pränatale Immunstimulation führte schon zu anhaltender, peripherer und zentraler Erhöhung von 
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proinflammatorischen Zytokinen, erhöhter Produktion des Amyloidvorläuferproteins (APP, 
Englisch: amyloid precursor protein, dessen Spaltprodukte die Hauptbestandteile der Amyloid-
Plaques sind) und erhöhter Phosphorylierung von Tau (dem Hauptbestandteil von 
neurofibrillären Bündeln). Zudem führte diese, zu Störungen des Kurzzeitgedächtnisses in den 
gealterten Nachkommen. Die zweite Immunstimulation während des Erwachsenenalters 
verschlimmerte den histopathologischen Phänotyp noch weiter. Neben der Aktivierung von 
Mikroglia und Astrozyten konnte eine weitere Zunahme von APP festgestellt werden, begleitet 
von der Entstehung von APP-positiven Plaques und einer pathologischen Ansammlung von 
phosphoryliertem Tau-Protein in neuronalen Zellkörpern und Dendriten. 
In der ersten Studie haben wir die Charakterisierung der altersbedingten Reelin positiven 
Ablagerungen, welche im Hippocampus von Nagern sowie nicht-humanen Primaten gefunden 
wurden, auf menschliches hippocampales Gewebe erweitert. Insbesondere interessierte uns die 
Frage, ob ähnliche Strukturen im menschlichen Gewebe vorhanden sind und ob diese in AD-
Patienten vermehrt vorkommen. Unsere Resultate zeigten, dass die Reelin Immunoreaktivität, 
entgegen der Beobachtung in Tieren, in Corpora Amylacea (CAm) zu finden ist. CAm sind 
altersbedingte Ablagerungen, die in bestimmten Hirnregionen, einschliesslich faserreicher 
Gebiete, vorkommen. Sie bestehen hauptsächlich aus Glukosepolymeren und Proteinen. Über 
ihre genaue Funktion und Entstehungsweise ist bis heute wenig bekannt. Der hohe Anteil an 
Polysacchariden deutet jedoch daraufhin, dass CAm wahrscheinlich etwas mit gestörtem 
Glukosehaushalt zu tun haben. Zudem sprechen die dendritischen und axonalen Proteine, die in 
CAm nachgewiesen wurden, und die Tatsache, dass keine Glia-Markern gefunden werden 
konnten, für eine neuronale Herkunft. Die Präsenz von A Peptiden und das erhöhte 
Vorkommen von CAm in faserreichen Hirnarealen deutet daraufhin, dass CAm durch Störungen 
der axonalen Funktion und Transport entstehen könnten – ein Mechanismus, der kürzlich für die 
Bildung von senilen Plaques und fibrillären Bündel vorgeschlagen wurde. Dies würde zudem mit 
den leicht erhöhten CAm levels in der ersten Schicht des Subikulums von AD Patienten im 
Vergleich zu nicht-dementen Kontrollen übereinstimmen. 
Die zweite Studie wurde entworfen, um die Auswirkung der Kombination von PolyI:C-
ausgelösten Änderungen mit NA Ablation zu prüfen. Unser Ziel war es, zu testen, ob gestörte 
NA Signalwege die neuropathologischen Veränderungen, die durch Entzündungsreaktionen 
ausgelöst werden, verstärken und damit eine treibende Kraft in der Pathogenese des sporadischen 
AD darstellen können. Zusätzlich wollten wir testen, ob die pränatale Immunstimulation eine 
Langzeitfolge auf die Regenerationsfähigkeit der NA Axonen hat. Dafür wurden C57Bl6/JOla 
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Wildtypmäuse pränatal und postnatal immunstimuliert und zusätzlich mit dem NA Neurotoxin 
N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) einfach oder mehrfach behandelt, um 
eine Langzeitablation von NA Axonen im Locus Coeruleus (LC) hervorzurufen. Es stellte sich 
heraus, dass eine pränatale Immunsystemaktivierung während der späten Embryonalentwicklung 
die Regenerationskapazität der NA Axone beeinträchtigt. Zudem konnten wir bestätigen, dass 
pränatale PolyI:C Behandlung einen Langzeiteffekt auf das angeborene Immunsystem hat. 
Jedoch konnte keine Korrelation zwischen diesen beiden Langzeitveränderungen im Gehirn 
gefunden werden. Dies deutet darauf hin, dass diese unabhängig voneinander entstehen. 
Überraschenderweise löste die doppelte Immunstimulation dieser Studie nicht die erwartete, 
vorherig beschriebene, starke und langanhaltende Immunantwort in gealterten Mäusen aus. 
Daher fanden wir auch in keiner der unterschiedlich behandelten Tiergruppen AD-assoziierten 
Veränderungen. Es konnten zudem keine Veränderungen in der Dichte der gemessenen, 
regenerierten NA Axone nach multiplen DSP-4 Behandlungen nachgewiesen werden. Dies weist 
darauf hin, dass die Regenerationskapazität gealterter Mäuse mit multipler DSP-4 Behandlung 
nicht durch die PolyI:C-Stimulation beeinflusst wurde. Zudem hatte die Kombination von 
PolyI:C und multiplen DSP-4 oder NaCl Behandlungen weder einen Effekt auf das 
Kurzzeitgedächtnis noch auf den Glukosehaushalt im Gehirn, den wir mittels Positron Emissions 
Tomographie (PET) untersuchten. Eine a priori Analyse, in der wir nur die NaCl-Kontrollgruppe 
mit der pränatal-PolyI:C-ausgesetzten Gruppe (gefolgt von mehreren NaCl Injektionen) 
verglichen, zeigte jedoch, dass die pränatal-immunstimulierten Tiere ein mildes aber 
signifikantes Defizit im Kurzzeitgedächtnis aufwiesen, vergleichbar mit früheren Studien. 
Um zu verstehen, woher diese Diskrepanz zwischen unseren und früheren Befunden stammt, 
haben wir zusätzlich eine dritte Studie durchgeführt. In dieser Studie testeten wir, welche Effekte 
verschiedene PolyI:C Chargen und der genetische Hintergrund zweier Mausstämme, die sich in 
der An-/Abwesenheit von -Synuclein unterscheiden, auf die akute systemische Antwort 
gegenüber einer Immunstimulation haben. Es wurden keine Unterschiede in der Antwort von 
proinflammatorischen Zytokinen gegenüber PolyI:C Injektion zwischen den verschiedenen 
Chargen oder Stämmen gefunden. Dies deutet darauf hin, dass die Mäuse in der zweiten Studie 
die zu erwartende PolyI:C-induzierte Immunantwort aufwiesen. Es gibt jedoch eine Menge 
anderer möglicher Ursachen – wie zum Beispiel eine eventuelle Desensibilisierung ausgelöst 
durch Stress –, die zu dieser Diskrepanz zwischen der jetzigen und der früheren Studie geführt 
haben könnten. 
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Da wir keine wesentlichen Veränderungen nach doppelter Immunstimulation in dieser Studie 
feststellen konnten, ermöglichen unsere Resultate keine Schlussfolgerung bezüglich der 
potenziellen Rolle des gestörten NA Systems in der Pathogenese von AD-ähnlichen 
Veränderungen in Wildtypmäusen. Dennoch konnten wir eine wichtige Interaktion zwischen 
pränataler Immunstimulation und der axonalen Regenerationskapazität von LC Neuronen in 
adulten Mäusen nachweisen. 
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ABSTRACT 
Sporadic Alzheimer’s disease (AD) is the most common ageing-associated dementia. AD is 
characterized by fast progression of cognitive decline and neurodegeneration. 
Histopathologically, it is defined by the presence of amyloid plaques and neurofibrillary tangles 
(NFTs), as well as neuroinflammation. At disease onset, alterations in brain glucose metabolism 
and energy supply as well as in the integrity of central cholinergic and monoaminergic neurons 
are evident. In contrast to the very rare familial form – caused by a single autosomal dominant 
mutation – sporadic AD represents a multifactorial disease with multiple mechanisms acting 
synergistically towards developing AD, or not. Over the past decades, a large number of genetic 
and environmental risk factors have been associated with increasing the risk to develop and/or 
promoting disease progression. 
The general aim of this study was to focus on three such systems known to be affected by normal 
ageing and exacerbated during early phases of the disease. They include Reelin signaling, 
chronic neuroinflammation, and the central noradrenergic (NA) system. All three systems 
comprise genetic polymorphisms associated with increased risk to develop AD. These 
polymorphisms are notably found in genes encoding components of the innate immune system, 
Reelin, DBH (dopamine -hydroxylase – the crucial enzyme in NA synthesis) and 2-adrenergic 
receptors. In line with these genetic findings, studies in transgenic animal models of AD have 
shown that acute systemic inflammatory insult, impaired NA transmission, and the reduction of 
Reelin expression strongly exacerbate the phenotype in AD-transgenic mice. 
Furthermore, in support for a key role of chronic neuroinflammation in the progression of 
sporadic AD, our lab has recently reported the development of AD-like pathological features in 
aged wild type mice subjected to a double (prenatal and postnatal) immune challenge, induced 
by the viral mimic polyriboinosinic-polyribocytidilic acid (PolyI:C) (“double hit” mouse model). 
The prenatal immune challenge resulted in sustained peripheral and central increase in pro-
inflammatory cytokine levels, increased levels of amyloid precursor protein (APP) (its cleavage 
products are the most abundant component of senile plaques) and increased levels of 
phosphorylated Tau (pTau) (the main component of NFTs). In addition, prenatal immune 
activation impaired short-term memory performance in old offspring. The second immune 
challenge during late adulthood exacerbated the histopathological phenotype, resulting in micro- 
and astrogliosis, further increase of APP levels and the formation of APP-positive plaques, as 
well as increased levels of paired helical filaments (PHFs) and a somatodendritic shift of pTau. 
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In the first study, we further characterized the age-dependent formation of Reelin-positive 
deposits, detected in the hippocampus of rodents and non-human primates, by focusing on Reelin 
aggregates in human hippocampal tissue. In particular, we aimed to determine whether similar 
structures are present in the human hippocampal formation and whether they are more abundant 
in AD patients compared to age-matched non-demented controls. The results revealed that, 
unlike in rodents and non-human primates, Reelin immunoreactivity was associated with corpora 
amylacea (CAm) – an ageing-associated structure located in particular brain regions, including 
fiber-rich domains, mainly consisting of polysaccharides and proteins. Their exact role and/or 
origin are not yet defined. However, the high content of polysaccharides points towards 
mechanisms that might involve impaired glucose metabolism. Further, detection of dendritic and 
axonal proteins, along with the lack of glial cell markers, strongly supports a neuronal origin. 
The presence of A peptides and the high abundance of CAm in fiber-rich regions further 
suggest that CAm evolve through impairment of axonal function and transport, as suggested for 
senile plaque and NFT formation by our lab. In accordance with this hypothesis, we detected a 
subtle but significant increase in CAm numbers in layer I of the subiculum of AD patients 
compared to non-demented controls. 
The second study was designed to explore the significance of combining PolyI:C-induced 
alterations with NA depletion. Thereby, we sought to determine whether altered NA signaling 
might be a driving force for neuropathological changes in animals subjected to pre- and/or 
postnatal immune challenges. In addition, we aimed to investigate whether a prenatal immune 
challenge could alter the regeneration capacity of NA axons. Wild type C57Bl6/JOla mice were 
subjected to a prenatal and a postnatal immune challenge, combined with injections of the NA 
neurotoxin N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) during ageing to cause 
enduring depletion of NA axons from the locus coeruleus (LC). We observed that prenatal 
immune activation during late gestation alters the regeneration capacity of NA axons in adult 
offspring. Further, we confirmed that prenatal PolyI:C exposure induces long-term alterations on 
the innate immune system, as reflected, for example, by the increased microglia located in the 
CA1 region of the hippocampus. However, there was no correlation between the severity of these 
effects on innate immune system and NA axonal regeneration, suggesting that they occur 
independently of each other.  
Surprisingly, double immune challenges combined with DSP-4 or NaCl injections in this study 
did not induce the expected strong and sustained immune response in aged mice, as previously 
described. Thus, we did not observe changes in AD-related proteins between the different 
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treatment groups. No changes in NA axon densities were detected, indicating that the 
regeneration capacity after multiple DSP-4 treatments was not affected by PolyI:C exposure 
(single or double). In addition, combined PolyI:C exposure and DSP-4/NaCl treatment had no 
effect on short-term memory performance or glucose metabolism measured by PET imaging. A 
priori analysis, however – comparing NaCl control to prenatal PolyI:C exposed followed by 
NaCl treatments – revealed a mild but significant impairment of non-spatial short-term memory 
performance, as reported previously. 
In search for possible causes for this discrepancy we performed an additional third study, where 
we assessed putative effects of different PolyI:C batches and genetic background of two mouse 
strains, differing by the presence/absence of -synuclein, on the acute response toward immune 
stimulation. We observed no difference in the pro-inflammatory cytokine responses towards 
PolyI:C between two different batches or strains, indicating that the mice used in this study 
responded as expected. Several other pitfalls, however, – including desensitization due to stress – 
could account for these discrepancies between the current and previous study. 
Large parts of our results remain inconclusive because of the absence of the required basis to 
study the role of NA signaling depletion in double immune-challenged mice. Nevertheless, we 
uncovered important interactions between the effects of a prenatal immune challenge and the 
regenerative capacity of LC neurons in the adult brain. 
 
  
General Introduction 
  1 
I. GENERAL INTRODUCTION 
Dementia, Alzheimer’s Disease and the Worldwide Burden 
Dementia is considered to be the number one disabling disease in age. In 2013, the number of 
people suffering from dementia was estimated to exceed 44 million worldwide (Alzheimer’s 
disease International, http://www.alz.co.uk/research/statistics). The most common form of 
ageing-associated dementia is late-onset or sporadic AD with an estimate of almost 36 million 
patients worldwide (2014, http://www.alzheimers.net/resources/alzheimers-statistics/). AD 
represents a chronic, progressive disease affecting cognitive functions. In initial stages, patients 
can still manage to pursue their daily routine. However, with time they become unable to manage 
normal life and depend on external help (family members or professional care givers). Advanced 
stages of the disease are characterized by complete loss of self-awareness and independency, 
requiring around-the-clock professional care.  
The incidence of AD doubles every 5 years after the age of 65. The chance to be diagnosed with 
AD at the age of 85 is, therefore, one in three. With the increasing life expectancy, the 
worldwide burden of AD will grow tremendously, with an estimate of approximately 100 million 
people who will suffer from AD by 2050. Thus, it is a major priority to understand the 
pathological mechanisms underlying this devastating disease and to devise novel treatment 
strategies allowing at least the prolongation of the phase of independence and relieving the 
burden upon public health care systems. 
Alzheimer’s Disease 
The psychiatrist and neuropathologist Alois Alzheimer was one of the first scientists who 
systematically evaluated and correlated neuropathological with neuropsychological changes. 
More than a century ago, he presented his first case of Auguste D. whom he declared to suffer 
from a pre-senile form of dementia with the concomitant appearance of two neuropathological 
characteristics, amyloid plaques and NFTs. Despite intensive research, the pathological 
mechanisms underlying this form of dementia still remain unresolved. Only 5 drugs are approved 
today, which mildly improve some cognitive symptoms in early stages of AD patients 
(Cummings et al., 2014)(Alzheimer’s Society, http://www.alzheimers.org.uk). 
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Next to the progressive and severe loss of cognitive functions, AD is characterized by extensive 
neurodegeneration, leading to severe brain tissue atrophy of both grey and white matter. Further, 
early characteristics of the disease include increased oxidative stress, neuroinflammation, as well 
as impairment in brain glucose uptake and metabolism. 
Two types of AD are distinguished. The familial, or early-onset (EOAD) form associated with 
fast and severe progression and – as indicated by the name – affecting people below the age of 
60. EOAD is caused by dominant inheritance of a single mutation located in one of the three 
genes PSEN1, PSEN2 and APP. The second type is the sporadic or late-onset (LOAD) form, 
which accounts for more than 99% of all AD cases (Iqbal and Grundke-Iqbal, 2010). In this 
form, ageing is considered the highest risk factor affecting people older than 65. During my PhD 
thesis, I focused on the latter type. 
Two Histopathological Hallmarks 
Senile Plaques – Extracellular Amyloid 
AD-associated senile plaques consist of many peptides with amyloid- (Abeing the principal 
biochemical components (Ueda et al., 1993). A comprise different species and arise through 
proteolytic processing of the APP, a type I transmembrane glycoprotein. The physiological 
function of APP remains largely elusive. It has, however, been associated to be involved in 
cognitive performances (Luo et al., 1992, Huber et al., 1993) as well as to participate in the 
immune response towards injury or other insults (Ciallella et al., 2002, Itoh et al., 2009, Song et 
al., 2013). APP can be cleaved by 3 enzymes, -, -, and -secretase. Dependent on the sequence 
of cleavage, A species (A 1-37, -38, -40, -41, or -42) are produced (amyloidogenic -secretase 
followed by -secretase cleavage) or not (non-amyloidogenic -secretase followed by -
secretase) (Benilova et al., 2012). 
Apeptides (in particular A 1-42) gained increasing interest by the fact that monomers are prone 
to self-assemble into oligomers (2-6 peptides) followed by further aggregation into intermediate 
assemblies (several oligomers), which can grow into fibrils and then assemble into insoluble 
fibers (fibrillary plaques) (Rambaldi et al., 2009). Oligomers of A1-42 have been shown to have 
neurotoxic features (Chromy et al., 2003, Ono et al., 2009), notably in vitro and/or at high doses. 
However, the nature and significance of this neurotoxicity for AD pathophysiology remains 
unresolved (Benilova et al., 2012). Next to putative harmful effects, others have assigned 
neurotrophic properties to shorter forms of A (Whitson et al., 1989, Yankner et al., 1990). 
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Amyloidogenic cleavage results further in the production of soluble N-terminal fragment sAPP 
and the APP intracellular domain (AICD), which was suggested to have a nuclear signaling 
function (von Rotz et al., 2004). In contrast, non-amyloidogenic cleavage produces soluble 
APP (sAPP), which was associated with beneficial effects being involved in synaptic 
signaling (Furukawa et al., 1996), neuritic outgrowth (Mattson, 1994), synaptogenesis (Roch et 
al., 1994), synaptic plasticity (Luo et al., 1992, Huber et al., 1993), and cell survival and 
protection of neurons against excitotoxic, oxidative and metabolic insults (Mattson et al., 1993a, 
Mattson et al., 1993b); and the intracellular AICD and P3 fragment (Haass et al., 2012). 
Currently, it is considered that during AD pathogenesis a shift from non- to amyloidogenic 
processing of APP occurs, resulting in increased production of aggregation prone species. How 
and where these species are secreted into the extracellular space and where senile plaques are 
formed is still under debate. In the paragraph – “Inflammation Hypothesis” and Axonopathy in 
Sporadic AD – I present one possible scenario recently put forward by our lab, suggesting a 
sequence of events that could lead to the formation of senile plaques in AD.  
Neurofibrillary Tangles – Intracellular Amyloid 
NFTs – in contrast to plaques – are intracellular accumulations of amyloids following a 
remarkable pattern in their appearance during the disease progression. In contrast to senile 
plaques, their appearance and distribution pattern can be positively correlated with the cognitive 
impairments and thereby are applied as a useful tool in post-mortem staging of AD patients 
(Braak and Braak, 1991, Arriagada et al., 1992a, Arriagada et al., 1992b). The major component 
of NFTs is the microtubule (MT) stabilizing protein, Tau, which is concentrated in distal 
segments of axons. Under normal physiological conditions, Tau is continuously being 
phosphorylated and dephosphorylated (Iqbal and Grundke-Iqbal, 2010). Phosphorylation of Tau 
results in its detachment from MTs altering their stability (Ballatore et al., 2007). Excessive or 
aberrant phosphorylation, including N-terminus and C-terminus of Tau, causes pTau to 
redistribute from axonal to somatodendritic compartments (Ittner et al., 2010), self-assemble, and 
interact with other MT stabilizing proteins (MAP1 and MAP2). As a result, MTs are destabilized 
affecting the stability of axons and impairing transport mechanisms and synaptic function 
(Grundke-Iqbal et al., 1986, Iqbal and Grundke-Iqbal, 2010) (figure 3, box 1). Self-assembly of 
pTau leads to the formation of intracellular paired helical filaments (PHFs), which finally form 
NFTs and neuropil threads that can induce cell death (Ballatore et al., 2007, Iqbal and Grundke-
Iqbal, 2010). 
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Acetylcholine Hypothesis 
The earliest hypothesis formulated for the pathophysiology in AD is the “acetylcholine (ACh) 
hypothesis”. It arose during the late 60s to mid-70s, when systematic screenings of postmortem 
histopathological and biochemical alterations were performed and correlated with the mental 
state of patients. Several independent reports revealed an early deficit in the neocortical and 
hippocampal cholinergic system. These reports revealed decreased levels in presynaptic markers 
of cholinergic transmission, including decreased activity of choline acetyltransferase (ChAT) 
(Bowen et al., 1976, Davies and Maloney, 1976, Perry et al., 1977), reduced choline uptake 
(Rylett et al., 1983) and ACh release (Nilsson et al., 1986), reduced levels of nicotinic and 
muscarinic M2 receptors (Whitehouse et al., 1988, Nordberg et al., 1992) at presynaptic 
terminals, as well as atrophy of ACh producing cells in the basal forebrain and medial septum 
(Whitehouse et al., 1982, Francis et al., 1999), whereas levels of postsynaptic muscarinic 
receptors seemed to be less affected (Whitehouse et al., 1988, Nordberg et al., 1992). In the 
brain, ACh exerts a neuromodulatory and recently identified deterministic function on neurons 
affecting learning and memory (Picciotto et al., 2012, Sarter et al., 2014). Further, in vitro studies 
have demonstrated that stimulation of M1 muscarinic receptors resulted in decreased Tau 
phosphorylation (Sadot et al., 1996). Accordingly, a study performed in mice indirectly showed 
that muscarinic M1 affects the level of activated GSK-3 a major Tau kinase (see Paragraph 
“Reelin”) (Medeiros et al., 2011). Additional inhibition of GSK-3activation was revealed to be 
mediated through 7-nicotinic receptors (Krafft et al., 2012). 
Supporting a major role of ACh in AD pathogenesis is the fact that 4 out of the 5 currently 
approved drugs for the treatment of AD are reversible inhibitors of ACh esterase. Albeit not 
effective in all patients, these drugs temporarily promote cognitive improvements (Francis et al., 
1999, Cummings et al., 2014). However, the inconsistencies in therapeutic success and lack of 
long lasting effects of these drugs provided strong arguments to question the validity and 
relevance of the “ACh hypothesis”, even though the early and profound loss of cholinergic 
neurons in AD patients is indisputable. Therefore, the hypothesis has been revised to point out 
the major role of ACh as a co-factor in sporadic AD (Craig et al., 2011).   
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APP, PSEN1 and PSEN2 – “Amyloid Cascade Hypothesis” 
So far, more than 200 autosomal dominant mutations have been identified that cause familial 
AD. All of them have been identified confined to only 3 different genetic loci, including APP 
itself and the -secretase active core proteins presenilin-1 (PSEN1) and presenilin-2 (PSEN2) 
(Tanzi and Bertram, 2005, Bird, 2008, Bertram et al., 2010), and are associated with alterations 
in APP processing. Accordingly, altered ratios in A peptide composition – showing an increase 
in A1-42/40 ratio – have been reported in the cerebral spinal fluid (CSF) of AD patients. These 
discoveries led to the formulation of the “amyloid-cascade hypothesis”, which postulates that 
AD is induced by an increased production of neurotoxic A peptides and positions A upstream 
of all other pathological changes detected in AD (Hardy and Higgins, 1992, Hardy and Selkoe, 
2002). 
While this hypothesis accounts for many aspects of familial AD, accumulating evidence over the 
past years indicates that the sporadic form presumably depends on different distinct mechanisms 
independent of A. This evidence includes genome-wide association studies (GWAS) 
identifying several susceptibility genes associated with increasing the risk for AD (Bertram et al., 
2007, Harold et al., 2009, Hollingworth et al., 2011), none of which identifying APP or PSENs 
as risk genes. Further in vitro studies testing a subset of these susceptibility genes revealed that – 
unlike mutations in familial form – they had no effect on A1-42/40 ratio (Bali et al., 2012). 
Further various drug trials using active or passive immunization against A were – to date – 
unsuccessful (Becker et al., 2014, Cummings et al., 2014, Schneider et al., 2014). 
ApoE4 - the Strongest Genetic Risk Factor in Sporadic AD 
The strongest susceptibility gene identified was APOE, encoding the apolipoprotein E (ApoE) 
(Corder et al., 1993). ApoE belongs to the family of lipoprotein transporters involved in the 
regulation of lipid plasma levels and uptake into cells. ApoE is enriched in high density-like 
(HDL) lipoprotein particles, and in the brain, is the most prevalent lipoprotein mainly produced 
by astrocytes (Pitas et al., 1987a, Grehan et al., 2001). It is involved in cholesterol transport and 
neuronal uptake via apolipoprotein receptors (Pitas et al., 1987b), which was suggested to play a 
role in synaptogenesis and maintenance of synaptic connections (Pfrieger, 2003). However, its 
exact role in cholesterol homeostasis is not yet fully understood (Holtzman et al., 2012). In 
humans, 3 common apoE isoforms have been identified, apoE2, apoE3, and apoE4 encoded by 
their corresponding alleles APOE 2, 3 and 4 with APOE 4 being the allele strongest 
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associated to increase the risk and decrease the age of onset of sporadic AD. Carriers of one 
allele have an approximate 2-3 fold increased risk, whereas in carriers of two alleles the risk 
increases to approximately 12-fold (Corder et al., 1993, Gomez-Isla et al., 1996b, Roses, 1996, 
Bertram et al., 2007, Bertram and Tanzi, 2009). The mechanisms on how apoE4 contributes to 
the induction and progression of sporadic AD remain unclear; several studies expressing 
different isoforms in mice suggested an isoform-specific alteration in basal apoE concentration 
(with apoE2>E3>E4) (Kim et al., 2009). Further apoE4 was shown to deposit in neuritic plaques 
as well as NFTs (Hartig et al., 1997, Burns et al., 2003) and APOE 4 allele carriers were 
associated with increased levels of A deposits (Barthel et al., 2011). APOE 4 carriers display 
accelerated ageing-associated alterations, including volumetric changes in the hippocampus and 
the cerebral cortex correlating with cognitive performance (Reiman et al., 1998) and decreased 
levels of cerebral glucose levels – an early sign associated with AD (Shaw et al., 2007). 
ApoE undergoes proteolytic processing resulting in neurotoxic C-terminal truncated fragments 
detected in transgenic animals (Harris et al., 2003). In contrast to apoE3, apoE4 is more prone to 
proteolysis likely due to its decreased levels of lipidation (Koldamova et al., 2005, Boehm-Cagan 
and Michaelson, 2014) and was shown to affect cytoskeletal structures by increasing Tau 
phosphorylation resulting in the formation of tangle-like inclusions (Huang et al., 2001, Brecht et 
al., 2004). In addition, isoform specific alterations in the corresponding receptors have been 
detected (Holtzman et al., 2012). For example, hippocampal CA1 and CA3 pyramidal cells have 
decreased levels of the apolipoprotein receptor 2 (ApoER2) upon apoE4 compared to apoE3 
expression, further impairing lipid transport into neurons and decreasing  protective signaling 
pathways mediated through ApoER2, such as Reelin (see paragraph “Reelin”) (Holtzman et al., 
2012, Gilat-Frenkel et al., 2014).  
Despite the strong evidence for apoE4 involvement in major AD-associated processes, by far not 
all APOE 4 carriers develop AD. As for ACh, apoE4 therefore represents yet another co-factor 
that promotes the development and progression of AD.  
As put forward by (McDonald, 2002), sporadic AD therefore reflects a multifactorial disease 
with a multitude of mechanisms synergistically setting the path of developing AD, or not. Hence, 
AD represents a disease with high inter-patient variability in the presentation of pathological 
symptoms including cognition, appearance of pathological hallmarks, progression and 
responsiveness to drug treatment. Therefore, it is crucial to investigate ageing-associated 
changes, which are exacerbated in very early stages of the disease, and thereby classify patients 
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into different AD subtypes (Iqbal and Grundke-Iqbal, 2010). This approach might then allow us 
to design AD-subtype targeted drug treatments. 
 
Focusing on the role of chronic inflammation and the contribution of abnormal 
neurodevelopmental processes to age-related central nervous system (CNS) pathologies, our lab 
has recently developed a model of sporadic AD in wild type mice. The analysis of this model 
suggested that AD involves axonopathy of long-projecting neurons primarily induced by ageing-
associated changes with chronic neuroinflammation as one of the strongest driver in the disease 
pathogenesis (Krstic and Knuesel, 2013). 
Here, I will briefly introduce this hypothesis and further expand it by considering three 
additional systems that are affected by normal aging and worsened in early stages of the disease. 
Thereby, I will present a scenario on how AD onset and progression is determined by these 
systems, which interact synergistically to shift from healthy to pathological ageing. This scenario 
formed the starting point of my PhD thesis. 
The “Inflammation Hypothesis” and Axonopathy in Sporadic AD 
The association of increased brain inflammation with the strongest risk factor APOE 4 in 
sporadic AD (Egensperger et al., 1998) and a multitude of additional data have prompted our lab 
to develop the “inflammation hypothesis” with axonopathy. Here, I will very briefly delineate 
the main concepts (reviewed in (Krstic and Knuesel, 2013)). 
Next to the two histopathological hallmarks, amyloid plaques and NFTs, a prominent 
characteristic of AD is neuroinflammation detected by increased levels of pro-inflammatory 
cytokines, microglia activation and astrogliosis (Castellani et al., 2010). For several decades, 
neuroinflammation has been considered a consequence of potential toxic protein aggregations 
and neurodegeneration rather than a cause actively contributing to the onset of disease and its 
progression. However, the importance of inflammatory processes as a causative factor in 
neurodegenerative diseases has increasingly gained interest (Frank-Cannon et al., 2009, Pizza et 
al., 2011b, a). Several susceptibility genes identified in recent GWAS are related to the innate 
immune system (Harold et al., 2009, Lambert et al., 2009), and positron emission tomography 
(PET) imaging studies could positively correlate cognitive deficits of patients with the level of 
microglia markers but not with senile plaques (Edison et al., 2008, Yokokura et al., 2011). A 
determining role for inflammatory processes have further been shown by studies demonstrating 
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that inflammatory mediators, such as pro-inflammatory cytokines and chemokines, directly 
affect APP levels and processing (Goldgaber et al., 1989, Rogers et al., 1999, Ciallella et al., 
2002, Itoh et al., 2009, Song et al., 2013) as well as Tau phosphorylation (Li et al., 2003, 
Bhaskar et al., 2010) (figure 3, box 2). 
In vitro and in vivo studies have revealed a close link between A and Tau showing that A-
induced changes are dependent on the presence of Tau (Rapoport et al., 2002, Roberson et al., 
2007). However, the sequence of events leading to the appearance of amyloid plaques and NFTs 
in specific brain regions during disease progression is still unknown. Albeit several have 
suggested Aplaque formation to occur in the extracellular space by aggregation of secreted A 
species, electron microscopy studies have identified mitochondria and other organelles in plaque 
cores, suggesting that initial core formation occurs intracellular (Malamud N and Hirano A, 
1974, McGeer et al., 1992). Detection of APP and A species located to axonal swellings (Xiao 
et al., 2011) – described to appear prior to AD-related pathology in transgenic mice (Stokin et al., 
2005, Wirths et al., 2006), monkeys (Martin et al., 1994, Fiala et al., 2007) and AD patients (Yu 
et al., 2005) – indicates that the origin of amyloid plaques lay in these axonal swellings (Xiao et 
al., 2011). Intrigued by these and our own findings in regard to ageing-associated, intracellular 
Reelin accumulation (see Paragraph “Reelin”) Krstic and Knuesel propose that these intracellular 
aggregates evolve through impairment in the axonal transport machinery. Such transport deficits 
are suggested to be induced by cytoskeleton abnormalities found in AD patients (Iqbal et al., 
1986). Our lab has therefore suggested phosphorylation of Tau to be the major link between 
axonal transport deficits (i.e. microtubule destabilization) and neuroinflammation, as increased 
tau phosphorylation is induced by inflammatory stimulations. By that we suggest the following 
scenario to occur: 
Ageing is associated with increased neuroinflammation, e.g. due to ageing-associated 
impairments in mitochondrial function leading to the production of reactive oxygen species, as 
well as a gradual imbalance in protein metabolism and clearance. Ageing-associated increase in 
aberrant phosphorylation of Tau – presumably induced by neuroinflammation and oxidative 
stress – results in its detachment, translocation and aggregation in somatodendritic compartments 
leading to the destabilization of microtubule networks affecting axonal stability and transport. 
Consequently, impaired axonal transport is likely to cause intra-axonal accumulation of 
transported proteins along axons, such as APP and its cleaved fragments, which again further 
impair the transport machinery (figure 3, box 1). Healthy neurons will clear such accumulations 
by extrusion of these protein aggregates, which will be then cleared from the extracellular space 
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by microglia through phagocytosis. Ageing is associated with decreased phagocytic properties of 
microglia, thereby resulting in the accumulation of extracellular budd-offs, reflected in granular 
Reelin deposits (Knuesel et al., 2009). In contrast to healthy neurons, old and stressed neurons 
are likely to accumulate these intracellular aggregates instead of extruding them, likely hindering 
or fully blocking axonal transport. This will affect presynaptic terminals as they lack supply of 
newly synthetized proteins, resulting in loss of synaptic function and eventually synapse 
retraction. The loss of synaptic inputs could alter postsynaptic target cells. Ultimately, the protein 
clot will grow to a point where axons burst and leak, forming senile plaques and inducing strong, 
local immune responses. This again affects cells in target areas – both neurons and in particular 
microglia – which will be further stimulated, generating a vicious cycle promoting disease 
progression. Finally, axons will degenerate leaving dystrophic neurites and plaques along the 
projection and target areas and NFTs where the somas of the cells were located. 
This hypothesis provides a plausible chain of events occurring in AD, explaining early atrophy 
detected in areas harboring long-projection neurons (noradrenergic (NA) cells of the LC (see 
Paragraph “NA system”); ACh expressing cells of nucleus basalis of Meynert and medial septum 
(see Paragraph “ACh hypothesis”); and entorhinal cortex (EC) layer II pyramidal cells (see 
Paragraph “Reelin“)), as well as the first appearance of NFTs in these areas. It further explains 
loss in synapses and axonal impairments at early stages of AD (Bozoki et al., 2012, Cross et al., 
2013). Finally, it offers a reasonable explanation why the two histopathological hallmarks of AD 
do not appear in the same brain areas at the same time and why tangles follow a stereotyped 
regional pattern during disease progression, whereas plaques appear rather diffusely throughout 
the cerebral cortex (Duyckaerts et al., 1986, Braak and Braak, 1991, Duyckaerts et al., 1997, 
Krstic et al., 2013). 
Reelin 
Decreased levels of the extracellular matrix protein Reelin have been associated with early cases 
of sporadic AD (Chin et al., 2007, Herring et al., 2012). In line polymorphisms spanning the 
RELN locus identified by GWAS have been positively correlated with Tau pathology in healthy 
aged individuals (Kramer et al., 2011) or directly associated with AD (Seripa et al., 2008). 
Reelin is a large glycoprotein, which is expressed and secreted by Cajal Retzius cells located in 
the marginal zone during development. Serving as stop signal for both migrating neurons and 
growing fibers, it plays a crucial role in cortical lamination and lamina-specific axonal 
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innervation (Frotscher, 1998, Derer et al., 2001, Bock et al., 2003, Frotscher et al., 2003, 
Frotscher, 2010). In the adult brain, Reelin is mainly expressed by remaining Cajal Retzius cells, 
cortical -aminobutyric acid (GABA)ergic interneurons, and layer II pyramidal cells of the EC 
(Alcantara et al., 1998, Pesold et al., 1998, Martinez-Cerdeno and Clasca, 2002, Martinez-
Cerdeno et al., 2002, Abraham and Meyer, 2003). The latter are particularly vulnerable to 
neurodegeneration (Gomez-Isla et al., 1996a) and are among the first to contain NFTs at the 
onset of AD (Braak and Braak, 1991). 
Functional Reelin dimer binds to two receptors, the very low density lipoprotein receptor 
(VLDLR) and the ApoER2, both located in the plasma membrane (Trommsdorff et al., 1999). 
Upon binding of Reelin, receptor dimerization induces the phosphorylation of Dab1, which 
subsequently activates different cytosolic kinase cascades (Hiesberger et al., 1999, Strasser et al., 
2004, Kuo et al., 2005). Reelin signaling in the adult brain was demonstrated to modulate 
synaptic plasticity through direct alteration of AMPA and NMDA receptor composition (Sinagra 
et al., 2005, Qiu et al., 2006b) and NMDA receptor phosphorylation at the postsynaptic 
membrane (Weeber et al., 2002, Beffert et al., 2005). Accordingly, ageing-associated cognitive 
impairments in rats were correlated with decreased levels of Reelin in the EC (Stranahan et al., 
2011). Besides modulating synaptic plasticity, Reelin controls both actin and microtubule 
cytoskeleton dynamics affecting synaptogenesis (i.e. altering size, shape and density of spines in 
the dendritic compartments, as well as axonal and dendritic branching and growth) (Del Rio et 
al., 1997, Borrell et al., 1999, Liu et al., 2001, Jossin and Goffinet, 2007, MacLaurin et al., 2007, 
Qiu and Weeber, 2007, Niu et al., 2008). Reelin signaling was shown to inhibit the activity of 
two major Tau kinases – GSK-3 (Beffert et al., 2002, Bock and Herz, 2003, Huang et al., 2005) 
and CDK5 (figure 3, box 3) (Beffert et al., 2004) – both of which are associated with aberrant 
hyperphosphorylation of Tau detected in AD (Ballatore et al., 2007, Iqbal and Grundke-Iqbal, 
2010). Thus, Reelin deficiency was associated with increased levels of pTau (Hiesberger et al., 
1999, Beffert et al., 2002, Ohkubo et al., 2003). In vitro studies further revealed Reelin signaling 
to favor non-amyloidogenic processing of APP associated with increased production and 
beneficial effects of sAPP (see Paragraph “Senile Plaques – Extracellular Amyloid”) and 
decreased production of A peptides (Trommsdorff et al., 1998, Hoe et al., 2006). In line with 
this, reduced Reelin expression in transgenic mice overexpressing two mutations of familial AD 
resulted in earlier and persistent A plaque formation and the appearance of Tau pathology 
(Kocherhans et al., 2010). 
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Reelin is catalytically processed at two sites by the metalloproteinase ADAMTS-4 and 5 as well 
as the serine protease plasminogen activator (tPA) (Krstic et al., 2012b), resulting in the 
production of 5 different fragments. The physiological roles of these fragments are currently not 
understood. Various studies did, however, assign specific roles to the different Reelin domains. 
Thus, the N-terminal fragment is required for Reelin homo-dimerization – necessary to bind and 
activate receptors – and signaling (Kubo et al., 2002, Kohno et al., 2009). The receptor binding 
motif was identified on the central fragment (Jossin et al., 2004, Jossin et al., 2007). The C-
terminus is involved in protein folding (de Bergeyck et al., 1997) and is crucial for full activation 
of signaling pathways (Nakano et al., 2007, Kohno et al., 2009). In vitro studies have further 
shown that N-terminal cleavage occurs after endocytosis of Reelin/receptor complex and 
secreted into the extracellular space via recycling endosomes (Hibi and Hattori, 2009). In 
addition, N-terminal fragments are likely to aggregate (Utsunomiya-Tate et al., 2000), whereas 
Reelin fragments lacking the N-terminus interact with each other forming complexes that exceed 
the size of functional dimers (Kubo et al., 2002). The role and putative toxicity of these 
aggregates are unknown. 
Reelin expression and processing are affected in normal ageing, resulting in decreased levels of 
Reelin in interneurons as well as a concomitant accumulation of amyloid-like Reelin deposits in 
distinct areas of the hippocampus of aged mice (Knuesel et al., 2009). 3D reconstruction electron 
microscopy analyses, performed in our lab, revealed that these deposits were in part associated 
with neurites and contain intracellular organelles. Therefore, we suggested them to arise from 
extrusion processes as a consequence of impaired axonal transport, as described in the paragraph 
“The “Inflammation Hypothesis” and Axonopathy in Sporadic AD” (Doehner et al., 2012a). In 
line with axonal deficits induced by increased inflammatory processes, our lab could 
demonstrate that a prenatal immune challenge significantly accelerates the ageing-associated loss 
of Reelin in interneurons and appearance of Reelin deposits in the hippocampus (Knuesel et al., 
2009). Reduced Reelin expression is likely accompanied by a decrease in beneficial Reelin 
signaling and thereby affecting basic neuronal mechanisms, including synaptic plasticity and the 
axonal transport machinery. Therefore, it is conceivable that decreased Reelin signaling might 
exacerbate inflammation-induced alterations, promoting the shift from healthy to pathological 
ageing.  In accordance with this hypothesis, Reelin expressing cells in the adult brain are found 
along the olfactory-limbic pathway comprising areas known to be affected at early stages of AD 
(Bozoki et al., 2012, Cross et al., 2013, Krstic et al., 2013) 
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Prenatal Exposure to Inflammatory Insults and Its Long-Term 
Effect on Basal Brain Functions 
In recent years, it has become evident that maternal infections during pregnancy can have long-
term effects on neurodevelopmental processes, and represent a risk factor for neuropsychiatric 
and neurodegenerative diseases (Knuesel et al., 2014, Meyer, 2014). The fetal phase is a 
sensitive period during which external influences on pregnant mothers can induce major changes 
in the fetal environment and thereby interfere with developmental processes, including the CNS. 
Accordingly, experimental evidence shows that offspring exposed to prenatal maternal infections 
can exhibit major alterations in basal brain functions. Long-term modifications of 
neurotransmitter systems, including GABAergic (Richetto et al., 2014), glutamatergic (Meyer et 
al., 2008c) and the mesocorticolimbic dopaminergic (Vuillermot et al., 2010, Vuillermot et al., 
2012) systems, as well as altered basal state of microglia have been reported (Borrell et al., 2002, 
Krstic et al., 2012a). These alterations were consistently shown to have long-term effects on 
behavioral performances in tests of social interaction, anxiety, and cognition. Epidemiological 
studies, as well as various animal models of prenatal infection, report a clear association between 
prenatal exposure to inflammatory insults and the development of schizophrenia and autism. 
Additional evidence links prenatal immune challenges to other neurological diseases, including 
epilepsy, cerebral palsy, and albeit to a lesser extent to ageing-associated neurodegenerative 
diseases (Knuesel et al., 2014). 
In animal models, prenatal exposure to immune activation can be induced in various ways. Most 
common is the use of agents that mimic bacterial or viral infections and cause a strong rise in 
inflammatory cytokine and chemokine levels (Meyer, 2014). The synthetic double-stranded 
RNA PolyI:C is commonly used to mimic a viral infection. PolyI:C is a potent activator of the 
innate immune system and induces a robust, but time-limited, acute phase response that is 
typically seen after virus infections (Cunningham et al., 2007). 
PolyI:C is recognized by the transmembrane pattern recognition receptor the toll-like receptor 3 
(TLR3) localized on intracellular endosomes. TLR3 receptors are mainly expressed by peripheral 
dendritic and natural killer cells, which are most responsive towards retroviruses (Muzio et al., 
2000). Receptor activation induces intracellular signaling pathways, activating NFB 
(Alexopoulou et al., 2001), which triggers the expression of a whole set of immune genes, 
including inflammatory cytokines, and via the interferon regulatory factor (IRF) induces type I 
interferon (IFN) expression (figure 1) (Mallard, 2012). Systemic PolyI:C injection acutely 
upregulates peripheral as well as central cytokines, including increased expression of 
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cyclooxygenase 2 (COX2) and the pro-inflammatory cytokines interleukin (IL)-1, IL-6, tumor 
necrosis factor (TNF)-, as well as the anti-inflammatory cytokines IL-4 and IL-10 
(Cunningham et al., 2007, Mallard, 2012). 
In the CNS, TLR3 receptor expression has been identified in microglia (Olson and Miller, 2004, 
Town et al., 2006) and astrocytes (Farina et al., 2005). Intra-parenchymal injection of PolyI:C 
into the brain induces local inflammatory responses likely through glial TLR3 signaling (Melton 
et al., 2003, Town et al., 2006). However, PolyI:C cannot cross the blood brain barrier (BBB) 
(Mallard, 2012). It was therefore suggested that central immune responses, towards systemic 
PolyI:C application, reflect an indirect rather than a direct effect of PolyI:C on microglia. 
Another route through which PolyI:C can affect the CNS through the activation of blood vessel 
endothelial cells. Accordingly, endothelial cells respond to PolyI:C in a TLR3-dependent 
manner, including increased production of IFN (Garfinkel et al., 1992, Conaldi et al., 1997, 
Imaizumi et al., 2004, Ishikawa et al., 2004, Kraus et al., 2004, Imaizumi et al., 2005, Tissari et 
al., 2005). 
Acute elevation of serum cytokine levels in pregnant dams post-PolyI:C treatment has been 
shown to recover within hours; and yet they are potent enough to persistently alter 
neurodevelopmental processes (Meyer et al., 2006b, Meyer et al., 2008a). As for maternal serum 
cytokine levels, acute elevation of cytokines is detectable in the fetal brain (Meyer et al., 2006b, 
Abazyan et al., 2010). Similar to systemic PolyI:C-induced central changes, alterations in fetal 
environment represent mostly an indirect PolyI:C effect. There are three putative ways on how 
PolyI:C administration to pregnant dams can increase fetal cytokine levels: maternal 
inflammatory cytokines, which, in contrast to PolyI:C, cross the placental barrier (Zaretsky et al., 
2004, Dahlgren et al., 2006); cytokines that are produced in uterine and placental cells (Schaefer 
et al., 2005, Ashdown et al., 2006); and fetal cytokine production, which was shown to be 
dependent on the fetal developmental stage (Meyer et al., 2006b) (figure 1). Concomitant 
increases in the levels of IL-10 and TNF- mRNA and protein in the fetal brain after prenatal 
immune challenge was only observed when PolyI:C stimulation occurred during late gestation 
(Meyer et al., 2006b). Therefore, prenatal immune challenges can induce autonomous activation 
of the fetal immune system, which can outlive acute maternal immune reactions and could 
therefore affect fetal development during longer time periods. 
The time-point of immune activation during gestation is further determinant for the nature of 
neurodevelopmental alterations caused by prenatal exposure to PolyI:C (Meyer et al., 2006b). 
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Figure1: Indirect action of PolyI:C to increase fetal cytokine levels and affect the developing embryo. I.v. 
injected PolyI:C into pregnant dams (1) is endocytosed through leukocytes in the bloodstream (2). TLR3 receptors 
located in the membrane of endosomes recognize the synthetic double-stranded RNA and activate TLR-specific 
signaling pathways (3). These include the activation and translocation of NFB and IRF-3 to the nucleus where they 
activate a variety of genes resulting in increased production of inflammatory cytokines (red triangles) (4). These 
maternally produced cytokines enter the bloodstream, some of which can cross the blood-placental barrier (5). 
Alternatively, PolyI:C may increase fetal cytokine levels through placental-induced cytokine expression (6, blue 
triangle) or by fetal cytokine production (7, yellow triangle). Images were adapted from www.servier.com. 
 
 
Stimulation during early and mid-gestation results in multiple structural and functional brain 
abnormalities used to model schizophrenia and autism-related disorders. Stimulation during late 
gestation, on the other hand, is associated with subtle and more limited structural and functional 
alterations still potently disrupting behavioral performances (Meyer et al., 2006b, Meyer et al., 
2007, Meyer et al., 2008c). Further, manipulations during late gestation were shown to accelerate 
ageing-associated processes, including sustained increase in both peripheral and central pro-
inflammatory cytokine levels (Krstic et al., 2012a) as well as alterations in Reelin expression and 
aggregation discussed above (see Paragraph “Reelin”) (Knuesel et al., 2009).  
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“Double Hit” Model – Wild Type Mouse Model for Sporadic AD 
Based on this property of accelerating ageing-associated alterations, our lab sought to use this 
prenatal manipulation paradigm to study ageing-related changes relevant for sporadic AD. Upon 
receiving a second immune challenge during adulthood, wild type mice prenatally exposed to 
PolyI:C at GD17 developed a phenotype closely associated with sporadic AD (Krstic et al., 
2012a) (figure 2). PolyI:C administration to pregnant dams caused persistent increases in the 
levels of both peripheral and central cytokine in offspring up to the age of 15 months. Further, it 
caused an age-dependent increase in APP levels and alterations in Tau phosphorylation. The 
second immune challenge at the age of 12 months (“double hit”) exacerbated central 
inflammatory responses, as evidenced by microgliosis and astrogliosis, and caused further 
elevation of APP levels, appearance of APP-positive plaques, as well as increased levels of PHFs 
and a distinct relocalization of pTau to somatodendritic compartments.  
These findings are in accordance with studies demonstrating a direct link between inflammatory 
processes and increased expression of APP and Tau phosphorylation. However, most of these 
studies were performed in vitro (Goldgaber et al., 1989, Rogers et al., 1999) or through harsher 
approaches such as head traumas (Ciallella et al., 2002, Itoh et al., 2009) and intra-parenchymal 
application of cytokines (Song et al., 2013). A direct link between chronic increases in central 
cytokine levels and AD-associated changes was further demonstrated by injecting transgenic AD 
mice with PolyI:C at the age of 9 months, which strongly exacerbated plaque formation and glia 
activation (Krstic et al., 2012a). 
Ever since the identification of familial AD-inducing mutations, a large variety of transgenic 
mouse models overexpressing one to several of these mutations were produced and used to study 
both familial and sporadic AD. The combination of prenatal and postnatal PolyI:C exposure in 
wild type mice, therefore, enabled to develop a more physiological model to study ageing-
associated, AD-related pathological changes.  
These findings lend strong support to the hypothesis that early inflammatory events are key 
players in AD pathogenesis. And further suggests that maternal infections during late pregnancy 
can prime peripheral and central innate immune systems making them more vulnerable to 
following insults later during life.  
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Figure 2: “Double-hit” mouse model for sporadic AD – the central changes. Pregnant dams (GD17) are 
subjected to 5 mg/kg of PolyI:C (i.v.) injection. 15 months-old offspring that were exposed to only prenatal PolyI:C 
(“single hit”) develop ageing-dependent, AD-related changes, including central increased levels of pro-inflammatory 
cytokines (IL-1 and -1 and IL-6), activation of microglia and increased levels of APP and pTau. A second 
PolyI:C (5 mg/kg) exposure at the age of 12 months exacerbates this phenotype detected at the age of 15 months 
(“double hit”), resulting in more pronounced microglia activation and astrogliosis, further APP elevation and 
formation of APP-positive plaques as well as increased formation of PHFs and a somatodendritic shift of pTau. 
Images were adapted from www.servier.com.   
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The Noradrenergic System in AD 
The observation that the appearance of NFTs follows a specific regional pattern during disease 
progression stimulated research to understand where, how and when the disease starts. And even 
more so, whether the disease has a focal starting point, as suggested by the “ACh hypothesis” for 
the nucleus basalis of Meynert. A study systematically analyzing brain tissue from individuals 
aged between 0-100 reported a striking and highly reproducible ageing-dependent accumulation 
of hyperphosphorylated Tau in neurons of the LC (Braak et al., 2011). The LC consists of long 
projecting, noradrenaline (NA) secreting neurons that innervate the entire neuraxis. Intriguingly, 
the LC has been shown by several early studies to be severely affected in AD patients 
(Tomlinson et al., 1981, Iversen et al., 1983, Bondareff et al., 1987, Chan-Palay and Asan, 1989, 
German et al., 1992), in particular at disease onset (Grudzien et al., 2007). Therefore, it has been 
proposed that the LC could represent a seeding point for the formation of NFT, rather than the 
previously assumed EC (Braak and Del Tredici, 2012). The reason for its vulnerability to ageing-
associated diseases is currently not well understood. However, LC neurons have among the 
longest axons in the CNS and were shown to exhibit increased mitochondrial oxidative stress 
during aging (Sanchez-Padilla et al., 2014). In line with the proposed “inflammation hypothesis” 
and axonopathy for AD, it is conceivable that early changes in Tau hyperphosphorylation and 
aggregation are induced by increased inflammatory processes resulting from oxidative stress. In 
addition, oxidative stress has been shown to directly induce Tau assembly (Schweers et al., 
1995), further potentiating the formation of PHFs and early NFT-induced neurodegeneration 
(Grudzien et al., 2007). 
NA binds to and exerts its function through G-protein coupled adrenergic receptors (1, 2, 1, 
2) expressed in the CNS by neurons, astrocytes and microglia. NA is a major neurotransmitter 
in the sympathetic nervous system, whereas in the brain, it exerts a neuromodulatory function on 
attention, sleep, arousal, and cognitive processing (Berridge and Waterhouse, 2003). Selective 
attention modulation was shown in various animal models; stimulation and lesion studies 
performed in rats revealed that LC-mediated NA release increases attentional shift (Devauges 
and Sara, 1990, Yu and Dayan, 2005). Tonic LC firing has been further associated with 
explorative behavior coordinating sensory input, processing, motor output and feedback 
mechanisms (Usher et al., 1999). Phasic LC firing was shown to be induced by strong task-
relevant sensory stimuli associated with behavioral performance. Electrophysiological recordings 
in non-human primates revealed that LC phasic firing occurs immediately before behavioral 
output in a forced task-related test paradigm. This led to the suggestion that phasic LC firing is 
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associated with task-related performance rather than sensory input and processing (Clayton et al., 
2004). In general, both tonic and phasic LC firing contribute to subtle modulations that affect 
accurate and effective decision making.  
The NA system was further associated with regulation of sleep pattern. Tonic LC activity 
decreases during sleep, leading to increased levels of TNF- and IL1-, which are both known to 
induce non-REM sleep (Aston-Jones and Bloom, 1981, Opp, 2005). Intriguingly, an early 
symptom of AD is disturbance of sleep, which might impair sleep-dependent consolidation 
processes linked to cognitive performance (Hahn et al., 2014, Ownby et al., 2014, Peter-Derex et 
al., 2015). However, sleep deficits in AD patients mainly affect total REM sleep duration, which 
was attributed to modulation of ACh signaling (Platt and Riedel, 2011, Peter-Derex et al., 2015). 
To what extent decreased NA-mediated signaling accounts for disturbed sleep patterns in ageing 
and AD remains to be determined.  
NA signaling through both 2, and 1 receptors expressed on astrocytes was demonstrated to 
regulate normal brain glucose metabolism by modulating glycogenesis as well as glycogenolysis, 
and was, therefore suggested to regulate the bioenergetic homeostasis in neurons (Hertz et al., 
2007). Intriguingly, in vitro studies in cultivated astrocytes revealed that glycogenolysis and 
glycogenesis are both mediated via the same -adrenergic signaling pathway involving 
intracellular cyclic AMP (cAMP) production, but in a time-dependent manner (Sorg and 
Magistretti, 1992). NA therefore could function as a homeostatic regulator to keep glucose levels 
in balance and ready to be shuttled to neurons.  
NA was further associated with brain energy homeostasis by the fact that NA is a potent 
modulator of cerebral blood flow. Expression of adrenergic receptors was detected in vascular 
endothelial cells and smooth muscle cells (Nathanson and Glaser, 1979, Wroblewska et al., 1984, 
Bacic et al., 1992). LC stimulation was shown to both increase brain perfusion by increasing 
local cerebral blood flow (Toussay et al., 2013), as well as decreasing it, likely dependent on the 
frequency of stimulation (Goadsby and Duckworth, 1989). Further NA signaling was linked to 
increased permeability and thereby facilitating transport via BBB (Raichle et al., 1975, Borges et 
al., 1994, Sarmento et al., 1994). Light- and electron microscopy studies revealed close 
associations of LC terminals with astrocytic processes in close proximity of brain microvessel. It 
was therefore suggested that NA is exerting its modulatory function on brain vasculature via 
neuron-glia-vasculature interactions (Cohen et al., 1997). The study performed in rats by 
Toussay et al. showed that activity-dependent increase in brain perfusion is modulated by LC 
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activity (Toussay et al., 2013). They further supported the neuron-glia-vasculature interaction by 
the fact that increased blood flow was induced by vasoactive compounds produced and secreted 
by activated neurons and astrocytes rather than directly by LC innervation.   
The immune system is the third system closely related to AD, which is modulated by NA 
signaling. NA has been identified as a potent permissive modulator of central immune responses 
by directly affecting microglia cells mainly via 2-adrenergic receptors. The major role of 
microglia during normal conditions is to survey brain parenchyma. In response to injury, 
microglial cells proliferate, migrate to the area of insult, induce phagocytosis of injured brain 
tissue or pathogens, and express and secrete inflammatory cytokines and chemokine to attract 
more immune cells, as well as to induce their controlled inflammatory reactions. Upon binding to 
2-adrenergic receptor on microglia, NA decreases the production of pro-inflammatory cytokines 
(Hetier et al., 1991, Feinstein et al., 2002, Heneka et al., 2010), thereby protecting the brain from 
avert effects of overproduction and hyper-activation of inflammatory processes (Griffin et al., 
1998, Campbell, 2004, Griffin, 2006). While microglia process extension was shown to be 
dependent on purinergic signaling, soma migration was attributed to NA signaling. This was 
evidenced in both in vitro and in vivo studies, showing that NA depletion results in the 
suppression of microglia migration (Heneka et al., 2010). In line, stimulation of -adrenergic 
receptors in cultured microglia promoted migration (Kettenmann et al., 2011). Activation of 2-
adrenergic receptors was shown to promote A phagocytosis and degradation in microglia 
culture systems (Kong et al., 2010) and was confirmed by depletion studies, resulting in 
significantly decreased phagocytosis of A (Heneka et al., 2010).  
In accordance with these findings, NA lesion studies in transgenic AD animal models revealed 
sustained exacerbation of AD related phenotypes including strong and early upregulation of 
neuroinflammatory processes and increased plaque formation, as well as increased cognitive 
deficits (Heneka et al., 2006, Kalinin et al., 2007, Pugh et al., 2007, Jardanhazi-Kurutz et al., 
2010, Rey et al., 2012, Hammerschmidt et al., 2013). Finally, in line with LC atrophy in AD 
patients, degeneration of LC neurons has been reported in an AD-transgenic mouse model 
(German et al., 2005).  
Taken together, it is conceivable that early loss of protective NA signaling together with 
increased inflammation during ageing synergistically promote the shift from healthy to 
pathological ageing (figure 3, box 4). 
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Impaired Glucose Metabolism, Bioenergetic Insufficiency 
High blood pressure, vascular diseases, and insulin resistance (diabetes type II) have early on 
been associated with increasing the risk of AD. As these diseases are all related to alterations in 
blood vessel function and thereby thought to affect brain energy supply, bioenergetic deficiency 
has been proposed to play a fundamental role in the pathological mechanisms involved in AD. 
The brain - albeit representing only 2% of the body weight is a highly oxygen (app. 20% of total 
body O2) and energy (approximately 25% of total body glucose) consuming organ. And the 
major energy substrate for the brain is blood glucose. Thereby, altering blood supply or blood-
brain metabolite exchange can have major effects on brain function.  
Hypometabolism has been confirmed by several neuroimaging PET studies showing region-
specific reductions in glucose uptake in AD patients (Mosconi et al., 2005). The accuracy of 
these studies is such that they allow distinguishing between healthy controls and AD patients 
(Herholz et al., 2002). It was debated, however, whether decreased glucose uptake solely 
reflected decrease in the demand due to brain atrophy or whether glucose deficiency is apparent 
before major synapse and neuronal degeneration. Recent studies have demonstrated that 
impaired glucose uptake is detectable in early prodromal cases, lacking evident brain atrophy 
(Mosconi, 2005, Mosconi et al., 2008a, Mosconi et al., 2008b). The reasons for these early 
changes are yet unknown and need further clarification. However, several labs favor the view 
that systemic alterations – including insulin resistance – induced by western diet play a major 
role in altering brain glucose uptake mechanisms. 
Impairment in brain glucose uptake will eventually lead to energy deficiency, which can have 
devastating effects on proper neuronal signaling, function – including axonal transport 
machinery – and thereby cell survival. In addition, combining glucose uptake deficits with 
alterations in local storage and release upon glycogen turnover – through deficient NA signaling 
and its modification on brain perfusion and BBB permeability (figure 3, box 4) – could further 
amplify the deficit in energy supply.  In line with this, apoE4 has been associated with increased 
susceptibility of the BBB to injury (Bell et al., 2012) and decreased glucose metabolism has been 
detected in young healthy APOE e4 carriers (Shaw et al., 2007).  
Intriguingly, several studies using prenatal immune challenges have detected alterations in 
metabolic processes, including increase in food intake and fat deposits, glucose tolerance and 
insulin resistance (Dahlgren et al., 2001, Nilsson et al., 2001, Niklasson et al., 2006, Meyer et al., 
2009, Pacheco-Lopez et al., 2013, Meyer, 2014). 
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Figure 3: Risk factors in AD and how they affect cytoskeletal integrity and axonal transport promoting the 
formation of senile plaques and NFTs. Schematic overview of the main neuronal changes (i.e. increased 
phosphorylation of tau and increased expression of APP) proposed to result in the formation of senile plaques and 
NFTs (Krstic and Knuesel). Box1: Disturbance of axonal transport and its consequences: Motor proteins kinesin 
(anterograde transport) and dynein (retrograde transport) are essential to transport cargo from the soma to synapses 
and vice versa. They are dependent on ATP (the “fuel” for cells) and microtubule (MT) stability, which is assured 
through microtubule stabilizing proteins such as Tau. Tau is continuously phosphorylated (pTau) and 
dephosphorylated. Upon phosphorylation it detaches from microtubules. In pathological condition (AD) this 
equilibrium between pTau and Tau is disturbed resulting in aberrant hyperphosphorylation of Tau, which detaches 
from MT and translocates to somato-dendritic compartments. This results in destabilization and depolymerization of 
MT, impairment in transport and to axonal accumulations of cargo proteins (including APP) and other cellular 
components (such as mitochondria). In addition impaired transport leads to lack of crucial synaptic proteins (e.g. 
neurotransmitters) resulting in impaired synaptic transmission (overview of neuron). Box2: Neuroinflammation: 
Ageing is associated with increased inflammation resulting in increased cytokine levels. In the brain of AD patients 
this activation is increased, resulting in elevated production and secretion of pro-inflammatory cytokines – 
predominantly produced by activated microglia – that can promote APP transcription and stimulate phosphorylation 
of Tau in neurons. Box3: Reelin signaling: One of the major targets of Reelin signaling pathways are the two Tau 
kinases (GSK-3 and CDK5) resulting in their inhibition. MCI and AD patients display decreased levels of Reelin 
in the brain, and could therefore account for decreased inhibition of GSK-3 and CDK5 leading to increased 
phosphorylation of Tau and thereby instability of MT network. NA system: decreased NA detected in AD patients 
could result in: increased levels of pro-inflammatory cytokines due to decreased NA-mediated inhibition of cytokine 
expression in microglia. Further it might contribute to the glucose and energy (ATP) deficiency detected early in the 
disease progression by impaired glycogen turnover in astrocytes, decreased brain perfusion and BBB permeability. 
This bioenergetic deficiency can have major effects on basic cellular processes including axonal transport. Images 
were adapted from www.servier.com.  
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In line with this, PET imaging studies could correlate hypometabolism with increased microglia 
markers in immune-challenged rats (Yokokura et al., 2011).  These findings suggest that long-
term changes induced by prenatal immune challenges prime – next to players of the innate 
immune systems – mechanisms involved in systemic metabolism, rendering it more vulnerable 
to ageing-associated changes and resulting in impaired brain glucose uptake; thereby decreasing 
brain energy supply as detected in AD. 
Taken together, the findings summarized here show how multiple, functionally interconnected 
systems, can drive normal into pathological ageing, in particular upon conditions of chronic 
activation of the immune system. During aging, certain environmental and or genetic 
predispositions might reach a threshold beyond which these systems will synergistically harm 
each other, resulting in the switch from healthy to self-propagating pathological ageing.   
Of all mechanisms discussed above, I have investigated three systems in more detail during my 
PhD (see overview figure 3). First, I focused on the role of ageing-associated Reelin aggregation 
detected in animals and expanded these studies to the analysis of Reelin aggregates in the human 
hippocampal formation. In particular, I wanted to test whether Reelin deposits could be involved 
in AD pathogenesis, as seen for altered Reelin signaling pathway. Second, I have investigated 
the role of NA depletion in the “double hit” mouse model of sporadic AD to evaluate whether 
concomitant alterations of the immune and NA systems are sufficient to potentiate the AD-like 
phenotype seen in wild type mice, allowing to further study specific changes detected in sporadic 
AD. 
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II. AIM OF THE THESIS 
The overall objective of this thesis was to evaluate the potential contribution of the three 
particular systems Reelin, neuroinflammation and the NA system in sporadic AD, using human 
brain tissue and a modified “double hit” model of pre and postnatal immune challenges in wild 
type mice. 
 
Study I Reelin Immunoreactivity in Neuritic Varicosities in the Human Hippocampal 
Formation of Non-Demented Subjects and Alzheimer’s Disease Patients 
 
In this study we aimed to further characterize ageing-associated changes in Reelin, detected in 
rodents and non-human primates, by focusing on Reelin deposits in human cortical tissue. we 
hereby aimed to answer the following questions: 
 Does Reelin in the human hippocampal formation accumulate in aggregates similar to 
those described in other mammals? 
 Do these aggregates have a distribution pattern similar to that detected in animals? 
 What other components are detected in association with Reelin deposits and what could 
be their origin? 
 Does the amount of Reelin deposits correlate with the occurrence of AD? 
To address these questions, we performed immunohistochemistry (IHC) with antibodies against 
Reelin in paraffin-embedded sections containing the hippocampal formation of AD patients and 
age-matched, non-demented individuals combined with unbiased stereological analyses. To 
determine the composition of Reelin aggregates and thereby their putative origin, we performed 
immunoperoxidase staining supplemented by double immunofluorescence staining using various 
antibodies against axonal, synaptic, and glial markers. In parallel to this analysis, we performed 
immunoblotting of cerebrospinal fluid (CSF) of AD patients and age-matched, non-demented 
controls to examine putative alterations in Reelin levels and proteolytic processing. 
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Study II Effects of Acute and Chronic Noradrenergic Axon Depletion in a Wild Type 
Mouse Model of Sporadic Alzheimer’s Disease 
 
Here, we aimed to understand the significance of combining PolyI:C-induced alterations with 
NA depletion, in order to determine whether altered NA signaling, known to occur early in AD, 
might be a driving force for neuropathological changes in animals subjected to pre- and/or 
postnatal immune challenges. we hereby aimed to answer the following questions: 
 Can prenatally evoked long-term changes induced by PolyI:C exposure affect the 
regeneration capacity of NA axons upon axonal depletion by DSP-4? 
 Does chronic NA depletion aggravate AD-like neuropathology in PolyI:C-exposed wild 
type mice during aging? 
To address these questions, we performed IHC and immunoblotting experiments. Due to the 
large number of mice required for this study, we developed a new technique allowing the 
preparation of extracts for immunoblotting from one hemisphere and sections for IHC from the 
other hemisphere, without compromising the quality and sensitivity of either technique. This 
approach allowed me to study both biochemical and histochemical changes within the brain of 
the same mouse, minimizing the number of mice. The technique involves perfusion of 
anesthetized mice with oxygenated artificial CSF (aCSF) to keep brain tissue alive, followed by 
immediate immersion fixation with paraformaldehyde for histology, and homogenization for 
biochemistry (see Appendix, Notter et al., 2014 EJN). This approach enables direct comparison 
of protein distribution within brain sections and semi-quantitative analyses of protein levels 
measured in immunoblotting experiments. 
Two cohorts of mice were prepared to address each of these questions. The first cohort was 
exposed prenatally to PolyI:C and postnatally treated with a single injection of the NA 
neurotoxin DSP-4 to deplete axons from the LC. Regeneration of these axons and putative 
activation of microglia and astrocytes, APP expression/processing and Tau phosphorylation and 
distribution were assessed 3 months later. The second cohort was likewise exposed prenatally to 
PolyI:C, followed by repeated DSP-4 injections every 3 months during 9 months, and a second 
exposure to PolyI:C at 12 months of age. At the age of 15 months, cognitive performance was 
tested behaviorally, brain glucose uptake measured by PET imaging, and histology/biochemistry 
performed to assess the status of the NA system, activation of microglia and astrocytes, and 
alterations in APP expression/processing and Tau phosphorylation and distribution. 
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III. RESULTS 
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Abstract 
Background: Reelin and its downstream signaling members are important modulators of actin 
and microtubule cytoskeleton dynamics, a fundamental prerequisite for proper 
neurodevelopment and adult neuronal functions. Reductions in Reelin levels have been 
suggested to contribute to AD pathophysiology. We have previously reported an age-related 
reduction in Reelin levels and its accumulation in neuritic varicosities along the olfactory-limbic 
tracts, which correlated with cognitive impairments in aged mice. Here, we aimed to investigate 
whether a similar Reelin-associated neuropathology is observed in the aged human hippocampus 
and whether it correlated with dementia status.  
Results: Our immunohistochemical stainings revealed the presence of N- and C-terminus-
containing Reelin fragments in CAm, aging-associated spherical deposits. The density of these 
deposits was increased in the molecular layer of the subiculum of AD compared to non-
demented individuals. Despite the limitation of a small sample size, our evaluation of several 
neuronal and glial markers indicates that the presence of Reelin in CAm might be related to 
aging-associated impairments in neuronal transport leading to accumulation of organelles and 
protein metabolites in neuritic varicosities, as previously suggested by the findings and 
discussions in rodents and primates.  
Conclusion: Our results indicate that aging- and disease-associated changes in Reelin levels and 
proteolytic processing might play a role in the formation of CAm by altering cytoskeletal 
dynamics. However, its presence may also be an indicator of a degenerative state of neuritic 
compartments. 
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Introduction 
The increase in human life expectancy has entailed a pronounced rise in age-associated 
neurodegenerative diseases with the most prominent form being AD, affecting over 26 million 
people worldwide (Brookmeyer et al., 2007). Despite extensive research performed during the 
past, no efficient therapies for this progressive brain disease are currently available. Most of the 
scientific approaches were based on the “amyloid cascade hypothesis” that placed the β- and γ-
secretase-generated Aβ peptides as causal factors of the pathophysiology (Hardy and Higgins, 
1992, Hardy and Selkoe, 2002). While this may hold true for the familial form of AD with its 
dominant mutations in either the amyloid precursor protein (APP, (Van Broeckhoven et al., 
1990, Goate et al., 1991)) or presenilin 1 and 2 (PSEN; (St George-Hyslop et al., 1992, 
Sherrington et al., 1995)) genes, the initiating trigger of the aging-associated, sporadic form of 
AD is still unknown. Based on recent experimental evidence demonstrating that multiple 
exposures to viral-like immune challenges are sufficient to induce AD-like neuropathology in 
aged wild type mice (Krstic et al., 2012a), we were able to identify a crucial trigger and to 
reconstruct the temporal-spatial sequence of pathophysiological changes that characterize the 
earliest disease stages. The integration of experimental data of the last three decades enabled us 
to substantiate and expand our findings to propose a cellular mechanism of the neuropathological 
changes and its progression across interconnected brain areas that characterize sporadic AD 
(Krstic and Knuesel, 2013, Krstic et al., 2013). The new hypothesis highlights the detrimental 
effect of chronic inflammatory conditions on basic cellular functions in long-projection neurons 
of the olfactory-limbic system during aging. The selective vulnerability of these neurons includes 
inflammation-induced impairments in the Reelin-mediated signaling pathway across these 
fundamental neuronal networks (Krstic et al., 2013). By binding to the ApoER2 and the VLDLR 
(Hiesberger et al., 1999, Strasser et al., 2004), the extracellular matrix protein Reelin regulates 
cytoskeletal dynamics essential for migrating neurons (D'Arcangelo et al., 1995, Borrell et al., 
1999), developing neurites (Leemhuis et al., 2010, Meseke et al., 2013) and adult spines (Pujadas 
et al., 2010, Freiman et al., 2011). The signaling pathway involves cytosolic cascades that 
ultimately inhibit the major tau kinases, Glycogen Synthase Kinase 3β (GSK-3β) and Cyclin-
Dependent Kinase 5 (CDK5) (Beffert et al., 2002, Bock et al., 2003, Huang et al., 2005), as well 
as activates the LIM1 kinase and increases n-cofilin phosphorylation (Chai et al., 2009) to 
modulate both the microtubule and actin cytoskeleton, respectively. Engaging the same signaling 
pathway, Reelin also exerts a crucial role at adult synaptic sites by modulating NMDA receptor 
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functions (Weeber et al., 2002, Qiu et al., 2006a, Qiu et al., 2006b, Qiu and Weeber, 2007, Chen 
et al., 2010). Recent experimental evidence further highlighted that Reelin maintains synaptic 
plasticity by competing with ApoE4 to prevent the latter from sequestering NMDA, AMPA, and 
ApoER2 receptors in intracellular compartments (Chen et al., 2010). In line with the well 
described aging-associated synaptic impairments, Reelin expression has been shown to decline in 
aging rodents, correlating with hippocampus-dependent learning and memory performance 
(Knuesel et al., 2009, Stranahan et al., 2011). Furthermore, Reelin accumulates within neuritic 
varicosities in both rodents and non-human primates (Knuesel et al., 2009, Doehner et al., 
2012b), possibly related to the aging associated decrease in Reelin signaling and its protective 
modulation of cytoskeleton dynamics (Krstic et al., 2013). In agreement with these experimental 
data, recent GWAS performed in elderly, non-demented individuals identified three single 
nucleotide polymorphisms (SNPs) in the Reelin gene that significantly correlated with increased 
Tau phosphorylation and concomitant appearance of NFTs (Kramer et al., 2011). Moreover, 
immunohistochemical investigations involving human brains revealed significantly decreased 
levels of Reelin in patients with mild cognitive impairments (MCI) and AD compared to non-
demented subjects (Chin et al., 2007, Herring et al., 2012). Further evidence of altered Reelin-
mediated signaling in AD was provided by genetic (Seripa et al., 2008) and biochemical studies 
(Saez-Valero et al., 2003, Botella-Lopez et al., 2010) suggesting that decreased Reelin 
production may contribute to the initiation and progression of AD by impairing synaptic 
functions, cytoskeleton stability and proper axonal transport. Interestingly, alterations in Reelin 
glycosylation, its proteolytic cleavage and degradation, as well as changes in its mRNA stability 
were shown to be changed in brain homogenates of AD patients (Saez-Valero et al., 2003, 
Botella-Lopez et al., 2010), further highlighting the importance of proper Reelin signaling during 
aging. 
Here, we investigated the localization and levels of Reelin in the postmortem human brain by 
selectively assessing its putative accumulation in neuritic varicosities in non-demented elderly 
and patients with AD by IHC and unbiased stereological analyses. Complementary 
immunoblotting of corresponding CSF samples was performed to examine potential alterations 
in Reelin proteolytic processing. 
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Materials and Methods 
Human Tissue 
Formalin fixed paraffin-embedded hippocampal brain tissue blocks of eight AD patients and 
eight age-matched non-demented individuals were obtained from the Netherland Brain Bank, 
Amsterdam, Netherlands (table 1). Blocks were de- and re-paraffinized with fresh paraffin. 
Serial sections (5 μm) were cut on a sliding microtome with an inter-section interval of 100 μm. 
CSF (obtained postmortem from the lateral ventricles with an 18GA 3.50 inch spinal needle) of 
each subject was thawed and centrifuged at 20’000 rpm for 15 minutes at 4 °C, the supernatant 
aliquoted and stored at −80°C until further use. Quality assessments revealed no blood 
contaminations in the CSF samples. Additional test tissue for qualitative investigations included 
paraffin-embedded sections (cut at 10 μm) from the hippocampus of 6 non-demented and 6 age-
matched AD patients (kindly provided by Professor Manuela Neumann, German Center for 
Neurodegenerative Diseases (DZNE) Tübingen and Institute of Pathology and Neuropathology). 
Antibodies 
The following antibodies were used: mouse monoclonal anti-Reelin recognizing the N-terminus 
(clone G10, MAB 5364, Milipore 1:200 and clone 142, MAB 5366, Milipore 1:200); mouse 
monoclonal anti-Reelin antibodies (C-terminal subrepeats 8A and 8B, 1:200 each, kindly 
provided by Professor André Goffinet, University of Louvain Medical School, Brussels, 
Belgium); rabbit polyclonal anti-amyloid β (1-40/42), (AB5076; Millipore, 1:200); mouse 
monoclonal anti APP-A4, clone 22C11 (MAB348 Millipore, 1:500), mouse monoclonal anti-
PHF Tau (clone AT100, MN1060; Thermo Scientific, 1:1000); polyclonal rabbit anti-Tau pS422 
(44-764G, Invitrogen,1:1000); rabbit polyclonal anti-GFAP (Z0334, DAKO, 1:2500); mouse 
monoclonal anti-GFAP (MAB 360, Millipore, 1:10’000); rabbit polyclonal anti-Iba1 (019–
19741, Wako Pure Chemical, 1:2000); polyclonal rabbit anti-MAP2(26*) (microtubule-
associated protein 2) (AB5622, Chemicon, 1:2000); polyclonal rabbit anti-Synapsin-1 (A-6442, 
Molecular Probes, 1:1000); polyclonal rabbit anti-Synaptophysin (A010, DAKO, 1:500); rabbit 
polyclonal anti-α-Synuclein (ab52168, Abcam, 1:250); mouse monoclonal anti-CD 45 (M0701, 
1:100, kindly provided by Prof. Karl Frei, Department of Neurosurgery, University Hospital 
Zürich, Switzerland). 
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Table 1 Details of human postmortem brain tissue included in the analyses.   
NBB-
Code 
Sex Age 
(years) 
PMD 
(h.min) 
Brain weight
(g) 
Braak 
stages* 
Apoe 
genotype 
Clinicopathological  
data 
pH (csf) [Protein] 
mg/ml 
Controls 
         
07-082§ M 81 7.55 1194 2 0 3/3 Renal insufficiency and 
decompensatio cordis 
6.23 4.6 
00-142 F 82 5.30 1260 1 A 3/2 Myocardial infarct 6.60 3.14 
03-061 F 83 5.30 1274 1 B 3/2 Squamous cell 
carcinoma of the left 
maxilla 
6.48 3.62 
05-083 F 85 5.00 1217 1 B 3/3 Multi organ failure after 
a ruptured abdominal 
aneurysm 
6.72 4.46 
98-157§ M 85 5.13 1383 2 A 3/2 Cardiac tamponade 6.23 2.92 
04-061 F 88 6.15 1121 ? B 3/3 Old age 6.98 2.79 
96-105§ M 88 5.40 1120 4 4/3 Cardiac arrest 6.65 1.4 
96-044§ F 90 5.50 1046 2 A 3/3 unknown 7.00 2.79 
AD          
06-013§ M 81 4.50 1193 4 C 4/4 Dehydration, sepsis? 6.42 3.02 
09-105 F 82 5.25 999 5 C n/a Heart failure 6.08 3.63 
00-138§ F 84 5.15 1098 5 C 3/3 Pneumonia with 
dehydration 
6.65 2.2 
97-093 M 86 5.35 1250 5 C 4/3 CVA/Myocardial 
infarction 
6.39 1.93 
06-044 F 86 5.55 930 4 B 4/3 Cachexia 6.85 1.8 
04-064 F 88 6.25 1079 5 C 3/3 Organ failure due to 
dehydration 
6.60 2.88 
97-003§ M 88 5.10 984 5 B 4/3 Pneumonia 6.45 2.38 
96-049 F 90 3.50 925 5 4/3 Dehydration 7.02 2.81 
 
*According to (Braak and Braak, 1991, 1995).                   PMD = postmortem delay 
§ Tissue blocks containing hippocampus and EC.  
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Immunohistochemistry 
Immunoperoxidase Staining  
Sections were deparaffinized in xylol (3 times for 3 minutes), rehydrated in decreasing ethanol 
concentrations (twice 100%, 96%, 70% and twice dH2O for 3 minutes each) and washed in 50 
mM Tris-saline, pH 7.4 (1xTris). The following antigen retrieval techniques were applied: two 5-
minute citrate buffer microwave irradiations at 800 W (to visualize Reelin-producing cells with 
anti-Reelin 142 antibody, see additional file 1: figure S1), 10-minute citrate buffer microwave 
irradiation at 80°C, either followed by a 10-minute pepsin treatment (Doehner et al., 2010) or 
not, and a 5-minute 95% formic acid (FA) treatment (to visualize Aβ plaques). Furthermore, a 
10-minute 3% H2O2/methanol treatment was used to block endogenous peroxidase reactivity. 
Sections were then incubated for 30 min in blocking solution (1xTris containing 5% normal 
horse serum, 5% normal goat serum, 4% of bovine serum albumin (BSA)), transferred to the 
primary antibody solution (diluted in 1xTris, containing 2.5% normal horse serum, 2.5% normal 
goat serum, 2% BSA) for overnight incubation at 4°C. Sections were washed in 1xTris and 
incubated for 30 minutes with biotinylated secondary antibodies (1:200 in same solution as used 
for primary antibodies). After 3 washes in 1xTris, sections were processed for the 3,3-
diaminobenzidine (DAB; Sigma–Aldrich Inc.) immunoperoxidase using the Avidin-Peroxidase-
Complex (ABC, Vectastain Elite kit) staining techniques as described previously (Hsu et al., 
1981; Loup et al., 1998; Loup et al., 2000). To visualize cell nuclei and CAm, sections were 
counterstained with Harry's Hematoxylin (HHS-128, Sigma-Aldrich; very weak staining of 
CAm) or Ehrlich’s Hematoxylin (100 ml dH2O, 100 ml 96% ethanol, 100 ml glycerol, 10 ml 
glacial acetic acid, 2 g hematoxylin, 3g kalialaun, 0.4g sodium jodate; strongly reacts with CAm 
(MacKenzie, 1993), kindly provided by Charlotte Burger, University of Zurich, Institute for 
Anatomy). In brief, sections were incubated for 2 minutes in the Hematoxylin solution, rinsed in 
tap water, differentiated in acetic alcohol and blued in running tap water for 10 minutes, 
dehydrated and coverslipped with Eukitt (Erne Chemie). Toloidinblue staining was performed 
according to standard protocols. 
Immunofluorescence Staining 
The protocol was identical to the described immunoperoxidase staining with the following 
changes: All washing steps and antibody dilutions were done in phosphate-buffered saline (PBS) 
at pH 7.4. Sections were blocked for 1 hour and incubated for 45 min with the secondary 
antibodies (coupled to either Alexa Fluor488 or Cy3 (dilution 1:1000 and 1:500, respectively; 
Molecular Probes, Invitrogen). To reduce lipofuscin-associated auto-fluorescence in aged cells, 
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sections were incubated in 0.1% Sudan Black (Carl Roth GmbH) dissolved in 70% methanol for 
2 minutes, briefly washed with PBS and air-dried (Schnell et al., 1999). Sections were then 
coverslipped with Dako-DAPI solution (Dako) or ProLong Gold Antifade reagent (Invitrogen) to 
visualize cell nuclei.  
Microscopy and Image Acquisition 
Immunoperoxidase-stained sections were scanned and visualized with an automated upright 
slide-scanning microscope (Zeiss) in brightfield mode and the Pannoramic Viewer 1.8.3.0 (3D 
Histotech Ltd), respectively. High magnification images were acquired with a brightfield light 
microscope (Axioscop 2, Zeiss) connected to a digital camera (AxioCam, Zeiss) and captured 
with AxioVision software (Version 4.5., Zeiss), or with a confocal microscope (LSM 710, Zeiss) 
and processed with Imaris 7.1.1 software (Bitplane Inc.) and Adobe Photoshop CS5 (Adobe) 
software. 
Quantitative and Statistical Analyses 
Stereological estimations of Reelin-positive CAm area and density were performed using the 
Stereo Investigator 10.50 software (Microbrightfield Bioscience). Two sections with an 
intersection distance of 200 μm were used for quantification. The following regions were 
included for the analyses based on the density of the deposits (figure 1): fornix, stratum 
lacunosum moleculare (SLM), layer I of subiculum, layer I of pre/parasubiculum and layer I of 
EC (West and Gundersen, 1990; West and Slomianka, 1998). Other areas of the hippocampal 
formation were not included to minimize measurement errors. The Cavalieri estimator with a 
grid spacing of 100 μm was used to estimate the area of the region of interest. For fractionator 
sampling, an unbiased counting frame sized between 80 and 200 μm (depending on the deposit 
density) was applied to estimate the Reelin-positive CAm profile density. Concomitantly, the 
individual CAm areas were estimated using the nucleator with 4 rays. The area fraction (AF) was 
calculated using the following equation: AF = NCA x ACA/Atot, where NCA is the estimated 
profile number of Reelin-positive CAm within the measured area, ACA is the mean area of CAm 
within the measured area, and Atot is the total area measured. Statistical analysis of the area and 
density of Reelin-positive CAm was performed using StatView software. For each brain region, 
a factorial ANOVA was performed with Group (2 levels: ND and AD) and Deposit type (2 
levels: filled vs hollow) as independent variables, and AF (area fraction), ACA (mean CAm 
size), NCA (estimated number of Reelin-positive CAm) as dependent variables. Pearson’s 
product moment correlations were performed between Reelin-positive CAm (AF, filled and 
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hollow combined) and Western blot data (full-length Reelin, NR2, NR6 and 60 kDa fragments). 
Statistical significance was set at p < 0.05. 
Western Blot Analysis 
Protein concentrations of the CSF samples were measured using NanoDrop (table 1). Equal 
volumes of CSF were analyzed. The sample preparation was performed as previously described 
(Krstic et al., 2012b). Western blotting was done as described (Krstic et al., 2012b) with the 
following adaptations: 3–8% Tris-Acetate Midi Gels were used (NuPAGE Novex Tris-Acetate 
Midi Gel). The electrophoresis was performed using the Xcell4 SureLock Midi-Cell system 
(Cat.No. WR0100, Invitrogen). Proteins were blotted onto PVDF membranes using the Novex 
Semi-Dry Blotter (Cat.No. SD1000, Invitrogen). Films were scanned and analyzed using ImageJ 
Launcher software; intensities of bands were measured (area under the curve (AUC)) and 
quantified. Reelin immunoreactivity was statistically compared between ND and AD subjects 
using the non-parametrical Mann–Whitney U test using StatView software. Statistical 
significance was set at p < 0.05. Scanned films were processed with Adobe Photoshop CS5 for 
visual display (Adobe software). 
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Results 
Reelin Immunoreactivity in the Human Hippocampal Formation 
To analyze the localization and levels of Reelin in the human hippocampal formation we 
performed an immunoperoxidase staining using Reelin antibodies recognizing the N- (G10 and 
142) and C-terminal domains of Reelin (R12/14), to identify putative enrichments in proteolytic 
fragments of Reelin. Paraffin-embedded sections of ND and AD (n = 8, table 1) were employed. 
We detected spherical Reelin-positive structures varying in their size from approximately 60 up 
to 250 μm2 predominantly located in fiber-rich structures (figure 1 and additional file 1: figure 
S1) in both groups of subjects. They were most abundant in the fornix, enriched in myelinated 
axons of afferent and efferent projection neurons. A high density of these immunoreactive 
deposits was also evident in the neuropil of layer I of the pre-/parasubiculum and subiculum. 
Fewer deposits were detected in layer I of the EC and the SLM of the hippocampus (see figure 
1A for overview). In some cases, Reelin deposits were located in the hilus and rarely also in the 
pyramidal layer of CA3 and CA1. The immunoreactive signals were specific for Reelin, since 
control stainings with isotypic immunoglobulins (IgGs) (mouse anti-human CD45) or the 
omission of primary antibodies did not yield any specific labeling (figure 1D-E). The control 
staining using the well-characterized anti-CD45 antibody also indicated that the Reelin-
immunoreactivity was not linked to putative invading lymphocytes. Based on their distinct 
morphology and enrichment in fiber-rich structures, however, we reasoned that they might be 
related to CAm, the age-related spherical bodies suggested to contain a collection of neuronal 
breakdown products including aggregated proteins and abnormal glycogen bodies (Cavanagh, 
1999, Meng et al., 2009). Indeed, hematoxylin (according to Ehrlich) and toloidinblue 
counterstaining identified the Reelin-positive structures as CAm. While all antigen retrieval 
techniques applied here diminished the Hematoxylin or Toloidinblue stainings, the 
immunoreactive anti-Reelin signal associated with CAm was never affected (see methods and 
additional data).  
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Figure 1 Reelin immunoreactivity in the aged human hippocampal formation. A. Reelin (G10 antibody) 
immunoperoxidase labeling in combination with hematoxylin (Ehrlich) counterstaining. The tissue section was 
obtained from an 88 year-old ND individual. The color-coding represents the areas included in the stereological 
analysis: 1 = fornix, 2 = stratum lacunosum moleculare (SLM), 3 = molecular layer of subiculum, 4 = molecular 
layer of pre/parasubiculum, 5 = molecular layer of entorhinal cortex (EC). B. Higher magnification view of Reelin-
positive deposits in the fornix. Arrow points to a filled deposit, arrowhead indicates a hollow deposit. C. Reelin 
(G10) immunoperoxidase labeling combined with toloidinblue counterstaining in the fornix border area. Tissue 
section was obtained from an 80 year-old AD patient. D. Control staining using isogenic IgGs (mouse anti-human 
CD45 antibody) following antigen retrieval (microwave irradiation in citrate buffer plus pepsin pretreatment) and 
Hematoxylin (Harrys) counterstaining. Brain section was obtained from a 79 year-old ND individual. Arrowhead 
points to a CD45-negative deposit, insert represents a CD45-positive lymphocyte associated with a brain capillary. 
E) Control staining without primary antibody following antigen retrieval and Hematoxylin/Eosin counterstaining. 
Brain section was obtained from an 81 year-old ND individual. Arrowhead points to an immune-negative deposit. 
Scale bars: A = 2 mm, B - D = 30 μm. 
 
 
Reelin-Positive Deposits in AD versus Non-Demented Subjects 
With our staining protocol, we were able to identify two different types of Reelin-positive CAm: 
1) A filled type; with the entire area of CAm being Reelin immunoreactive (figure 1B arrow), 
and 2) a hollow type; with Reelin immunoreactivity being located around the acidic core of CAm 
(figure 1B arrowhead). Here, we were interested to determine whether their density differed 
between ND and AD subjects. We performed a stereological analysis within selected areas of the 
hippocampal formation (figure 1). The statistical evaluation of AF using a one-way ANOVA 
revealed a significant increase in the area covered by the deposits in AD patients compared to 
ND controls in the molecular layer of the subiculum (F(1,28) = 4.31, p = 0.047). A similar 
elevation in deposit area in AD versus NA subjects was seen in the pre/parasubiculum, however, 
the ANOVA only yielded a statistical trend (F(1,26) = 3.21, p = 0.085; figure 2C). No statistical 
group difference regarding the density of Reelin/CAm was evident in the other brain areas (all F 
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< 0.93, all p > 0.36). The statistical analysis, however, revealed a significantly higher density of 
the filled compared to the hollow type in all areas investigated (fornix: F(1,26) = 11.47, p = 0.002; 
SLM: F(1,28) = 14.34, p = 0.001; subiculum: F(1,28) = 15.52, p = 0.001; pre/parasubiculum: F(1,26) = 
13.52, p = 0.001; EC: F(1,10) = 20.95, p = 0.001), that was independent of the dementia status 
(figure 2). Despite this dominance of filled deposits, the significant increase in total amount of 
deposits in the subiculum molecular layer in AD was not solely attributed to filled deposits 
(ANOVA: group x type interaction: F(1,28) = 2.00, p = 0.168) but related to a concomitant 
increase in both types of deposits. 
 
Figure 2 Summary of stereological analyses of Reelin-positive deposits in ND versus AD individuals. A-E. 
Scatter plots of the estimated density of filled and hollow deposits in different areas in the human hippocampus 
representing the % area covered by Reelin deposits in relation to the total region of interest (AF, area fraction). 
Horizontal lines represent group average. Statistical analysis yielded a significant group effect for the subiculum 
(F(1.28) = 4.312, p = 0.047), and showed a similar trend for the pre/parasubiculum (F(1,26) = 3.21, p = 0.085). Note that 
4 out of 8 ND and 5 out of 8 AD hippocampi blocks were dissected at a level where no EC was present. F. 
Overview of estimated filled and hollow deposit densities across the five brain areas analyzed. Values are displayed 
in box plot graphs, with the box dimension indicating the 75th (top) and 25th percentile (bottom) and the mean line. 
The upper and lower error bars indicate the minimum and maximum, respectively. One way ANOVA analysis 
revealed a significant main effect of deposit type in all areas analyzed that was independent of the dementia status: 
1) fornix: F(1,26) = 11.45, p = 0.002; 2) SLM: F(1,28) = 14.34, p = 0.001; 3) subiculum: F(1,28) = 15.52, p = 0.001; 4) 
pre/parasubiculum: F(1,26) = 13.52, p = 0.001; 5) entorhinal cortex: F(1,10) = 20.95, p = 0.001, statistical significance 
was set at p < 0.05.  
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Reelin Levels in the Human Cerebral Spinal Fluid 
To assess whether the immunohistochemical findings correlate with the levels of Reelin and its 
physiologically produced proteolytic fragments in the CSF, previously investigated in AD and 
ND subjects but yielding conflicting results (Botella-Lopez et al., 2006; Ignatova et al., 2004; 
Saez-Valero et al., 2003), we performed a biochemical analysis of the CSF samples collected for 
each individual of our study. Besides the well-described immunoreactive bands representing full-
length Reelin, the NR6 (310 kDa) and NR2 (180 kDa) fragments, we detected an additional band 
running at around 60 kDa. This recently described novel N-terminal Reelin fragment (Krstic et 
al., 2012b) likely represents the ADAMTS-5-mediated degradation product of Reelin (figure 3A) 
that is enriched in aged brain tissue homogenates (Krstic et al., 2012b) and detected upon 
internalization (TN, unpublished findings). Semi-quantitative analysis of two repeated 
experiments revealed high between-subjects variability and no significant differences regarding 
the levels of Reelin and the three proteolytic fragments emerged between AD and ND subjects 
(figure 3B). 
 
Figure 3 Reelin levels in the CSF. A. Anti-Reelin 142 immunoreactive signals on Western blots at low exposure 
time (40 seconds) to visualize the NR2 fragment. A’) Higher exposure time (18 minutes) of the same blot as A to 
visualize full-length (~460 kDa), NR6 (~ 310 kDa) and the additional band at ~ 60 kD. Images of immunoblots were 
cut in half to separate ND from AD for visual display. The short vertical lines at the bottom of the blot indicate 
joined bands for visual presentation. The HiMark Pre-Stained Standard was used as ladder. B. Semi-quantitative 
analysis of the levels of full-length Reelin and its proteolytic fragments in the CNS. Scatter plots representing 
relative optical densities expressed in arbitrary units (arb. unit) of CSF samples obtained from ND and AD 
individuals. Lines represent the group median. Mann–Whitney U-test revealed no significant differences between 
groups. 
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However, despite the unknown causal link and the limitations of our sample size, a correlation 
analyses highlighted a significant relationship between the levels of the 60kDa fragment and the 
overall CAm density in subiculum and pre/parasubiculum in ND subjects (subiculum: r = 0.857, 
p = 0.004; pre/parasubiculum: r = 0.845, p = 0.006) that was lost in AD patient (subiculum: r = 
0.098, p = 0.826: pre/parasubiculum: r = 0.275, p = 0.529), pointing to putative alterations in 
Reelin proteolytic degradation in AD. None of the other parameters (subfields, Reelin fragments) 
yielded any significant relationships and no confounding effect of the postmortem interval, pH, 
brain size or ApoE genotype contributed to this effect. 
Levels of AD-Relevant Proteins in Reelin-Positive CAm 
Based on the Reelin-dependent modulation of several AD-relevant pathways, including APP 
proteolytic processing (Kocherhans et al., 2010; Rice et al., 2013) and Tau phosphorylation 
(Kocherhans et al., 2010; Krstic et al., 2012a), we were interested in determining whether these 
and other disease-associated proteins were present in the aging-associated Reelin-CAm deposits. 
Double-immunofluorescence stainings using antibodies raised against the N-terminal domain of 
APP and β−amyloid sequence 1-40/42 (Aβ1–40/42) or anti-Aβ1–40/42 in combination with anti-
Reelin antibodies revealed their co-localization in most CAm in all areas independent of disease 
state (figure 4A). However, the intensity varied depending on the antigen retrieval technique 
used, in line with previous reports using paraffin-embedded postmortem human brain samples 
(Lucassen et al., 1993; Shi et al., 1991). For both, N-terminal APP and Aβ1–40/42 antibodies the 
antigen retrieval methods applied here either strongly decreased the staining intensity (citrate 
irradiation and pepsin treatment) or completely diminished it (95% FA; additional figure 2) in 
comparison to non-pretreated sections, suggesting the presence of soluble APP and/or APP 
fragments rather than Aβ aggregates. Double immunofluorescence stainings using anti-Tau, 
pTau or PHF in combination with anti-Reelin antibodies revealed the presence of Tau, however, 
no enrichment in pTau species in Reelin-positive CAm (figure 4, Additional file 2: figure S2). 
To confirm and further investigate their origin, we performed double-immunofluorescence 
staining using additional antibodies recognizing synaptic, axonal and dendritic proteins. In 
accordance with previous findings α-Synuclein (Wilhelmus et al., 2011), our double-
immunofluorescence staining confirmed the presence of α-Synuclein in Reelin-positive CAm. As 
with the Aβ1–40/42 antibodies, the signal intensity dropped upon antigen retrieval technique 
(additional figure 2). 
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Figure 4 AD-relevant proteins are present in CAm. Representative images of double immunofluorescence 
labeling involving brain sections obtained from an 82 year-old ND individual counterstained with the nuclear dye 
DAPI (blue). Red channels show the anti-Reelin (antibody 142; A, C, D, E), anti-N-APP (B), and anti-PHF Tau 
(paired helical filament, F) stainings. Green channels depict the anti-Aβ1–40/42 (A’-B’), anti-α-Synuclein (C’, F’), anti 
Tau (D’) and anti-pTau (E’) signals. Merged channels are shown in A”-F”. Inserts in E’ and F highlight NFT in 
CA1 region stained with anti-pTau and anti-PHF Tau antibodies, respectively. Scale bars = 10 μm. 
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However, anti-Synapsin-1 and anti-Synaptophysin stainings did not show a positive signal of 
these two abundant synaptic proteins within CAm (figure 5). On the other hand, the dendritic 
marker, MAP2, was detected in CAm using immunoperoxidase staining (figure 5), confirming a 
neuronal origin and indicating that CAm may originate from both dendritic and axonal 
compartments. Based on previous findings reporting an association of CAm with astroglia 
(Cavanagh, 1999), we were interested in determining whether Reelin-positive CAm show a 
similar relationship to glial cells. To this end we performed an immunhistochemical analysis 
using antibodies against glial fibrillary acidic proteins (GFAP) to stain astrocytes as well as an 
anti-Iba1 antibody to label microglia.  
 
Figure 5 Dendritic and synaptic proteins in the aged human hippocampus: Differential association with 
CAm. Immunoperoxidase-hematoxylin staining of brain sections obtained from an 85 year-old ND individual. A. 
Representative images of the CA2 subfield and fornix (A’) labeled with the dendritic cytoskeletal marker anti-
MAP2. Note the strong immunoreactivity in pyramidal cell bodies and dendrites, as well as CAm (A’). B-C. 
Immunoperoxidase staining using anti-Synapsin-1 (B) and anti-Synaptophysin antibodies (C) depicting the CA2 
pyramidal cell layer (B, C), the dentate gyrus molecular layer (B’, C’) and the fornix (B”, C”). While a characteristic 
synaptic immunoreactivity of both markers was evident in the hippocampus proper and dentate gyrus, no 
accumulation of these synaptic proteins was seen in CAm. Scale bars: A-C = 30 μm, A’-C’ = 30 μm. 
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As reported, the GFAP immunoreactivity was highest in all fiber-rich structures, as well as 
prominent in glial endfeet enclosing the cerebral vasculature vessels and ventricle walls (figure 
6). In areas with high labeling, GFAP immunoreactivity was found in association with CAm. 
However, the glial marker was found to be restricted to the border of deposits, but was not 
associated with any of the other markers that were enriched in CAm, such as APP, Aβ or α-
Synuclein. No co-association of Iba1 with CAm was obtained by either immunoperoxidase or -
fluorescence stainings. Rather, the staining intensity was homogenous across all areas, indicating 
that these aging-associated neuronal structures are inert and do not provoke a microglia 
activation. 
 
 
Figure 6 Association of astrocytes but not microglia with Reelin/CAm deposits. Immunohistochemical analyses 
involving brain sections obtained from an 82 year-old ND individual. A. Representative image of the fornix labeled 
with anti-GFAP antibodies and hematoxylin (Ehrlich) staining. Note the GFAP immunoreactivity enclosing the 
CAm in the dense glial network. Insert represents a Reelin/CAm deposit in an area with low GFAP intensity. B. 
Double immunofluorescence staining with anti-Reelin antibody (142, red, B’) and anti-GFAP antibody (green, B”). 
Nuclei are visualized with DAPI-enriched mounting medium. C. Immunoperoxidase staining using anti-Iba1 
antibody and hematoxylin (Ehrlich) counterstaining. The pretreatment of the tissue sections with 10 minute citrate 
irradiation completely diminishes the CAm labeling (arrowhead). D. Double immunofluorescence staining using 
anti-Reelin antibody (142, red, D’) and anti-Iba1 antibody (green, D”). Scale bars: A, C = 30 μm; B, D = 10 μm. 
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Discussion 
Here we describe for the first time the presence of the extracellular matrix protein Reelin within 
spherical depositions in the human hippocampal formation. Our immunohistochemical stainings 
revealed the presence of considerable amounts of N- and C-terminus-containing Reelin 
fragments in these deposits. Stereological analyses indicated that their density in the 
hippocampal formation is largely independent of the dementia status; however, it revealed a 
trend towards higher levels in patients with AD and a putative link to alterations in Reelin 
proteolytic processing. Based on hematoxylin and toluidinblue labeling and their distinct 
morphology, it is highly conceivable that Reelin and its fragments constitute a major component 
of CAm, a prominent structure of the aging human brain whose origin and biological 
significance in the CNS is poorly understood. In the following, we summarize the current status 
of the CAm literature and discuss the presence and putative role of Reelin in their formation in 
the human hippocampal formation. 
Aging-Associated CAm in the Human Hippocampal Formation 
Despite the numerous studies, the role of CAm during aging and neurological diseases has 
remained obscure. They are commonly seen in the glial feltwork of subpial, subependymal, and 
perivascular regions, but can also be detected in fiber-rich areas in the CNS, most prominently 
within the hippocampal formation (Cavanagh, 1999). The major components of CAm are 
glucose polymers, presumably linked to aging associated glucose metabolism defects, peptides 
and proteins (approximately 4%), many of which have been linked to cellular stress responses 
(Cisse et al., 1991; Selmaj et al., 2008; Wilhelmus et al., 2011). Several studies indicated that 
they evolve from neurons, astrocytes or oligodendrocytes due to the presence of cell-specific 
proteins (Buervenich et al., 2001; Cavanagh, 1999; Meng et al., 2009; Singhrao et al., 1994). 
However, it is currently unclear whether their glial association is the result of phagocytosis of 
remnants of degenerated neurons/neurites and vascular metabolites (Meng et al., 2009; Singhrao 
et al., 1995) or an indicator of glia pathophysiology/degeneration (Suzuki et al., 2012). In line 
with these data, neurological and neurodegenerative diseases such as temporal lobe epilepsy, 
multiple sclerosis, and AD are characterized by elevated levels CAm (Singhrao et al., 1995; Van 
Paesschen et al., 1997), and these spherical bodies were shown to correlate with neuronal loss 
associated with hippocampal sclerosis (Van Paesschen et al., 1997). The frequent detection of 
CAm within axons and terminal neurites in the aging ocular system (Rejdak et al., 2011), as well 
Results Study I: Discussion 
46 
as the prominent accumulation of axonal proteins including Tau (Loeffler et al., 1993; 
Wilhelmus et al., 2011), APP (Tate-Ostroff et al., 1989), and α-Synuclein (Wilhelmus et al., 
2011), indicate that they may form in response to cellular stress and/or aging-related impairments 
in cytoskeletal stability and axonal transport that ultimately lead to axonal swellings, a 
mechanism recently proposed for amyloid plaque formation in AD (Krstic and Knuesel, 2013). 
Reelin Accumulates in Two Types of CAm – Link to Its Expression Pattern? 
Intriguingly, many of the areas enriched in CAm overlap with the localization of Reelin. This 
relates to the well characterized cell types in the murine brain that are part of the entorhino-
hippocampal, lateral olfactory and retino-collicular tract as well as the parallel fiber system of 
the cerebellum (Alcantara et al., 1998; Martinez-Cerdeno and Clasca, 2002; Martinez-Cerdeno et 
al., 2003; Pesold et al., 1998; Ramos-Moreno et al., 2006). Furthermore, in vitro studies reported 
the expression of Reelin in progenitor cells of oligodendrocytes as well as mature 
oligodendrocytes (Siebert and Osterhout, 2011), highlighting the possibility that the Reelin 
immunoreactivity associated with CAm in fiber-rich areas like the fornix may stem from its 
production and secretion by progenitors of oligodendrocytes and oligodendrocytes (Siebert and 
Osterhout, 2011). Studies in primates identified additional areas with Reelin-positive cells 
showing a wider distribution of Reelin throughout cortical areas than in any other species, 
indicating that Reelin influences most cerebral circuits in higher mammals (Martinez-Cerdeno et 
al., 2002). Findings in macaque monkeys showed strong Reelin immunoreactive soma of Cajal-
Retzius cells located in layer I, pyramidal neurons in EC layer II, and interneurons of the 
subicular complex molecular layer (subiculum, pre/parasubiculum), areas which harbor 
considerable amounts of Reelin-positive CAm. It is conceivable that these cells, shown to 
degenerate during preclinical stages of AD (Baloyannis, 2005; Kordower et al., 2001; Price et 
al., 2001) are a major source of Reelin that is detected within CAm. In line with the findings that 
Reelin is transported along axons and secreted to act on postsynaptic cells (Martinez-Cerdeno et 
al., 2003; Pesold et al., 1998; Ramos-Moreno et al., 2006), the deposits located in the SLM, the 
projection zone of the layer II pyramidal cells, are most likely distal axonal accumulations of 
Reelin. It is conceivable that aging-associated impairments of axonal stability and hence axonal 
transport increase the likelihood of accumulations of transported proteins and organelles. This 
may aggravate during phases of cellular stress that is frequently accompanied by increased levels 
in damaged and misfolded proteins, which show a much higher propensity to aggregate (for 
recent review, see (Krstic and Knuesel, 2013)). It is therefore plausible, that the decrease in 
Reelin levels during aging (Chin et al., 2007; Herring et al., 2012; Knuesel et al., 2009) with its 
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concomitant in- and decrease in Tau (Hiesberger et al., 1999; Kocherhans et al., 2010) and n-
cofilin phosphorylation (Chai et al., 2009), respectively, may reduce axonal and dendritic 
cytoskeletal stabilities and strongly impair transport from and to synaptic sites. In agreement 
with this hypothesis, our data showed that highly abundant and cellular stress-induced/associated 
axonal proteins such as APP and α-Synuclein co-accumulate with Reelin in CAm. Our findings 
that the FA pretreatment (used to detect Aβ peptides in amyloid plaques) abolished the anti-Aβ1–
40/42 immunoreactivity in CAm indicates that soluble APP and/or APP fragments, rather than Aβ 
peptide aggregates, accumulate in CAm, which is in line with previous reports (Tate-Ostroff et 
al., 1989). The presence of MAP2 in CAm may be indicative of dendritic varicosities or related 
to missorting of this dendritic cytoskeletal protein into axonal compartments. In support of a 
putative protein mistargeting, we did not find evidence of pTau species in Reelin-positive CAm, 
a result that is also in agreement with previous studies (Loeffler et al., 1993; Wilhelmus et al., 
2011). This phenomenon may also be linked to potential dephosphorylation of Tau in the 
putative acidic (Krstic et al., 2012a) and/or protein cross-linking and polymerization 
environment (Wilhelmus et al., 2011), a potential scenario that would also explain the lack of 
Synapsin-1 and Synaptophysin immunoreactivity in CAm. It is further conceivable that the 
change in glucose metabolism – potentially linked to aging-related alterations in glial support – 
promote the formation of abnormal polysaccharide chains that further block axonal transport. 
The presence of Reelin in the filled type of CAm could be indicative of such an axonal 
pathophysiology as previously suggested by the findings and discussions in rodents and primates 
(Doehner et al., 2012; Fiala et al., 2007; Krstic and Knuesel, 2013). However, the detection of 
Reelin in the hollow type shows that the core of CAm can be formed independently of Reelin 
and could indicate that this rare type of spheroid might be linked to the accumulation of Reelin in 
astrocytic endfeet (Doehner et al., 2010). This is in agreement with the findings shown here and 
by others that GFAP-positive astrocytes are associated with but not found in the core of CAm 
(Singhrao et al., 1994). This hypothesis is also in line with our previous findings, demonstrating 
with 3D-electron microscopy that Reelin-positive varicosities can be extruded from neurites and 
detected in astrocytic endfeet, potentially related to phagocytosis (Doehner et al., 2012). The lack 
of CAm-associated microglia activation reported here is also indicative that these spherical 
bodies are inert, despite the presence of putative toxic peptides, proteins and cellular metabolites 
(Singhrao et al., 1995). The distinct association of Reelin at the boarder of CAm – particularly 
prominent in the hollow type - may be linked to its extracellular secretion and accumulation 
around CAm that precludes a microglia response. Altogether, this may explain why CAm – 
despite their close association with aging-associated neurodegenerative processes linked to 
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impairments in glucose metabolism, protein synthesis, transport and degradation – have no major 
effects on the physiology of neighboring neurons. It would be highly relevant to assess the levels 
of Reelin associated with CAm localized outside the hippocampal formation (i.e. hypothalamic 
nuclei), which have been reported to display pronounced cytoskeletal alterations during the 
course of aging and AD (Swaab et al., 1993). 
Reelin Levels and Deposits in AD Compared to ND Individuals 
Previous reports indicated that several neurological and neurodegenerative conditions are 
accompanied by an increase in CAm, potentially linked to higher levels of cellular stress. 
However, quantitative data are largely missing. Here, we intended to assess the density of 
Reelin-positive CAm with an unbiased stereological approach involving five distinct areas of the 
hippocampal formation, complemented with immunoblot analyses to measure the Reelin levels 
in CSF samples of the same ND and AD individuals. Our stereological analysis revealed that the 
total amount of Reelin-positive CAm – independent of the type of deposit - was found to be 
increased in the subicular complex of AD compared to ND individuals. However, due to the 
small cohort and the high between subject-variability, only the density in the subiculum 
molecular layer yielded a significant group effect. Despite the limitation due to the small sample 
size, our data indicate the increase in CAm density may reflect the aggravation the aging-related 
impairments in cellular functions that result in increased intracellular accumulation of missorted, 
misfolded or poorly degraded proteins which is known to be increased in AD (Krstic and 
Knuesel, 2013). It is very likely that putative differences in other areas measured were covered 
by an aging effect, as there is a clear age-dependent increase in the number of CAm (Cavanagh, 
1999). Currently, it is unknown how these histopathological changes relate to the level of Reelin 
protein and its proteolytic products in the CSF. While our assessment of full-length Reelin and 
its proteolytic fragments in the CSF revealed no statistical differences between groups, a 
correlation analyses highlighted a significant relationship between the levels of the 60kDa 
fragment and the overall CAm density in the susubiculum and pre/parasubiculum in ND subjects 
but not AD patients. While a higher sample size is absolutely required to substantiate this 
finding, the preliminary data indicate that the accumulation of Reelin in CAm might be related to 
its proteolytic degradation, a phenomenon that appears to be altered in AD versus ND subjects. It 
will also be highly relevant to assess Reelin levels in CSF and brain tissue homogenates in 
younger cohorts of ND subjects, as well as MCI and early stages of AD, which is expected to 
show larger differences to age-matched ND individuals. Differences in the age range of the 
subjects included in previous studies may have also accounted for the conflicting results  
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regarding the levels of Reelin and its fragments in the CSF published earlier (Botella-Lopez et 
al., 2006; Ignatova et al., 2004; Saez-Valero et al., 2003). It would be therefore highly relevant to 
investigate the levels of Reelin and all its proteolytic fragments (including the 60 kDa product) 
and its putative enrichment in neuritic varicosities in a substantially larger cohort of human 
subjects across aging and AD. 
Conclusion 
Altogether, our results indicate that aging- and disease-associated changes in Reelin levels and 
proteolytic processing might play a role in the formation of CAm by altering cytoskeletal 
dynamics. Its presence may also be an indicator of a degenerative state of neuritic compartments. 
However, this remains to be experimentally determined using preclinical models of aging and 
AD. 
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Additional Files 
Additional Text 
We detected the Reelin-positive deposits using various antibodies raised against different Reelin 
epitopes (Additional file 1: figure S1A-C). Reelin deposits were stained with all antibodies used, 
independently of the antigen retrieval technique. To visualize CAm with hematoxylin or 
toloidinblue, antigen retrieval was omitted in order to maintain the coloration. figure 1E 
illustrates the high morphological variations in Reelin/CAm deposits. Besides the prominent 
staining of Reelin within deposits, we also detected intracellular Reelin immunoreactivity in 
pyramidal cells of the cornu ammonis, particularly in CA3 and to lesser extent CA1 pyramidal 
cells, using N-terminal but not C-terminal targeting antibodies (Additional file 1: figure S1F), in 
line with a previous report (Kramer et al., 2011). These immunoreactive signals were, however, 
only seen using an antigen retrieval approach involving microwave irradiation in citrate buffer 
followed by pepsin pretreatment (see material and methods). Chromatin filters and high 
magnification microscopy revealed Reelin to be present within cytosolic vesicles (insert, 
Additional file 1: figure S1F). To visualize Reelin-expressing cells, which were sparse in our 
cohort of aged non-demented individuals and shown to further decrease in AD patients (Chin et 
al., 2007; Deguchi et al., 2003), repeated microwave irradiation in citrate buffer had to be applied 
(Additional file 1: figure S1C, insert). 
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Additional 1: Figure S1 Immunoperoxidase stainings of paraffin-embedded hippocampal brain sections. A. 
Anti-Reelin immunoreactivity (G10 antibody) in tissue section obtained from a 63 year-old ND individual following 
antigen retrieval with microwave irradiation in citrate buffer and pepsin pretreatment. B. Brain sections of an 89 
year-old AD patient, processed for antigen retrieval (citrate and pepsin pretreatment), stained with anti-Reelin (142) 
antibodies. C. Anti-Reelin (142 antibody) immunoperoxidase and hematoxylin staining of tissue section obtained 
from an 88 year-old ND individual following repeated microwave irradiation in citrate buffer. Insert shows a Reelin-
expressing cell located in SLM. D. Reelin immunoreactivity (R12/14 antibodies) in tissue section of a ND individual 
(63 years old) pretreated with citrate and pepsin. E. Morphological variations of Reelin-positive deposits located in 
five brain regions included in the stereological analysis. Representative pictures of immunoperoxidase staining using 
anti-Reelin antibody (G10) combined with microwave irradiation in citrate buffer and pepsin pretreatments. F. 
Reelin immunoreactivity in pyramidal cells of AD patient (80 years old) visualized with anti-Reelin antibody (G10) 
following citrate/pepsin pretreatments. G. Reelin immunoreactivity (R12/14 antibodies) in tissue section of an AD 
individual (78 years old) pretreated with citrate and pepsin. Arrowheads point to cytosolic vesicles with 
immunopositive Reelin labeling. Scale bars: A-D, F =30 μm; E = 25 μm.  
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Additional 2: Figure S2 Antigen retrieval and its effect on staining intensities of AD-relevant proteins in 
CAm. Representative images of immunofluorescence staining involving brain sections obtained from a ND 
individual (82 years old) counterstained with the nuclear dye DAPI (blue). Antigen retrieval involved either 
microwave irradiation in citrate buffer followed by pepsin incubation (A-B) or a 95% formic acid (FA) pretreatment 
(C). A. Double labeling using anti-α-Synuclein (red, A) and anti-Reelin (G10, green, A’) antibodies, merged in A”. 
B. Anti-Aβ1–40/42 antibody (red, B) combined with anti-Reelin antibodies (G10, green, B’) show a large degree of 
overlap (B”, merged). C. Double immunofluorescence staining using anti-pTau (red, C) and anti-Aβ1–40/42 antibodies 
(green, C’). Note that the FA treatment destroys the anti-Aβ1–40/42 signal in the CAm but not in amyloid deposits 
(arrowhead). The pixel brightness is increased in the merged channels to visualize the presence of the 
immunonegative deposits (C”). Scale bars = 10 μm. 
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Abstract 
The LC is one of the first structures affected in AD. It consists of long projecting NA neurons 
innervating the entire neuraxis. Noradrenaline (NA) is known to play a role in inflammatory 
responses, regulation of neurovascular coupling and energy metabolism, as well as to contribute 
to attention and cognitive processing. The early impairment of NA signaling could, therefore, be 
a key player shifting normal to pathological ageing. Recently we have shown that combined 
prenatal and postnatal systemic immune challenges (“double hit” model) induced with the viral 
mimic PolyI:C evokes an AD-like pathology in aged wild type mice (Krstic et al., 2012a). Here, 
we aimed to evaluate the role of NA signaling in pathological mechanisms involved in sporadic 
AD by combining the PolyI:C model (single or double immune challenges) with DSP-4 
treatment, a drug which selectively targets LC axons and causes widespread NA denervation in 
the CNS and subsequent degeneration of LC neurons. Specifically, we aimed to determine 
whether a prenatal inflammatory insult during late gestation affected the regeneration capacity of 
LC neurons at both young and advanced age. Further, we evaluated whether the AD-related 
phenotype detected in the double hit PolyI:C model was exacerbated by the loss of NA 
innervation, using histological, biochemical, behavioral and PET imaging  approaches. 
Prenatal PolyI:C-exposed mice were treated with DSP-4 at the age of 3 months and analyzed 3 
months later. They exhibited a significant decrease in NA axon density in the primary visual 
cortex (V1) and CA1 area of the hippocampus, indicative of impaired regeneration, but no 
change in LC neuron survival. The combined treatments did not exacerbate inflammatory 
responses induced by the prenatal immune challenge and, therefore, did not result in detectable 
microgliosis or astrogliosis. A second cohort of mice prenatally exposed to PolyI:C was 
repeatedly treated with DSP-4 until 12 months of age and received a second PolyI:C exposure 
(i.v.). They were tested behaviorally at 16 months, subjected to PET imaging to assess cerebral 
glucose uptake, followed by postmortem histological and biochemical analyses. Unexpectedly, 
double PolyI:C exposure did not evoke a strong inflammatory response as reported previously 
using a similar protocol (Krstic et al., 2012a). In accordance, we did not observe AD-like 
changes in these double immune-challenged mice, which served as a “control” towards the 
“double hit” model previously described. Chronic NA axonal depletion had no additional effects 
on APP expression and proteolytic processing, Tau phosphorylation, expression of inflammatory 
markers in microglia, and glucose uptake.  However, prenatal immune-challenged mice exhibited 
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at 16 months of age a mild deficit in non-spatial short-term memory, a well characterized 
phenotype in this model. 
These results indicate that prenatal PolyI:C exposure induces a persistent deficit in the 
regenerating capacity of NA axons in young adult mice. However, NA depletion does not 
accelerate AD-related changes in aged mice in which the prenatal immune challenge failed to 
induce a chronic pro-inflammatory state. 
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Introduction 
AD is characterized by severe, progressive loss of cognitive functions, extensive 
neurodegeneration, neuroinflammation, and the appearance of amyloid plaques and NFTs. 
Ageing is considered to be the main risk factor of sporadic AD. The pathophysiological 
mechanisms underlying this form of the disease, in particular the early changes that shift normal 
to pathological ageing are yet poorly understood. 
One of the first brain structures to be affected in AD is the LC, a brainstem nucleus that harbors 
long-projecting NA neurons innervating the entire neuraxis (Grudzien et al., 2007, Braak et al., 
2011, Braak and Del Tredici, 2012). A general decrease in NA levels in the brain of AD patients 
is detected, as a consequence of early neurodegeneration of the LC (Tomlinson et al., 1981, 
Iversen et al., 1983, Bondareff et al., 1987, Chan-Palay and Asan, 1989, German et al., 1992) and 
likely due to increased NA metabolism in its remaining cells (Hoogendijk et al., 1999). 
The NA system regulates numerous neuronal processes that might contribute to the 
ethiopathology of AD, including attention, arousal, and cognitive processing (Berridge and 
Waterhouse, 2003, Rinaman, 2011). Adrenergic receptor activation was shown to potentiate 
glutamate buffering and potassium clearance, both assuring proper synaptic signaling during 
phases of high neuronal firing (Pesce et al., 2003, Hayes et al., 2004). NA was further associated 
with a regulatory function in brain energy supply by its modulatory effect on different levels, 
including brain perfusion (Toussay et al., 2013), BBB permeability (Raichle et al., 1975, Borges 
et al., 1994, Sarmento et al., 1994) and astrocytic glycogenesis and glycogenolysis (Sorg and 
Magistretti, 1992). NA signaling also regulates inflammatory processes, as evidenced by reduced 
production of pro-inflammatory cytokines by microglia as well as stimulation of their migration 
and phagocytosis (Heneka et al., 2010, O'Donnell et al., 2012). The alkylating agent DSP-4 is an 
experimental tool to deplete NA innervation in the CNS, and thereby study its function (Jonsson 
et al., 1981). A single intraperitoneal injection (i.p.) of 50 mg/kg DSP4 induces profound axonal 
degeneration, followed by partial regeneration, selectively of LC neurons (Fritschy and Grzanna, 
1992). Several studies performed in transgenic AD mice have reported that DSP-4 treatment 
potentiates AD-like neuropathology, including increased neuroinflammation, A plaque 
formation, synaptic loss, impaired glucose uptake, as well as cognitive impairments (Heneka et 
al., 2006, Kalinin et al., 2007, Pugh et al., 2007, Jardanhazi-Kurutz et al., 2010, Rey et al., 2012, 
Hammerschmidt et al., 2013). 
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Our group has recently shown that major signs of AD-like pathology, including age-dependent 
increase in APP expression and Tau phosphorylation, occur in wild type mice subjected to a 
prenatal immune challenge during late gestation – induced by treating pregnant dams with the 
viral mimic PolyI:C. A 2nd PolyI:C injection at the age of 12 months (so-called “double hit” 
model) leads to further increases in APP levels and results in APP-positive plaques, increase in 
PHFs and somatodendritic shift of pTau, and activation of both microglia and astrocytes (Krstic 
et al., 2012a). Prenatal PolyI:C exposure at GD17 also causes selective cognitive deficits in non-
spatial short-term memory (Krstic et al., 2012a), which might be linked to increased levels of 
APP, known to impair cognitive performance in transgenic mice (Simon et al., 2009). These 
features suggested that the “double hit” model might be useful to investigate the mechanisms of 
sporadic AD (Krstic and Knuesel, 2013). 
In the present study, we combined the “double hit” model with DSP-4 treatment to address the 
following specific aims: 1) Do inflammatory mechanisms, triggered PolyI:C-induced immune 
challenge, affect the regeneration capacity of NA axons?  2) Does chronic NA depletion 
aggravate AD-like neuropathology in PolyI:C-exposed wild type mice during aging, thereby 
providing potential clues for the significance of alterations in the central NA system detected in 
AD patients? 
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Materials and Methods 
Animals 
All animal experiments were carried out in accordance with Swiss law on animal 
experimentation and approved by the cantonal veterinary office of Zurich. 
Experiments were performed with time-pregnant C57Bl6/JOla mice purchased from Harlan 
Laboratories (Horst, the Netherlands). Pregnant dams were shipped on gestational day (GD) 14 
and injected with PolyI:C at GD17. Offspring (for the complete list see table 1) were housed in 
an optimized in-house hygiene area (Institute of Pharmacology and Toxicology, University of 
Zurich, Switzerland) under a 12 hour light/dark cycle, with access to food and water ad libitum 
until 3, 5, 6 or 16 months of age. 
At the age of 12 months, immediately after DSP-4 injections, mice were ear-marked using a 
sterile ear-marking tool. 
Polyriboinosinic-Polyribocytidilic Acid (PolyI:C) Injections 
Pregnant mouse dams of the C57Bl/6JOla strain were given a single intravenous injection (i.v.) 
of 5 mg/kg PolyI:C potassium salt (P9582, 50 mg; Sigma-Aldrich Chemie GmbH, Buchs, 
Switzerland) dissolved in 0.9% sterile, pyrogen-free NaCl. Calculation of dose was based on the 
pure form. The injection volume was 5 mL/kg body weight or an equivalent volume of saline at 
GD17. The animals were mildly restrained during the injection procedure using an acrylic mouse 
restrainer (PlasLabs, Inc. #561-RC). After the injection, dams were immediately returned to their 
home cage and left undisturbed until the first cage change 1 week after delivery. A group of 
offspring (see table 1) was injected with PolyI:C or NaCl at the age of 12 months as described in 
(Krstic et al., 2012a).  
N-(2-chloroethyl)-N-Ethyl-2-Bromobenzylamine (DSP-4) Injections 
Starting at the age of 3 months, mice were i.p. injected with 50 mg/kg DSP-4 dissolved in 0.9% 
sterile, pyrogen-free NaCl or an equivalent volume of NaCl. Due to light sensitivity and 
instability, DSP-4 was freshly dissolved after every other mouse. Mice of the 1st cohort were 
treated only once; for the 2nd cohort (figure 1A) this procedure was repeated 3 times every 3 
months  
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Table 1 Animals used in this study. 
Age  
(months) 
Prenatal 
treatment (i.v.) 
Postnatal 
treatments (i.p.) 
Postnatal treatment 
(i.v.) 
Group 
abbreviation 
Number of 
mice/group 
3  NaCl DSP-4   - ND 10 
 PolyI:C DSP-4 - PD 10 
5 NaCl - -  8 
 PolyI:C - -  8 
6  NaCl DSP-4 - ND 10 
 PolyI:C DSP-4 - PD 10 
16  NaCl NaCl NaCl NNN 12 
 PolyI:C NaCl NaCl PNN 8 
 PolyI:C NaCl PolyI:C PNP 11 
 PolyI:C DSP-4 NaCl PDN 10 
 PolyI:C DSP-4 PolyI:C PDP 11* 
 NaCl DSP-4 PolyI:C NDP 12 
 
*one mouse with hydrocephalus, was excluded for IHC and PET analyses 
 
Behavioral Testing 
To assess whether NA depletion worsens the cognitive deficits reported previously in aged 
prenatally immune-challenged mice (Krstic et al., 2012a), animals of the 2nd cohort (table 1 and 
figure 1A) were subjected to two different tests using the elevated Y-maze. The first task 
assessed spatial short-term memory performance using the sample/choice paradigm (described 
below). The second task tested non-spatial short-term memory performance (spontaneous 
alternation). 
Apparatus 
The Y-maze apparatus consisted of 3 identical arms (500 mm long × 90 mm wide) surrounded by 
transparent (in sample/choice task) or opaque (covered with white paper for the spontaneous 
alternation test) plexiglas walls 100 mm in height. The 3 arms radiated from a central equilateral 
triangle. The floor of the maze was either covered with sawdust bedding, which was changed 
between each test run (for sample/choice task) or kept uncovered and cleaned with water 
between each test run (spontaneous alternation task). The maze was placed onto a desk which 
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was encircled by black curtains (to separate the maze from the rest of the room, approximately 
1.5 x 1.5 m) to assure optimal conditions such as light intensity and spare the mouse from 
putative distractions other than visual cues placed on the wall and curtains, if needed). A digital 
camera was mounted above the Y-maze apparatus. All experiments were videotaped and 
simultaneously analyzed using EthoVisionPro tracking system (Version 2.2.14, Noldus 
Information Technology,) 
Procedure for Sample/Choice Task 
Before starting the test, the mouse was transferred to an empty cage. Sample phase: one arm of 
the maze was blocked using a plexiglas blocker (between mice and groups the blocked arm was 
alternated to avoid bias). The mouse was placed in the start arm - this was kept constant between 
the two phases but was alternated between mice and groups to avoid bias - and allowed to 
explore the two arms. After 5 min the mouse was taken out of the maze and returned to the 
empty cage. The bedding was changed and the blocker removed. After a delay of approximately 
2 min the mouse was put back into the start arm and allowed to explore the maze for another 5 
min. The percent of time spent in the novel and familiar arms was calculated after 2 min of 
testing. Chance level is defined as 33.3%, indicating that the mouse has no preference towards 
the novel arm and therefore was not able to distinguish between familiar and novel arms. Total 
distance moved was recorded and analyzed to assess general activity during the choice phase.  
Procedure for Spontaneous Alternations 
Before starting the test, the mouse was transferred to an empty cage. The mouse was then placed 
into one arm of the Y-maze (kept constant for all animals). An observer located in the same room 
– separated by the curtains – monitored the mouse through the video camera, and recorded the 
number and sequence of arm entries (defined as entry of the whole body into an arm) during a 
period of 5 min. Alternation was defined as entry into the 3 arms in any non-repeating order (for 
example, ABC, BAC, CBA). The percentage of alternation was calculated as the total number of 
alternations divided by the possible number of alternations given by the number of arm entries 
(total number of arm entries -2). Chance level is defined as 50% alternation. In addition to the 
analysis of percentage alternation, the total number of arm entries was recorded and analyzed to 
assess general activity during the 5-min test period.   
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[18F]-Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) Measurement 
FDG PET Acquisition 
1 week before PET acquisitions, animals were transferred to the animal imaging center at the 
ETH Zurich. Animals were housed under approved conditions and had free access to food and 
water before the experiments. Animals of all 6 groups (NNN n = 8; PNN = 7; PNP = 9; PDN = 
10; PDP = 8; NDP = 9) were weighed immediately prior to PET imaging (27.7 g to 59.7 g). Mice 
were anesthetized with isoflurane (5 % for induction, 2.5 to 3.5% for maintenance during image 
acquisition) in a mixture of air and oxygen (70/30%). After induction, animals were placed in the 
scanner and a tail vein catheter (PE10 tube) was placed for [18F]-FDG injection. Immediately 
before PET acquisitions, a blood sample was collected for the measurement of the glucose level 
(ranging from 4.1 to 9.5 mM).  
[18F]-FDG (5.18 to 15.52 MBq in 112 µL saline) freshly obtained from the University hospital 
Zurich (routinely produced for clinical use) was injected over a period of 3 min with a syringe 
pump (Harvard Apparatus). The mouse was centered in a scanner with a 4.8 mm axial field of 
view (VISTA eXplore [GE Healthcare]). First a computed tomography scout image was acquired 
and bed position was adjusted, if necessary, in such a way that the head and the thoracic region 
were acquired simultaneously. PET coincidence events were acquired in list mode over a 45 min 
scan period. PET acquisitions and tracer injections were started at the same time. During 
imaging, the respiratory rate was monitored (1025L; SA Instruments) and maintained at 90 bpm 
by adjusting isoflurane concentration if required. In addition, mouse body temperature was kept 
at 37°C by a fan controlled by a rectal temperature probe. 
Once a day, the PET scanner was calibrated to kBq/cm3 by means of a 5-mL syringe filled with a 
[18F]-FDG solution of known radioactivity concentration (~1 MBq/mL). With the same settings 
as for the PET mouse scans a static scan of 5 min was acquired. 
Image Analysis 
PET images were reconstructed to a nominal voxel size of 0.3875 x 0.3875 x 0.775 mm (actual 
resolution of 0.9 mm in full width at half maximum in the center of the field of view (FOV) with 
a 3-dimensional FORE/2-dimensional OSEM algorithm). Scatter correction was applied. Data 
were not corrected for attenuation. List mode data were rebinned (30 x 10 sec, 20 x 15 sec, 5 x 
60 sec, 6 x 300 sec). Finally, the last 15 min of acquisition were averaged and taken for further 
analysis. The software package PMOD 3.5 (PMOD Technologies Ltd, Zürich, Switzerland) was 
then used for PET data analysis. For each mouse brain, volumes of interest (VOIs) were drawn 
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for the following regions guided by a mouse magnetic resonance template (Mirrione et al., 
2007), which was co-registered to our PET data: Cerebral cortex, left and right hippocampus, 
thalamus, olfactory bulb (OB) and cerebellum. 
Tracer uptake was expressed in kBq/cm3 using the syringe calibration. Dividing the tissue tracer 
uptake by the injected activity per gram of body weight yielded the standardized uptake value 
(SUV). 
Tissue Preparation for Immunohistochemistry and Biochemistry 
Tissue preparation was performed as previously described (Notter et al., 2014). In brief, mice 
were deeply anesthetized with sodium pentobarbital (Nembutal; 50 mg/kg; i.p.) and perfused 
intracardially with 15–20 mL ice-cold, oxygenated aCSF [containing (mM) NaCl 125, KCl 2.5, 
CaCl2, 3.7, MgCl2 2, NaHCO3 26, NaH2PO4 1.25, glucose 25], pH 7.4, at a flow rate of 10–15 
mL/min. Animals were decapitated, the brain immediately extracted from the skull and divided 
into 3 blocks: cerebellum/brainstem and each of the 2 hemispheres. The right hemisphere and the 
cerebellum/brainstem were immediately immersion-fixed for 3 hours in ice-cold, freshly 
prepared fixative [4% paraformaldehyde dissolved in 0.15 M sodium phosphate buffer 
containing 15% saturated picric acid], pH 7.4, before it was rinsed with PBS (pH = 7.4) and 
cryoprotected overnight in 30% sucrose in PBS at 4°C. 
The fixed tissue was then frozen and cut with a sliding microtome at a thickness of 40 m into 
serial sagittal (hemisphere) or coronal (brainstem/cerebellum) sections collected in ice-cold PBS. 
The sections were stored at -20°C in cryoprotectant solution (50 mM sodium phosphate buffer, 
pH 7.4, containing 15% glucose and 30% ethylene glycol; Sigma-Aldrich) until used for IHC. 
The left hemisphere was used for Western blotting. It was dissected on ice to separate the 
hippocampus, cortex, entorhinal/piriform cortex, and OB. Tissue was immediately frozen with 
dry ice in safe-lock Eppendorf tubes and stored at -80°C until lysis. 
Immunohistochemistry 
All staining were performed in either 1:18 (all analyses of sagittal sections) or 1:2 (stereological 
counting of LC neurons) series.  
After rinsing the sections in Tris-buffer (pH 7.4), they were incubated overnight at 4°C under 
constant agitation in primary antibody solution (0.2% Triton X-100, 2% normal serum and the 
antibody of choice (table 2)).  
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Table 2 List of primary antibodies used in this study. 
Target Distributor Description, Ca. no. Dilution Application 
cAPP Immunogens Rabbit poyclonal, custom made, 
S511_112 
1:100’000 
1:200’000 
IHC (DAB) 
WB 
nAPP Millipore, Billerica, MA, 
USA 
Mouse monoclonal, (A4), N-
terminal, clone 22 C 11, 
MAB348 
1:5000 WB 
CD11b eBioscience Inc. Monoclonal rat, 14-0112 1:2000 IHC (DAB) 
CD68 AbD Serotec Ltd, 
Oxford, UK 
Rat monoclonal, clone FA11, 
MCA1957GA 
1:3000 IHC (DAB) 
COX2 Abcam Rabbit polyclonal, ab15191 1:4000 IHC (DAB) 
GFAP Dako Schweiz AG, Baar, 
Switzerland 
Rabbit polyclonal, Z 334 1:15’000 IHC (DAB) 
Iba1 Wako Rabbit polyclonal, 019-19741 1:3000 IHC (DAB) 
Noradrenaline 
transporter 
(NAT) 
Mab Technologies, Inc. Mouse monoclonal, NET05-2 1:5000 IHC (DI) 
Tau Thermo Fisher Scientific, 
Waltham 
Mouse monoclonal, total Tau, 
clone Tau-5  
1:48’000 WB 
pTauT205 Abcam Rabbit polyclonal, Ab4841 1:20’000 WB 
Tyrosine 
hydroxylase (TH) 
Thermo Fisher Scientific, 
Waltham 
Rabbit polyclonal, AB152 1:3000 
1:5000 
IHC (DAB) 
IHC (DI) 
 
 
Immunoperoxidase staining: Sections were washed 3 x 10 min in Tris buffer and incubated for 
30 min at room temperature in biotinylated secondary antibodies (Jackson ImmunoResearch 
Laboratories Inc., West Grove, PA, USA) diluted 1:300 in Tris buffer containing 2% normal 
serum, followed by 3 washes in Tris-buffer. Sections were then incubated for 30 min in ABC 
solution (Vectastain Elite kit; Vector Laboratories, Burlingham, CA, USA), washed again and 
processed for immunoperoxidase staining using 3,3-diaminobenzidine (DAB; Sigma–Aldrich 
Inc.) as a substrate and hydrogen peroxide following the manufacturer’s instructions. After 3 
thorough washes in PBS, the sections were mounted onto gelatinized glass slides and air-dried 
overnight, dehydrated through ethanol, cleared in xylene and coverslipped with resinous 
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(EukittTM™; Sigma-Aldrich) mounting medium or DPX mountant for histology (06522; Sigma-
life science) for dark-field microscopy. 
Immunofluorescence staining: sections were washed 3 x 10 min in Tris buffer, incubated for 30 
min at room temperature with secondary antibodies coupled to Alexa488 (diluted 1:1000; 
Molecular Probes, Eugene, OR, USA), Cy3 (diluted 1:500; Jackson Immunoresearch). After 
incubation - shielded from light - sections were washed thoroughly, mounted onto gelatinized 
glass slides, coverslipped with Dako fluorescence mounting medium and stored in the dark at 
4°C. 
Nissl Staining 
To determine the number of LC cells, brainstem sections were stained with Cresyl violet. Every 
other coronal section containing cerebellum and brainstem was rinsed in PBS, mounted onto 
gelatinized glass slides and air dried overnight. The slides were dipped successively in the 
following solutions: 5 min in dH2O, 5 min in filtered Cresyl violet solution (C18H15N3O3, M 
321.34, Fluka BioChemika, Cat. no. 10510-54-0), 30 sec in dH2O and cleared in 96% ethanol 
containing 0.5% acetic acid until the desired coloration was obtained, 5 min in isopropanol, 5 
min in isopropanol:Xylene (1:2) and 4 times in xylene for 2 min. They were then coverslipped 
with Eukitt.  
Image Acquisition 
Images were acquired in 4 ways: 
For display, images were acquired with a color digital camera using either bright- or dark-field 
illumination (Zeiss Axioskop, Jena, Germany). Digital images were taken with a 10x (air, 
numerical aperture (NA) 0.75) objective. 
1st cohort, CD68 IHC: sections were scanned with an automated upright slide scanning 
microscope (Zeiss) in the bright-field mode; specific scanning settings were programmed with 
the Mirax Viewer 1.8.3.0 (Zeiss) software. Image acquisition was performed by a digital camera 
(Axiocam monochrome CCD, 1288 x 1040 pixels with a pixel size of 0.23 m, Zeiss) using a 
20x objective (air, NA 0.8). Areas of interest were exported as TIFF files for densitometry 
analysis using either ImageJ or the Mirax Viewer (3D Histech Lid., Germany). 
2nd cohort, TH and CD68 IHC: images were acquired with a black and white digital camera 
using either bright- or dark-field illumination (Zeiss Apotome, ImagerZ1, Jena, Germany). 
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Digital images were acquired with a 10x (air, NA 0.3) objective for TH staining or 20x (air, NA 
0.8) objective for CD68 staining. 
Double fluorescence staining: Sections were visualized by confocal laser scanning microscopy 
(LSM-700; Zeiss, Jena, Germany) using a 40× (oil, NA 1.4) objective and sequential acquisition 
of separate channels. Z-stacks of consecutive optical sections (20-23; 1024 × 1024 pixels, spaced 
0.6 μm in z) were merged and projected using the maximal intensity mode using the image 
analysis software Imaris (Bitplane, Zurich, Switzerland) for display. 
Cropping of images, adjustments of brightness and contrast were performed using Adobe 
Photoshop and were identical for each staining. A sharpening filter was applied to images of TH 
staining. 
Immunohistochemistry Analysis 
TH Staining 
The density of TH immunopositive axons was determined using an intensity threshold algorithm 
(ImageJ software) and calculated as percentage surface in the area of interest. The average 
density per mouse was calculated from 2-3 serial sections spaced 720 μm. 
CD68 Profile Count Analysis 
The density of microglial cells was determined using threshold segmentation and the particle 
count tool of ImageJ. Average profile density per mouse was calculated in 2-3 serial sections 
spaced 720 μm. 
Iba1 Profile Count Analysis 
To confirm the results of the CD68 immunostaining, microglial cells were counted 
stereologically in sections stained for Iba1 (2-3 serial sections spaced 720 μm) using the 
Mercator software (Mercator Pro rev. 7.8.2, Explora Nova, La Rochelle, France). The sections 
were viewed using an Axioplan 2 bright-field microscope (Zeiss, Feldbach, Switzerland) with 
20x (air, NA 0.75) objective. The following counting parameters were used: a counting frame 
100 x 100 μm and a space between frames of 80 μm. The cell number was calculated by optical 
fractionator with the following parameters: section thickness 40 μm and optical fractionator 
sampling fraction (ssf): 1/18. The volume was calculated based on: V = ∑A x tnom x 1/ssf; with V 
representing analyzed volume, A representing analyzed areas, and tnom representing nominal 
section thickness (40 μm). The number of cells was depicted as number of cells/volume 
analyzed. 
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Densitometry Analysis 
Densitometry analyses of immunoperoxidase staining intensity were performed using the MCID 
software of Imaging research Inc.. Images were digitized using a precision illuminator and 
photo-camera. Grey values were calibrated using the Kodak step tablet no. 310ST607. The 
intensity values in the different areas of interest were normalized to the intensity of the whole 
section to correct for variations in background staining – observed, in particular, in ND mice 
with antibodies against inflammatory markers. 
Stereological Analysis of LC Cell Number 
The number of LC cells was determined stereologically in Nissl-stained sections. A 1:2 series of 
serial sections was viewed using an Axioplan 2 bright-field microscope (Zeiss, Feldbach, 
Switzerland) with 40x (oil, NA 1.3) objective. The number of cells were counted and estimated 
with Mercator software (Mercator Pro rev. 7.8.2, Explora Nova, La Rochelle, France).  The 
following counting parameters were used: counting frame 50 x 50 μm and a space between 
frames of 30 μm. Only cells with nucleoli in focus were counted. Cell number was calculated by 
optical fractionator with the following parameters: section thickness 40 μm and ssf: 1/2. 
Western Blotting 
Brain lysis and sample preparation were performed as previously described (Krstic et al., 2012a), 
with the following adaptations: Tissue was sonicated in 300 μL (hippocampus) or 200 μL 
(cortex, EC and OB) ice-cold RIPA buffer and centrifuged at 40,000 g at 4°C for 20 min. Total 
protein concentration in the supernatant was measured with a spectrophotometer (NanoDrop; 
Thermo Fisher Scientific Inc., Rockford, IL, USA). 
Protein separation and immunoblotting were performed as described (Krstic et al., 2012a), using 
samples of  80 (cortex), 60 (hippocampus and EC) and 40 (OB) μg protein (1st cohort) or 40 μg 
protein (2nd cohort) loaded onto 8-12% Bis-Tris Midi Gels (NuPAGE Novex Bis-Tris Midi Gel, 
26 wells). The electrophoresis was performed using the Xcell4 SureLock Midi-Cell system 
(Cat.No. WR0100, Invitrogen). Proteins were separated during 40 (cAPP) or 45 (all other 
markers) min at 200V. Proteins were blotted for 30 min at 20V using the Novex Semi-Dry 
Blotter (Cat.No. SD1000, Invitrogen). 
Proteins were visualized using the primary antibodies listed in table 2. Signals were visualized 
either with a chemiluminescence system with antibodies coupled to horseradish peroxidase 
(classical X-ray film exposure to detect C-terminal cleaved fragments of APP, or for stronger 
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signals the Fujifilm system and ImageReader LAS-1000 software, using Adobe Photoshop to 
visualize bands) or with fluorescence with secondary antibodies coupled to a fluorochrome 
(Odyssey infrared imaging system). 
Signal Quantification 
Each Western blot was performed at least 3 times and the figures show representative blots and 
their corresponding quantifications.  
Chemiluminescence signals were analyzed using ImageJ Launcher software. The intensity of the 
bands of interest (AUC) was determined and normalized to the actin band in the same lane. 
Fluorescence signals were analyzed using the (Odyssey ImageStudio 3.1.4 software).  
In the 2nd cohort, the 64 samples were analyzed in 2 different ways: The 64 samples were evenly 
distributed among 3 midigels (chemiluminescence). This did not allow pooling of data (making 
the number of samples to be compared very small). To be able to pool the data, 4 midigels were 
loaded as follows: for each gel samples from the same 8 NNN controls (serving as internal 
control) were taken and the remaining lanes were filled up with different samples from the 
remaining groups (figure 7 and supplementary figure S4). Each signal was first normalized to the 
corresponding actin signal and then normalized to the mean of the internal controls.  
Statistical Analyses 
Data are presented as mean ± SEM. Values were tested for Gaussian distribution using the 
Kolmogorov-Smirnov test (Prism software, GraphPad version6). Outliers were determined and 
excluded using the Gubb’s test – also called ESD (extreme studentized deviate) – in online 
Quick Calcs provided by GraphPad Software. Statistical analyses in the 1st cohort were made 
using unpaired t test, two-tailed (Prism software, GraphPad version6). Statistical analyses in the 
2nd cohort were made using one-way ANOVA followed where appropriate by Bonferroni - test 
(Prism software, GraphPad version6) or Fisher’s least significant difference (LSD) post-hoc test 
(StatView software). 
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Results 
Effect of DSP-4 on Prenatally PolyI:C-Exposed Mice 
The 2 cohorts of mice and their treatment paradigms used for this study are depicted in figure 1A 
and summarized in table 1. The first cohort consisted of 10 prenatally-exposed PolyI:C (P) mice 
and 10 NaCl (N) controls were subjected to a single postnatal DSP-4 (D) injection at 3 months of 
age and subsequently examined histologically at 6 months (group abbreviations for PolyI:C-
exposed mice are PD and ND for NaCl controls, respectively). The purpose of these experiments 
was to determine whether the regeneration capacity of LC axons in young adult mice is 
influenced by the effects of PolyI:C exposure. In addition, we aimed to evaluate whether 
combined PolyI:C and DSP-4 treatment influences innate immunity and induces changes in AD-
associated proteins levels at this stage. These results will be presented in figures 2 to 4. Post-hoc, 
this cohort was completed by a group of prenatally-exposed PolyI:C mice  that were not treated 
with DSP-4 to evaluate the effect of PolyI:C alone on innate immunity.  
The 2nd cohort consisted of 64 mice that were also exposed prenatally to PolyI:C (or NaCl) and 
received DSP-4 injections every 3 months starting at 3 months of age (NaCl injections served as 
control). At 12 months – 7 days after the last DSP-4 injection – mice were either treated with 
PolyI:C or NaCl  i.v. (as in the “double hit” model (Krstic et al., 2012a)) and aged for additional 
3 months before undergoing behavioral tests. Finally, prior to tissue collection [18F]-FDG PET 
imaging was performed to evaluate cerebral glucose uptake in the different treatment groups. 
This cohort consisted of the following 6 groups (nomenclature: the 1st letter stands for prenatal 
PolyI:C or NaCl treatment; the 2nd for multiple postnatal DSP-4 or NaCl treatments; and the 3rd 
for postnatal PolyI:C or NaCl treatment (figure 1A and table 1)), NNN animals served as basal 
controls. PNN and PNP represented the single and double immune challenged groups. PDN 
allowed validating NA depletion after prenatal PolyI:C exposure and the PDP NA depletion in 
mice pre- and postnatally exposed to PolyI:C, respectively. NDP served as a control towards 
PDP to validate the importance of the prenatal PolyI:C exposure. This group was necessary, 
since we have previously shown that postnatal PolyI:C alone had no effect on AD-like changes 
in aged animals (Krstic et al., 2012a). We were, therefore, interested in seeing whether postnatal 
PolyI:C in a NA depleted background was sufficient to induce changes. Two control groups were 
omitted: NNP, for the reason mentioned above, that postnatal PolyI:C has no effect on AD-like 
changes in aged wild type animals.  
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And the NDN group, because pilot experiments revealed that a single DSP-4 treatment in aged 
mice did not affect AD-related proteins or inflammatory responses (data not shown). In line, 
previous studies observed no AD-like changes after multiple DSP-4 treatments in C57BL/6J 
mice (Heneka et al., 2006). 
Preliminary IHC experiments in tissue from 16 to 20 month-old mice showed that mouse 
monoclonal antibodies could not be used due to high levels of non-specific binding of secondary 
antibodies (against mouse IgG) occurring in tissue of old mice. Therefore, we selected antibodies 
from non-rodent species for all IHC experiments. Nevertheless we verified in young mice that 
TH antibodies can be used to visualize LC axons by double labelling with a polyclonal rabbit 
antibody against tyrosine hydroxylase (TH) and a mouse monoclonal against the NA transporter 
(NAT). As expected, TH and NA immunofluorescence is co-localized in brain areas innervated 
by NA axons, e.g., the primary somatosensory (S1) (figure 1B) and visual (V1) cortex, as well as 
the CA1 area of the hippocampus, and the thalamus (basolateral nucleus) (not shown). The 
striatum, which is mainly innervated by dopaminergic neurons and contains only a few, isolated 
LC axons, was almost completely devoid of NAT immunofluorescence (figure 1B). Some TH-
positive axons, lacking NAT-staining, were seen, as expected, in the frontal cortex.  
 
 
 
 
 
 
Figure 1: Effect of DSP-4 in prenatal PolyI:C-exposed animals. A. Treatment paradigm of the two cohorts used 
for this study. Black bar represents intravenous (i.v.) PolyI:C (5 mg/kg) or NaCl injections (prenatal exposure at 
GD17 and postnatally at 12 months). Green bars represent intraperitoneal (i.p.) DSP-4 (50 mg/kg) injection for the 
1st cohort, or DSP-4 (50 mg/kg) or NaCl injection for the 2nd cohort. Blue bar represents behavioral experiments (Y-
maze spontaneous alternation and sample/choice test). Red bars represent (18F)-FDG PET imaging study. Tissue was 
collected after completion of PET imaging studies at 16 months of age. Abbreviations: gestational day (GD), months 
(mo), days (d). B. Double immunofluorescence staining for tyrosine hydroxylase (TH) (B; red) and NA transporter 
(NAT) (B’; green) in primary somatosensory cortex (S1) and striatum/frontal cortex of 5 month-old control mice, 
imaged by confocal laser scanning microscopy. Images represent stacks of 20-23 pictures spaced 0.6m.  Merged 
images (B”) illustrate the paucity of dopaminergic axons (TH+/NAT-; arrowheads) in cerebral cortex, as well as the 
absence of NA axons (TH+/NA+) in the striatum. Scale bar: 20 m. C. Demonstration of DSP-4 toxicity in 
prenatally PolyI:C immune-challenged mice. Dark-field microscopy images of sections stained by 
immunoperoxidase against TH in the primary visual cortex (V1) and CA1 from naïve or prenatal NaCl (ND) and 
prenatal PolyI:C (PD) mice 7 days after DSP-4 treatment. NA axon depletion is clearly evident by the drastic 
reduction of TH-positive axons, and it did not differ between the 2 treatment groups. Abbreviation: stratum oriens 
(SO), stratum pyramidale (SP), stratum radiatum (SR), stratum lacunosum moleculare (SLM) and molecular layer of 
dentate gyrus (DG (ML)), scale bar: 200 m.  
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To evaluate whether exposure to PolyI:C could have an effect on DSP-4 toxicity, we injected 
adult prenatally-exposed PolyI:C/NaCl mice with DSP-4 and examined them 7 days later, when 
LC axon degeneration was expected to be maximal in rodents (Jonsson et al., 1981, Fritschy et 
al., 1990, Fornai et al., 1996). DSP-4 treatment caused an almost complete loss of TH-positive 
LC axons (figure 1C). Based on visual examination, no difference in axon densities between the 
2 groups was evident in any of the regions examined (frontal cortex, S1, V1, CA1, thalamus, 
striatum), indicating that prenatal immune challenge had no detectable effect on DSP-4 acute 
toxicity. 
Prenatal Immune Challenge: LC Axonal Regeneration Capacity  
An extensive LC axonal regeneration study performed in rats revealed that there is a region-
specific difference in the temporal pattern of axonal regeneration after a single DSP-4 treatment 
(Fritschy and Grzanna, 1992). They observed the fastest reinnervation in thalamus, followed by 
the cerebral cortex (in a rostro-caudal manner) and the hippocampus. Interestingly, hindbrain 
areas such as tectum and cerebellum remained devoid of axons 1 year after DSP-4 treatment. 
This study confirmed the remarkable regeneration capacity of LC axons in the absence of any 
other perturbation in the adult CNS. The mechanisms governing the specific pattern of regrowing 
axons, however, are still unknown. 
To evaluate whether prenatal PolyI:C exposure could have an effect on the regeneration capacity 
of LC axons, we performed IHC staining against TH in sagittal brain sections of 6 month-old 
mice (cohort 1; injection paradigm see figure 1A). Densitometry analysis of TH-positive axons 
was performed in cortical areas (frontal, S1 and V1) and the hippocampus (CA1 - including 
stratum oriens (SO), stratum pyramidale (SP) and stratum radiatum (SR) - and the molecular 
layer of dentate gyrus (DG (ML)). The cortical area furthest away from the LC, V1 and the CA1 
area, displayed a significantly lower axon density in animals that were prenatally challenged with 
PolyI:C compared to NaCl controls (unpaired t test, two-tailed: CA1: t18 = 2.97, p = 0.008; V1: 
t17 = 2.38, p = 0.029; frontal: t18 = 1.63; S1: t18 = 2.05; DG (ML): t17 = 1.64) (figure 2A and B). 
DSP-4 treatment is known to induce subsequent partial neurodegeneration of LC neurons. To test 
whether PolyI:C exposure had an effect on LC cell survival, a stereological counting of LC 
neurons in Nissl-stained coronal brainstem sections was performed. The analysis revealed no 
significant difference in the number of LC neurons between the 2 groups (unpaired t test, two-
tailed: t16 = 0.96). The number of LC neurons was reduced by 17% (ND) and 14% (PD) 
compared to 6 month-old naïve mice (figure 2C). This result indicates that prenatal immune 
   Results Study II: Results 
77 
activation affects axonal regeneration mechanisms in the adult brain without worsening 
neurodegeneration. 
 
Figure 2: Effect of prenatal PolyI:C on the regeneration capacity of NA axons 3 months after DSP-4 
treatment. A. Representative dark-field microscopy image of DAB stained sections against tyrosine hydroxylase 
(TH) from ND (left) and 2 different PD (middle and right) mice. Representative images of immunoperoxidase 
staining against TH in sections from ND (left) and 2 PD (middle and right) mice. Axonal regeneration in the primary 
visual (V1) cortex and CA1 region (including SO, SP, SR, SLM, DG (ML)) is evidenced by the partial recovery of 
TH staining (compared to naïve mice shown in figure 1C); scale bar: 200 m. B. Quantifications of density (area 
fraction) of TH-positive axons in frontal cortex, S1, V1, CA1 region and the molecular layer (ML) of the DG 
(mean ± SEM).  Significant decrease of axon density is detected in V1 and CA1. C. Representative Nissl-stained 
coronal section of the brainstem containing the LC (arrows), scale bar: 200 m. Unbiased quantification of neuron 
density is presented relative to naïve mice (Mean ± SEM). Statistical test: unpaired t test, two-tailed; *p < 0.05. 
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Combined Prenatal PolyI:C and DSP-4: Microglia and Astrocytes 
We have previously shown that prenatal PolyI:C exposure leads to a sustained increase in  pro-
inflammatory cytokine levels (Krstic et al., 2012a). However, evident IHC changes in microglia 
and astrocyte reactivity were only detected in 15 month-old animals that received a 2nd PolyI:C 
treatment at 12 months of age.  
To evaluate whether the temporary loss of LC axons could have had an effect on immune cell 
activation in mice primed with PolyI:C, we performed IHC staining against the following 
immune cell markers: CD68 – a lysosome-associated membrane glycoprotein known to be 
increased in activated microglia cells; Iba1 – a cytoplasmic calcium binding adaptor molecule; 
CD11b – a part of the complement receptor 3 complex; COX2 – known to be increased in 
inflammation; and GFAP – an intermediate filament which is selectively expressed by 
astrocytes. All markers were quantitatively analyzed by profile counting and/or densitometry 
analysis in the same areas as those in which TH-axon densities were measured. The results are 
provided in figure 3 and S1.  
For CD68 staining, profile counting revealed that prenatally PolyI:C-exposed mice (PD) exhibit 
an increase of approximately 13% in the number of microglial cells in CA1 compared to ND 
mice (unpaired t test, two-tailed: CA1: t17 = 3.27, p = 0.005; V1: t18 = 0.47) (figure 3A). This 
result was confirmed by stereological analyses of the CA1 region in sections stained against Iba1 
(unpaired t test, two-tailed: CA1: t17 = 2.74, p = 0.014) (figure 3C). All other areas analyzed 
showed no difference in terms of profile counts (unpaired t test, two-tailed: frontal: t18 = 1.63; 
S1: t18 = 1.23; DG (ML): t16 = 1.75, thalamus: t15 = 0.23) (figure 3B). 
To evaluate to what extent the increase in CD68 positive microglia is dependent on NA 
depletion, we performed the same analysis in sections obtained from a separate group of 5 
month-old mice prenatally subjected to PolyI:C or NaCl (see table 1). Profile count analysis 
revealed a significant increase of approximately 18% in PolyI:C compared to NaCl exposed mice 
(unpaired t test, two-tailed: CA1: t14 = 2.29, p = 0.038) (figure 3D). As in the 1st cohort, numbers 
of microglia cells were unchanged in cortical regions (unpaired t test, two-tailed: S1: t12 = 1.5), 
indicating that DSP-4 treatment does not influence the increase in CD68-positive cells occurring 
after prenatal PolyI:C.  
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Figure 3: Effect of PolyI:C on microglia activation in 1st cohort. A. Representative bright-field microscopy 
images of the CA1 region from both treatment groups, depicting CD68 immunoperoxidase staining; scale bar: 200 
m. Corresponding quantification of CD68-positive profile count analysis in CA1 (mean ± SEM) are depicted on 
the right side, showing increased microglia in PD compared to ND. B. Quantification of CD68-positive profile count 
analyses in the primary somatosensory cortex (S1), primary visual cortex (V1), thalamus (basolateral nucleus) and 
the molecular layer of the dentate gyrus (DG (ML)) (mean ± SEM); revealed no significant difference in any of 
these regions. C. Representative bright-field microscopy images of Iba1 immunoperoxidase staining in the CA1 area 
of both treatment groups; scale bar: 200 m. Corresponding unbiased quantification of Iba1-positive cells in the 
CA1 area are depicted on the right side confirming the increase in the PD group compared to ND (mean ± SEM). D. 
Post-hoc quantification of CD68-positive profile count analysis in CA1 (mean ± SEM) in sections from prenatal 
NaCl or PolyI:C-exposed 5 month-old mice are depicted on the right side, showing increased microglia in PD 
compared to ND. Statistical test: unpaired t test, two-tailed; **p < 0.01, *p < 0.05.  
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Densitometry analyses in sections stained against GFAP (unpaired t test, two-tailed: CA1: t18 = 
3.86, p = 0.001) and CD11b (unpaired t test, two-tailed: CA1: t18 = 2.67, p = 0.016), but not 
against COX2 (unpaired t test, two-tailed: CA1: t18 = 1.70) and CD68 (unpaired t test, two-tailed: 
CA1: t18 = 1.70), further confirmed that CA1 display higher levels of inflammatory markers in 
PD mice compared to ND. In addition to CA1, the same changes were detected in DG (ML) 
(unpaired t test, two-tailed: GFAP: t18 = 3.54, p = 0.002; CD11b: t18 = 2.30, p = 0.034) (figure 
S1). Since CA1 was among the regions with the lowest reinnervation, we checked whether axon 
density correlated with the number of microglia. For both markers, no correlation between 
number of microglia cells and axon densities were detected. Further analyses revealed no 
significant correlation between any of the inflammatory marker analyzed and axon densities 
(relative staining intensities of GFAP and CD11b (CA1) and COX2 (V1) with axon densities). 
Therefore, it is unlikely that microglia proliferate more in PD mice due to decreased levels of 
NA and vice versa. The densitometry analyses in the remaining areas are represented in figure S1 
and statistical analyses summarized in table 3. No significant changes were observed. These 
results suggest that the hippocampal formation is particularly prone to changes in inflammatory 
markers induced by PolyI:C.  
Combined Prenatal PolyI:C and DSP-4: AD-Related Proteins 
We have shown before that mice exposed prenatally to PolyI:C exhibit an age-dependent 
increase in levels of AD-related proteins, such as APP (full length and its cleavage products), as 
well as age-dependent differences in phosphorylation of Tau. Therefore, we hypothesized that 
the inflammatory changes detected in PD mice could accelerate these changes and result in 
earlier or stronger increase of APP levels and Tau phosphorylation. 
We performed Western blot analyses using brain lysates from the contralateral hemisphere of the 
mice used in the IHC experiments. The following brain structures were analyzed: whole 
hippocampus, EC, frontal cortex (motor area) and the OB. All Western blots were performed at 
least 3 times using the chemiluminescence detection method, and the results illustrated were 
replicated at least once. In figure 4, 1 representative Western blot for each antibody used is 
depicted (hippocampus lysates).   
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Figure 4: Western blot analyses of AD-related protein expression in the hippocampus of mice from 1st cohort. 
A representative Western blot for each marker is presented along with the densitometry analysis of the 
corresponding protein bands (line indicates group mean ± SEM). Molecular weights in kDa are indicated. Samples 
were loaded either by alternating between lysates from PD and ND lysates (A-C) or PD lysates were loaded in the 
1st 10 lanes followed by ND (D). 60g of each sample was loaded and the respective loading control (actin band) is 
shown below each blot. A. Full length APP detected with an N-terminal antibody (apparent molecular weight, 100 
kDa). No changes were observed between the 2 groups. B. Tau, detected with a phosphorylation-independent 
antibody (apparent molecular weight between 50-60 kDa).  C. PTau, expected to run at a molecular weight slightly 
larger than Tau. Non-specific bands at 75 and 80 kDa were ignored. Again, no difference was observed between 
groups, even upon normalization of p-Tau over total Tau. D. Full-length APP and C-terminal fragments (CTFs) 
detected with a C-terminal antibody. 2 different exposures are shown for full length APP (apparent molecular 
weight, 100 kDa). CTFs dependent on - or -secretase cleavage are distinguished as indicated with arrows. 
Densitometry revealed no changes between groups.  
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The two to three bands (depending on the running buffer used during electrophoresis) migrating 
at around 100 kDa in APP Western blots against the N- (figure 4A) or C-terminus (figure 4D) 
represent full length APP. The bands could either reflect APP isoforms (Loffler and Huber, 
1992) or are the product of posttranslational modifications such as glycosylation, sulfation and 
phosphorylation (Walter and Haass, 2000). Intensities were measured using the ImageJ analysis 
software and normalized to actin. No differences in full length APP or the C-terminal cleavage 
product levels were detected between lysates of ND and PD mice (unpaired t test, two-tailed: 
nAPPFL: t18 = 0.56; cAPPFL: t18 = 1.87; CTF: t18 = 0.87; CTF: t18 = 0.64).  
Tau has an apparent molecular weight of 50-60 kDa and is slightly shifted upwards upon 
phosphorylation. pTauT205 antibody used here only detects Tau that is phosphorylated at 
threonine 205. Similarly to APP, no changes were detected in total Tau (unpaired t test, two-
tailed: t18 = 0.50) (figure 4B) or pTau (unpaired t test, two-tailed: t18 = 1.81) (figure 4C). 
Normalization of pTau to total Tau levels also revealed no differences between ND and PD mice 
(unpaired t test, two-tailed: t18 = 0.89). Similar results were obtained with Western blots 
performed with the other brain regions (figure S2). 
These findings suggest that the inflammatory changes induced by combined PolyI:C and DSP-4 
treatment were not sufficient to affect expression and/or processing of APP and phosphorylation 
of Tau at this age. 
Combined PolyI:C and Multiple DSP-4: LC Axonal Regeneration Capacity  
As we have shown in the 1st cohort, prenatal PolyI:C exposure affects both LC axonal 
regeneration and the immune response 3 months after DSP-4 treatment. However, this cohort did 
not show AD-like changes as reported to occur in 12 month-old mice prenatally challenged with 
PolyI:C (Krstic et al., 2012a). 
 
 
 
Figure 5: Effect of multiple DSP-4 injections in PolyI:C-exposed mice of 2nd cohort on the regeneration of NA 
axons. A. Overview of the experimental design, listing the 6 treatment groups analyzed. B. Dark-field microscopy 
images from sections stained by immunoperoxidase against tyrosine hydroxylase TH. For each group, one 
representative image of the primary visual cortex (V1) and the CA1 area are shown; scale bar: 200 m. C. 
Quantification of TH-positive axons in 6 selected regions (primary somatosensory (S1), primary visual (V1), CA1, 
molecular layer of the dentate gyrus (DG (ML)) and the thalamus (basolateral nucleus)), reporting the % of surface 
area covered by TH staining in the area of interest (mean ± SEM). In all regions except the thalamus (basolateral 
nucleus), DSP-4 treatment caused a decreased density of TH-positive axons, whereas pre- and/or postnatal PolyI:C 
exposure had no effect. Compared with figure 1, a partial regeneration is evident in all areas, leading to full recovery 
in the thalamus (basolateral nucleus). Statistical test: one-way ANOVA and Bonferroni post-hoc; ***p < 0.001, 
**p < 0.01* p < 0.05.  
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Therefore, we extended our analysis to aged mice and refined the model by applying multiple 
DSP-4 injections (every 3 months) to achieve a long-lasting depletion of LC axons, followed by 
a 2nd PolyI:C exposure at 12 months of age. Tissue was collected 4 months after the 2nd hit of 
PolyI:C (see overview figure 5A). Control mice were treated with vehicle (NaCl) instead of 
DSP-4 or PolyI:C. To assess the effect of multiple DSP-4 treatments on LC axonal density 
within the same regions as analyzed in the 1st cohort, we again performed IHC staining and 
quantifications against TH.  
To our surprise, repeated LC axonal depletion did not prevent axons from regenerating between 
12 and 16 months of age. The frontal cortex, as well as the CA1 region of the hippocampus, 
recovered more than half of the density compared to NaCl controls 4 months after the last DSP-4 
treatment (figure 5B and C). As expected, axon densities decreased in a rostro-caudal manner in 
cortical areas (from approximately 60% recovery (frontal) to 18% in V1), precisely reflecting the 
regeneration pattern seen after a single DSP-4 treatment. Differences between DSP-4 and NaCl 
treatment were less pronounced in DG (ML) although the group effect was highly significant 
(one-way ANOVA, DG (ML): F(5,57) = 5.44; p = 0.0004). No significant group effect was 
detected in the thalamus (one-way ANOVA, thalamus: F(5,51) = 2.45; p = 0.050) in line with the 
fact that this region is reinnervated fastest in rats post-DSP-4 treatment (Fritschy et al., 1992). 
Although a significant DSP-4 effect was detected (one-way ANOVA; frontal: F(5,62) = 26.87, p < 
0.0001; S1: F(5,61) = 75.60, p < 0.0001; V1: F(5,61) = 113.70, p < 0.0001; CA1: F(5,50) = 19.92, p < 
0.0001) the regeneration deficit seen in 6 month-old mice prenatally exposed to PolyI:C was not 
evident in this cohort. All 3 groups of DSP-4-treated mice exhibited the same density of TH 
axons, irrespective of pre- or postnatal PolyI:C exposure (figure 5C). Indicating that prenatal or 
postnatal PolyI:C-induced changes had no long-term effect on fiber regeneration capacity. 
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Combined PolyI:C and Multiple DSP-4: Microglia and Astrocytes  
As we have previously shown, prenatal PolyI:C exposure can lead to a chronic subthreshold 
inflammatory response reflected in sustained increased levels of pro-inflammatory cytokines 
measured in blood and brain tissue lysates. To induce central astro- and microgliosis, however, a 
2nd PolyI:C treatment in aged mice was needed. 
The 2nd cohort was designed to determine whether long-lasting LC axon depletion worsens the 
effects of a 2nd PolyI:C exposure (PDP vs. PNP mice or might even mimic a 2nd PolyI:C 
treatment (PDN) mice). The PNN and PNP groups served as controls to confirm the effects of 
the “double hit” model. Based on the results from the 1st cohort, showing increased number of 
microglial cells and increased GFAP immunoreactivity in CA1 in mice exposed to prenatal 
PolyI:C and DSP-4, we anticipated an aggravation of inflammatory responses in PDN and PDP 
mice. 
 
Figure 6: Effect of multiple DSP-4 injections in PolyI:C-exposed mice of 2nd cohort on microglia activation. A. 
Bright-field microscopy acquisitions from sections stained by immunoperoxidase against CD68. For each group, 1 
representative image taken from the CA1 area is depicted; scale bar: 200 m. B. Quantification of CD68-positive 
profile count analyses in CA1 area (mean ± SEM); no significant difference was observed in any of these regions. C. 
Quantification of CD68-positive profile count analyses in S1 (mean ± SEM) – serving as control area to exclude 
region specific differences; no significant main treatment effect was observed. 
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Unexpectedly, however, we could not detect any changes in the number of CD68-positive 
microglial cells in any of the treatment groups in the CA1 region compared to NNN control mice 
(one-way ANOVA, F(5,62) = 1.05). No change was detected in S1 either, which we analyzed here 
to exclude the possibility of region-specific effects seen in the 1st cohort (one-way ANOVA, 
F(5,59) = 2.38) (figure 6). 
To further evaluate putative changes in inflammatory processes, the following markers were 
investigated: CD68, GFAP and COX2. All staining patterns were of good quality, excluding 
technical issues in this tissue from 16 month-old mice. CD68 staining was mainly restricted to 
microglial cell bodies evenly distributed throughout the cortical areas (figure 6, figure S3). 
Inferring from their size and shape, microglial cells were not activated in any of the treatment 
groups. As for GFAP, no obvious astrogliosis was detected. COX2 staining was, as anticipated, 
selectively restricted to microglial cells and to CA3 and to a lesser extend to CA1pyramidal cells 
and granule cells of DG, in line with the expression pattern seen with in situ hybridization 
studies (Allen brain atlas, http://mouse.brain-map.org/).  
To determine whether the expression pattern of these markers – as seen in the “double hit” model 
(Krstic et al., 2012a) – rather than the number of cells was changed, we performed densitometry 
analyses in the same areas where the TH axon densities were measured. All values were 
normalized to the staining intensity of the whole section. No changes in any of the areas 
analyzed were detected for the 3 markers between the 6 treatment groups (figure S3 A-C). 
Altogether, these results indicate that brain innate immune cells were not altered in our cohort, 
and chronic LC axon depletion had no effect on astrocytes and microglia at the age of 16 months.  
Combined PolyI:C and Multiple DSP-4: AD-Related Proteins 
Despite these negative results on inflammatory markers, we tested the mice of the 2nd cohort for 
changes in AD-related proteins. Since our previous study showed that APP expression levels 
were strongly affected by either prenatal or pre- and postnatal PolyI:C exposures, we performed 
IHC staining, using an antibody raised against the C-terminus of APP. Densitometry analyses of 
CA1 (figure 7A) and all hippocampus subregions – CA1 SO, SP, SR, SLM, CA3 SP and stratum 
lucidum (SL), DG (ML) and granule layer (GL) –revealed no differences in staining intensity or 
laminar expression pattern (data not shown). In line with this result and the fact that brain 
immune cells were not activated in any of the treatment groups, densitometry analysis in all 
regions investigated in cohort 1 revealed no differences among the 6 groups (data not shown). 
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Figure 7: IHC and Western blot analyses of cAPP expression in the hippocampus of mice from 2nd cohort. A. 
Bright-field microscopy images from sections stained by immunoperoxidase against cAPP. For each group, 1 
representative image taken from the CA1 area is depicted; scale bar: 200 m. Densitometry analyses revealed no 
significant main effect between treatment groups. B. A representative Western blot against cAPP is presented, along 
with the densitometry analysis of the corresponding protein bands from all 4 Western blots (line indicates group 
mean ± SEM). Molecular weights in kDa are indicated. Samples were loaded as indicated. 40 g of each sample was 
loaded and the respective loading control (actin band) is shown below the blot. Full length APP is detected (apparent 
molecular weight 100 kDa). Along with IHC results, treatment groups showed no difference. 
 
 
To further support this finding, we performed semi-quantitative Western blot analyses using 
hippocampus lysates from the contralateral hemisphere of the mice used in the IHC experiments. 
Each experiment was performed 3 times, twice using chemiluminescence and once using 
fluorescence signal detection systems. In this assay all experimental groups were normalized to 
NNN precluding statistical analyses given the small sample size. A representative Western blot 
against cAPP using fluorescence detection is shown in figure 7B. The corresponding 
quantification supported the IHC findings showing no evident difference among treatment 
groups in the measured intensity of bands corresponding to full-length APP (figure 7B). This 
result was further replicated using an antibody against the N-terminus of APP (figure S4). No 
differences were further obvious in Western blot analyses with antibodies against Tau or pTau 
(figure S4). Based on these negative results, no other brain region was analyzed biochemically.
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Combined PolyI:C and Multiple DSP-4: Short-Term Memory Performance  
We have previously shown that prenatal PolyI:C exposure leads to age-dependent deficits in 
non-spatial short-term memory in 20 month-old offspring (Krstic et al., 2012a). As central NA 
signaling has been shown to have cognitive effects (Rinaman, 2011), we therefore hypothesized 
that NA depletion would exacerbate cognitive impairments in mice that were subjected to a 
single (prenatal) or combined (prenatal and postnatal) PolyI:C challenge. To assess this, we 
measured short-term spatial recognition memory using a sample-choice Y-maze paradigm. This 
test is based on the natural tendency of rodents to explore novel over familiar spatial 
environments (Dellu et al., 1992). In addition, we tested the animals’ cognitive performance 
using a spontaneous alternation test in the Y-maze, which measures non-spatial short-term 
memory (Lalonde, 2002) and was applied in our previous study (Krstic et al., 2012a). In addition 
to this, both tests have previously been used to identify cognitive impairments in PolyI:C-
exposed offspring (Bitanihirwe et al., 2010, Connor et al., 2012, Richetto et al., 2013). 
In the sample-choice Y-maze test, the critical measure of spatial recognition memory is the 
relative time spent in the novel (previously unexplored) arm during the choice phase of this test 
(figure 8A). As depicted in figure 8A’, NNN control animals failed to display a clear preference 
towards the novel arm versus the previously explored arms, and so did the animals from all other 
treatment groups. Hence, animals from all treatment groups mostly performed at chance levels 
(33% of time spent in the novel arm), and no group differences were detectable in regard to this 
measure of short-term spatial recognition memory (one-way ANOVA: F(5.58) = 0.70). There were 
also no group differences in the total distance moved (one-way ANOVA: F(5,58) = 0.75), 
suggesting that basal locomotor activity were not affected by the different treatments (figure 
8A’’). In the spontaneous alternation test of non-spatial short-term memory, the alternation 
scores ranged from 61.6±2.9% in the NNN group (highest score) to 46.3±5.2% in the PNN group 
(lowest score) (figure 8B’). ANOVA analyses, however, did not reveal a significant main effect 
of treatment (one-way ANOVA: F(5,56) = 1.12) indicating no behavioral deficit among the 
treatment groups both in spatial and non-spatial short-term memory.   
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Figure 8: Behavioral Y-maze test for short-term spatial and non-spatial memory performed in the 2nd cohort. 
A. Scheme of Y-maze sample/choice test designed to study spatial short-term memory performance. The Y-maze is 
transparent and spatial cues are given (indicated by the triangle, square and lines). Sample phase (upper maze): the 
mouse is allowed to explore 2 arms of the maze. Choice phase (lower maze): the mouse is able to explore all 3 arms. 
Spatial memory is evaluated by the time spent in novel arm. Chance level is set at 33% of time spent in the novel 
arm (line in bar plot (A’)). A’. % of time spent in novel arm is presented (mean ± SEM); number in bar represents 
sample size. No significant main effect was detected among treatment groups. A’’. Represents mean total distance 
moved ± SEM; No significant difference in movement was detected among treatment groups. B. Scheme of the Y-
maze spontaneous alternation test designed to study non-spatial short-term memory performance. The Y-maze is 
opaque and mice are allowed to freely explore all 3 arms. B’. % of alternation between arms of all treatment groups 
is depicted as mean ± SEM; Chance level is 50% alternation and indicated by dotted line. Comparison between 
treatment groups revealed no significant difference in main effect. B’’. Represents mean arm entries ± SEM; no 
difference in number of arm entries – as a measure of movement – was detected. 
 
 
Combined PolyI:C and Multiple DSP-4: Glucose Metabolism  
Functional changes in the brain such as glucose metabolism can be used as diagnostic tool for 
AD. [18F]-FDG PET imaging was shown to be able to distinguish healthy aged individuals from 
AD cases with high accuracy (Herholz et al., 2002). In addition to human applications, a 
previous study performed in a transgenic animal model for AD showed that NA depletion 
resulted in small reductions of cortical glucose uptake measured by micro-PET (Heneka et al., 
2006).  
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Figure 9: [18F]-FDG PET imaging study measuring glucose uptake in the 2nd cohort. A. Averaged standardized 
uptake values (SUV) per treatment group are presented in false color images. Values within brackets in the 
inscription represent the number of animals analyzed per group. Corresponding SUVs to false color coding is 
represented on the right side of the pictures. B. High resolution computed tomography image with region of interest 
(ROI) analyzed. ROIs analyzed: green = cortex; pink = right hippocampus, orange = left hippocampus; red = 
thalamus; yellow = cerebellum; red = OB. C. Mean SUVs from total brain, including all ROIs (± SEM). No 
difference among treatment groups was detected. D. Mean cortical uptake values relative to the cerebellum 
(± SEM). No significant difference was detected.  
 
 
Intrigued by these findings, we subjected the 16 month-old mice of the 2nd cohort to [18F]-FDG 
PET imaging to investigate whether NA depletion in the double immune challenged mice has a 
similar effect on regional glucose metabolism. Averaged SUVs for each treatment group were 
calculated (figure 9A). Regions of interest (ROI) were defined with the help of co-registered 
images of the mouse head taken by high resolution computer tomography (figure 9B). Semi-
quantitative analysis revealed no significant main treatment effect in SUV in any ROI analyzed. 
The SUVs of total brain [18F]-FDG uptake of the 6 examined groups are represented in figure 9C 
(one-way ANOVA F(5,50) = 0.58) whereas figure 9D represents the [18F]-FDG uptake normalized 
to the cerebellum (one-way ANOVA F(5,49) = 1.55), indicating that DSP-4 depletion independent 
on immune challenges had no effect on Glucose uptake into the brain. 
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Prenatal PolyI:C Effects 
To evaluate whether the lack of immune activation-induced phenotype and thereby differences 
between treatment groups was due to inefficacy of PolyI:C treatment we performed a priori 
comparison between NNN and PNN. We chose PNN since prenatal PolyI:C-exposed (GD17) 
offspring have been previously shown by us and others to develop a robust phenotype in regard 
to memory performance (Bitanihirwe et al., 2010, Connor et al., 2012, Krstic et al., 2012a, 
Richetto et al., 2013).  
As expected, TH fiber densities did not differ between NNN and PNN indicating that prenatal 
PolyI:C exposure has no long-term effect on basal NA axon densities. A priori comparison of the 
number of CD68-positive cells did not reveal significant increases in both CA1 and S1 in PNN 
compared to NNN nor did the intensity of the three inflammatory markers CD68, GFAP and 
COX2 increase. Significant increased intensity in COX2 was however detected in V1 (unpaired t 
test two-tailed: t18 = 2.998; p = 0.008). In contrast significant decreased CD68 staining intensities 
in PNN compared to NNN were detected in CA1 (unpaired t test two-tailed: t18 = 2.478; p = 
0.023), DG (ML) (unpaired t test two-tailed: t18 = 2.535; p = 0.021), striatum (unpaired t test 
two-tailed: t18 = 2.198; p = 0.041) and thalamus (unpaired t test two-tailed: t18 = 2.108; p = 
0.049). In line with the lack of increased inflammation in the hippocampus, densitometry 
analysis of cAPP levels measured in CA1 revealed no difference. Further glucose uptake 
measured with [18F]-FDG-PET imaging analysis revealed no significant difference between 
NNN and PNN.  
In line with previous findings (Connor et al., 2012, Krstic et al., 2012a), however, a priori 
comparison revealed that PNN animals displayed a significantly lower alternation score 
compared with NNN animals in the Y-maze spontaneous alternation task (unpaired t test, two-
tailed: t16 = 2.69; p = 0.016). By comparing the alternation scores of NNN animals to the 
inherent chance level score of 50%, we further found that the NNN group significantly 
performed above chance level (one-sample unpaired t test, two-tailed: t9 = 3.99; p = 0.003). The 
a priori comparisons between NNN and PNN animals, therefore, suggest that we could at least 
partially replicate previous findings of deficient spontaneous alternation in aged offspring 
exposed to prenatal PolyI:C treatment. 
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Discussion 
The present study shows that prenatal PolyI:C exposure induces persisting changes in the brain 
and/or immune system, which affect the regeneration capacity of NA axons, at least  in young 
adult mice. Further, we show that this prenatal immune challenge leads to an increased density of 
microglia within the CA1 area of the hippocampus, which is not influenced by NA depletion. 
Unexpectedly, subjecting mice of the second cohort to a prenatal and postnatal immune 
challenge and DSP-4 or NaCl treatments did not evoke the same response as previously detected 
in the “double hit” model of sporadic AD. Thus, the repeated PolyI:C exposure did not evoke 
neuroinflammation and subsequent changes in AD-related proteins in the aged cohort analyzed 
here, in contrast to what was reported in (Krstic et al., 2012a). Also, chronic NA depletion in 
mice exposed to PolyI:C either prenatally, or twice, did not enhance expression or processing of 
AD-related proteins, nor influence glucose uptake and metabolism at the age of 16 months. 
However, a well-characterized effect of prenatal PolyI:C on neurodevelopmental processes was 
reproduced, as evidenced by the mild deficit in non-spatial short-term memory observed in PNN 
compared to NNN mice. Among possible reasons, it is conceivable that the effects of prenatal 
and postnatal PolyI:C exposure differ between mouse strains or the handling stress caused by the 
repeated i.p. injections of DSP-4 or NaCl. Therefore, the lack of the AD-like phenotype in mice 
from cohort 2 precludes conclusions about the putative role of NA signaling in the pathological 
mechanism underlying sporadic AD. Nevertheless, our results show that an acute or chronic NA 
depletion of LC axons using DSP-4 has little, if any, effect on brain immune cells, whereas 
activation of peripheral immunity by prenatal PolyI:C reduces the regeneration capacity (or 
possibly TH expression) of LC axons in young adult mice. 
Prenatal PolyI:C Affects the Regeneration Capacity of NA Axons 
The TH-positive axon density measurements revealed a significant decrease in V1 and CA1 in 
PD compared to ND mice of the 1st cohort. Previous studies have shown that substantial 
regrowth and sprouting of NA axons into target areas occurs within weeks after depletion, 
independently of the toxin used (Bjorklund et al., 1975, Bjorklund and Lindvall, 1979, Fritschy 
and Grzanna, 1992). The pattern and speed of reinnervation varies between areas, from rapid and 
extensive reinnervation (thalamus, cortical areas and hippocampus) to very little recovery even 1 
year post injection (tectum and cerebellum) (Fritschy and Grzanna, 1992). Our findings show 
that mechanisms involved in axonal growth, as well as axonal guidance, are unaffected by 
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PolyI:C exposure. Decreased LC axon density in V1 – being the area measured furthest away 
from LC  points to an involvement of prenatal PolyI:C in the rate of regeneration. This 
conclusion is supported by deficits detected in the CA1 area  known to show fast reinnervation 
post-DSP-4 treatment (Fritschy and Grzanna, 1992) – as the path from the LC to the 
hippocampus is even longer than to V1. 
Studies conducted to investigate time-dependent LC neurodegeneration showed that rats 
displayed a 19% decrease of cells 2 weeks post injection of DSP-4 (50 mg/kg). This 
degeneration further increased to 36% after 6 months and finally resulted in a 57% loss of cells 
after 1 year (Fritschy and Grzanna, 1992). In the current study, we detected a depletion of 
approximately 15% after 3 months, which is less than expected but possibly due to the high 
variability in the number of cells loss upon a single DSP-4 injection (Fritschy and Grzanna, 
1991). No difference in terms of LC cell numbers were detected between ND and PD, indicating 
that prenatal PolyI:C exposure does not sensitize LC neurons to the effects of DSP-4. This was 
confirmed by previous studies showing that neurodegeneration is unaffected by toxic insults such 
as overexpression of AD mutations (Heneka et al., 2006, Jardanhazi-Kurutz et al., 2010). In the 
study from 2006, however, they reported a 50-60% decrease in LC cell numbers 6 months post 
treatment in both transgenic and wild type controls. Possible reasons for this discrepancy in 
neurodegeneration between our cohort and their mice are likely due to time of investigation post-
injection, injection paradigm, and mouse strain (C57Bl/6J).  
NA Depletion Does Not Increase Brain Immune Responses in Mice Prenatally Exposed to 
PolyI:C 
Previous studies have shown that NA depletion exacerbates immune responses towards toxic 
insults (Heneka et al., 2002). In line with this observation, our results at first suggested that the 
combined treatment of PolyI:C and DSP-4 can have an effect on immune responses. Microglial 
cell counts revealed an increase of approximately 13% in the CA1 area of the hippocampus of 
PD compared to ND mice. Further, we detected increases in staining intensity of CD11b (part of 
the complement system labeling microglia and dendritic cells) and GFAP (intermediate filament 
highly expressed by astrocytes) in areas of the hippocampus in PD compared to ND mice (figure 
S1). Post-hoc verification using a 2nd series of 5 month-old prenatal PolyI:C or NaCl challenged 
mice without NA depletion, however, revealed an increase of about 18% in CD68-positive 
microglial cell density in the CA1 area (figure 3D). This finding is in line with our previous 
observations that prenatal PolyI:C exposure affecting the brain’s innate immune system (Krstic 
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et al., 2012a). Hence, we can conclude that the prenatal PolyI:C-induced effects on innate 
immune responses are not exacerbated by NA depletion. 
As the CA1 area belongs to the 2 areas with impaired regeneration of NA axons (figure 2), we 
tested whether there is a relationship between the changes in immune cells and the regeneration 
capacity. The lack of correlation between the number of microglia cells and axon densities 
indicates that regeneration deficits – observed in the 1st cohort – are independent of the density of 
CD68-positive microglia. This conclusion is also supported by the fact that V1, albeit showing 
decreased LC axon density, had equal numbers of microglia in PD and ND mice. In addition, we 
found no correlation between LC axon density and relative intensities of GFAP and CD11b 
(CA1 area) and COX2 (V1) immunoreactivity. Therefore, we conclude that NA axon depletion 
does not impinge on the inflammatory changes induced by PolyI:C. 
NA Depletion After Prenatal PolyI:C Exposure Does Not Evoke AD-Related Changes in 
Young Adult Mice 
There is increasing evidence for inflammatory processes to be a major, early driving force in 
sporadic AD (for review see (Krstic and Knuesel, 2013)). Chronic inflammation increases APP 
levels (Goldgaber et al., 1989, Rogers et al., 1999, Ciallella et al., 2002, Itoh et al., 2009, Song et 
al., 2013) and causes hyperphosphorylation of Tau (Li et al., 2003, Bhaskar et al., 2010). In line 
with the lack of evident neuroinflammation – including microglia activation and astrogliosis  no 
difference in any of the AD-associated markers tested was detected in mice of the 1st cohort. Per 
se, this finding was not surprising, as we have shown previously that ageing is a crucial factor in 
the development of AD-related changes. However, it was conceivable that NA depletion 
following prenatal PolyI:C exposure would accelerate the appearance in AD-like changes, as 
they have been reported in models of familial AD. These studies, however, applied DSP-4 to 
transgenic mouse models for familial AD, which overexpress one to several human mutations in 
APP and presenilins, resulting in Aplaque formation, micro- and astrogliosis, increase in 
oxidative stress and inflammatory cytokines (Irizarry et al., 1997, Frautschy et al., 1998, 
Pappolla et al., 1998, Smith et al., 1998, Benzing et al., 1999, Dodart and May, 2005). Recent 
studies have further shown that overexpression of APP alone – even without mutation – has 
major effects on phosphorylation of Tau, neurochemical composition of proteins involved in 
synaptic signaling, cell survival, and behavioral performance (Neve and Robakis, 1998, Simon et 
al., 2009). Transgenic overexpression of mutated APP thereby alters basic neuronal mechanisms 
making them more vulnerable to manipulations with DSP-4. Furthermore, NA depletion was 
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shown to impair microglia phagocytic function in transgenic animals resulting in decreased 
clearance of Aexplaining increased plaque formation seen in all NA depletion studies (Heneka 
et al., 2010). In line with this, NA depletion resulted in increased inflammatory response upon 
intracranial Ainjections resulting in increased inflammation (Heneka et al., 2002). Thereby, it 
is conceivable that DSP-4 treatment in transgenic animals shows this remarkable potentiation of 
phenotype due to basic impaired conditions in contrast to the subtle changes induced by prenatal 
PolyI:C exposure detected here. 
The Regeneration Capacity of LC Axons Is Retained Upon Multiple DSP-4 Treatments 
The expected degeneration and regeneration pattern of NA axons was still evident after multiple 
DSP-4 treatments (figure 5). Intriguingly, the pattern and density of TH-positive axons seen at 16 
months in mice from cohort 2 were comparable to those seen in a pilot experiment, in which 
aged mice (19 months) were analyzed 3 months after a single DSP-4 injection (data not shown). 
The toxic action of DSP-4 is dependent on uptake via the NA transporter (Ross, 1976). The exact 
mechanism of action however is still unknown (Jaim-Etcheverry and Zieher, 1980, Fritschy and 
Grzanna, 1989, Grzanna et al., 1989, Lyons et al., 1989). It is conceivable that multiple 
injections induce less degeneration if NAT expression were reduced during the maturation of 
regenerating axons, but there is no experimental data supporting this idea. Rather, a recent study 
using monthly DSP-4 injections applied throughout ageing detected no difference in regenerating 
axons in the cortex 1 ½ months after the last DSP-4 injection, independently of how many times 
it was applied  (Jardanhazi-Kurutz et al., 2010). Therefore, our findings confirm the robust 
capacity of NA axons to regrow even after repeated insults. 
However, the prenatal PolyI:C effect on NA axonal regeneration – detected in the 1st cohort – 
was lost upon multiple DSP-4 treatments. When designing the study, we selected not to include 
the NDN group, because we had seen in a pilot experiment that postnatal PolyI:C treatment in 16 
month-old animals has no effect on regenerating LC axons 3 months post DSP-4 (data not 
shown). Since the effect seen in the “double hit” model were not reproduced in 2nd cohort, we 
cannot determine whether multiple central NA depletions would overcome the prenatal PolyI:C 
effects. This would be conceivable, though, since a recent study reported that central NA 
depletion results in decreased cytokine levels in the spleen, indicating that central NA signaling 
indeed affects the peripheral immune system (Engler et al., 2010). However, because we saw no 
correlation in 1st cohort between regeneration impairment and activation of microglia, we 
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consider it unlikely that suppression of peripheral immune system through multiple DSP-4 
treatments overcame the regeneration deficit induced by PolyI:C in 1st cohort. 
Mild Prenatal PolyI:C Effect on Performance in Spontaneous Alternation Task 
Even though our study did not replicate the previous findings of increased central inflammation 
and subsequent AD-related changes in PolyI:C-exposed offspring (Krstic et al., 2012a), we 
nevertheless observed that the prenatal manipulation alone was sufficient to mildly impair short-
term non-spatial memory. Indeed, our a priori analysis between PNN and NNN offspring 
revealed that the former displayed a mild but significant decrease in spontaneous alternation 
relative to the latter group. This result, however, needs to be interpreted with caution because of 
the rather week – albeit significantly above chance level – performance in the NNN group. 
Consistent with this finding, numerous previous studies have reported that prenatal PolyI:C 
exposure can lead to long-term behavioral and cognitive impairments even in the absence of 
persistent changes in systemic or hippocampal inflammation (Willi et al., 2013, Arsenault et al., 
2014, Mattei et al., 2014). This dissociation suggests that at least some of the behavioral and 
cognitive disturbances induced by prenatal immune activation are likely to be caused by 
neurodevelopmental changes rather than by persistent effects on inflammatory processes. The 
neuronal substrates of prenatal infection-induced deficits in behavioral and cognitive functions 
likely involve abnormalities in various neurotransmitter systems and/or brain areas (Meyer and 
Feldon, 2009), including the prefrontal GABAergic system (Richetto et al., 2014) and the 
mesocorticolimbic dopamine system (Vuillermot et al., 2010, Vuillermot et al., 2012) as well as 
glutamatergic system (Meyer et al., 2008c). 
In addition to such neurodevelopmental changes, overexpression of wild type APP has 
previously been shown to lead to spatial and non-spatial learning deficits in the Morris water 
maze and the novel object recognition task, respectively (Simon et al., 2009). These findings 
suggest that the presence of increased APP levels can negatively affect cognitive functions. In 
contrast to this, our findings indicate that (mild) cognitive impairments following prenatal 
immune activation can occur in the absence of such AD-related pathology. It thus appears that 
the negative impact of APP on cognitive functions cannot be generalized from one model (or 
pathological condition) to another. 
Even though we did not further compare the cognitive performances between NNN offspring and 
offspring with multiple treatments using a priori comparisons, it appeared that the latter groups 
did not display any signs of impaired spontaneous alternation as we have observed it in the PNN 
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group. At present, we have no satisfactory explanation for this unexpected finding. However, the 
differential performance between animals subjected to prenatal immune activation alone (PNN) 
and animals receiving multiple treatments suggests that the postnatal manipulations exerted, if 
anything, a beneficial effect on non-spatial short-term memory deficits typically seen in animals 
exposed to prenatal immune activation alone. The mechanisms underlying these effects remain 
unclear and need to be further investigated. 
Possible Explanations for the Lack of Phenotype by Prenatal and Postnatal Immune 
Challenges in the 2nd Cohort 
So far there is little evidence that prenatal PolyI:C exposure induces sustained, increased levels 
of pro-inflammatory cytokines or microgliosis later in the brain. Most studies that addressed this 
issue were performed at early stages of development (GD9-12.5) – a stage where the embryonic 
immune system is still immature – and most effects of PolyI:C are therefore mediated through 
the activation of maternal immune system (Meyer et al., 2006b, Garay et al., 2013). Arsenault et 
al., comparing the effects of immune stimulation between the bacterial lipopolysaccharide (LPS) 
with PolyI:C at GD17, reported no sustained elevation of pro-inflammatory cytokines and CD68 
in the brain of offspring at postnatal day 10 (Arsenault et al., 2014). This stands in contrast to the 
study from our lab, which detected increased IL-1/IL-6 levels and microgliosis in the 
hippocampus of 15 months old progeny (Krstic et al., 2012a). However, no information is 
available on the central pro-inflammatory cytokine profile during adulthood (3-12 months).  
Therefore, it is possible that PolyI:C had the expected effect in this experiment, but that the 
deterioration seen by Krstic et al. did not occur due to desensitization caused by the repeated i.p. 
injections of DSP-4/NaCl. 
There are other possible pitfalls that need to be considered to explain the partial or total absence 
of phenotype. These include the strain of mice, their preparation (timed-matings, transport), the 
injection procedure, the effects of repeated stress through handling, litter effects, and the housing 
of the offspring. 
Differences between our previous and present work concern the strain and preparation of mice 
for PolyI:C injections. Here, we opted for ordering time-pregnant C57Bl/6JOla mice from Harlan 
laboratories, shipped on GD14, and injected with PolyI:C on GD17. As far as we are aware, 
housing conditions were similar between both studies. However, a major difference lies in the 
handling of mice repeatedly subjected to NaCl (i.p.) injections. 
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Mouse strain 
The C57Bl/6JOla strain - unlike the C57Bl/6JRcc strain used previously (Krstic et al., 2012a) - 
carries a spontaneous mutation, leading to the suppression of -synuclein expression. -
synuclein is considered to be mainly expressed in the brain, located in presynaptic terminals. The 
exact function of-synuclein is not yet understood, however, it was shown to be involved in 
SNARE complex assembly (Burre et al., 2010). Further, -synuclein is considered one of the 
most important players of Parkinson’s disease (PD) (Stefanis, 2012). However, -synuclein is 
also expressed in peripheral erythrocytes and in mononuclear cells. Interestingly, its expression 
is increased in peripheral blood mononuclear cells of PD patients and associated with increased 
glucocorticoid-induced apoptosis (Kim et al., 2004). This finding indicated for the first time a 
putative role of -synuclein in the peripheral immune system. What exactly this role is, still 
needs to be clarified. Assuming -synuclein does affect the peripheral immune system, we need 
to consider that its absence might have had a major impact on the immune response towards 
PolyI:C.  
Transport prior to PolyI:C injection 
In the previous study (Krstic et al., 2012a), PolyI:C injections were administered to in-house 
time pregnant mice, whereas in the current study, pregnant dams were shipped at GD14 and had 
only 3 days to recover from this stress. It is well established that stress reactions increase 
glucocorticoid levels in rodents. Early studies that measured corticosterone levels in mice that 
have been transported by plane or ship revealed that levels of corticosterone rise and remain 
elevated 48 hours after arrival (Landi et al., 1982). Others have suggested, however, that even 4 
days of acclimatization post-transport are insufficient despite normalization of corticosterone 
levels measured after 1 day upon arrival (Tuli et al., 1995). It is, therefore, plausible that 3 days 
of acclimatization for the pregnant mice of this study was not enough to return stress hormones 
to baseline and thereby putatively dampened the response towards an immune challenge. 
Litter effect 
As mice are multiparous species, a potential litter effect cannot be excluded for both the present 
and the previous study. Pups from the same mother are highly interdependent on many levels, 
including genetics, epigenetics, and environmental influences through the dam. This dependency 
can induce strong and persistent litter effects that could lead to false positive or false negative 
results (Zorrilla, 1997, Meyer et al., 2009). Such litter effects might as well account for the 
discrepancy towards prenatal and postnatal PolyI:C challenge in the previous and current study.  
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Effect of repeated stress induced by handling during i.p. injections 
In our previous study mice were subjected to one single postnatal i.v. injection at the age of 12 
months. The time before and after this single intervention they were left undisturbed in their 
home cages with the only disturbances being cage changes performed by animal caretakers. In 
the present study mice were subjected 4 additional times to single i.p. injections during aging. 
The effect of multiple injections of NaCl during ageing on behavioral performance, stress 
hormone levels and in particular on immune response has never been tested and represents a 
distinct difference between this and the previous study. It therefore remains unknown whether 
these 4 very mild stresses every three months desensitized offspring towards the second PolyI:C 
exposure resulting in the lack of increased inflammation in this study compared to the previous. 
Based on the results from Giovanoli et al, who showed that stress during a critical phase of 
development induced microglia activation in mice prenatally exposed to PolyI:C at GD9 
(Giovanoli et al., 2013), we expected that the stress related to DSP-4 or NaCl treatments might 
also activate microglia. The lack of effect seen after PolyI:C injections could be therefore 
conceived as evidence that repeated mild stress rather desensitizes the immune system, as 
suggested by (Lewitus and Schwartz, 2009). 
CONCLUSION 
While large parts of our results remain inconclusive because of the absence of chronic 
neuroinflammation induced by combined pre- and postnatal PolyI:C exposure, we nevertheless 
uncovered important interactions between the effects of a prenatal immune challenge and the 
regenerative capacity of LC neurons in the adult brain. Further in line with previous reports, we 
show that multiple DSP-4 treatments have no effects on AD-related proteins. Hence, we suggest 
that DSP-4-induced exacerbation of inflammatory responses require a certain level of peripheral 
and central inflammation. 
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Supplementary Results 
 
Table 3 Results from Student’s t test two-tailed for densitometry analyses in first cohort. 
 
*p < 0.05 
 
 
 
 
 
 
 
 
 
 
 
  
Area CD68 COX2 GFAP CD11b 
Frontal t17 = 0.72 t18 = 1.64 t18 = 1.70 t18 = 1.46 
S1 t18 = 2.00 t18 = 0.07 t18 = 0.53 t18 = 0.97 
V1 t17 = 1.28 t18 = 2.93 * t18 = 0.24 t17 = 1.11 
CA1 t17 = 1.21 t18 = 1.70 t18 = 3.86 * t18 = 2.67 * 
DG (ML) t18 = 0.17 t18 = 0.91 t18 = 3.54 * t18 = 2.30 * 
Thalamus t17 = 0.69 t17 = 0.09 t18 = 0.23 t17 = 1.67 
Striatum t18 = 0.35 t17 = 0.94 t18 = 0.35 t18 = 0.20 
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Supplementary Figure 1: Densitometry analyses of various immunoperoxidase staining against inflammatory 
markers in the 1st cohort. Bright-field microscopy images of immunoperoxidase-stained sections against the 4 
markers analyzed are represented. For each marker, 1 representative image taken from the CA1 area is depicted; 
scale bar: 200 m. Corresponding densitometry analyses are presented. A. CD68 staining and corresponding 
analyses in the frontal cortex, primary somatosensory cortex (S1), primary visual cortex (V1), CA1 area, molecular 
layer of the dentate gyrus (DG (ML)), thalamus (basolateral nucleus) and striatum revealed no significant 
differences between treatment groups (mean ± SEM). B. Staining pattern and corresponding densitometry analysis 
revealed significant increase of the inflammatory marker COX2 (mean ± SEM). C. Staining pattern and 
corresponding densitometry analysis revealed significant increase of GFAP in CA1 and DG (ML). Remaining areas 
showed no difference (mean ± SEM). D. Staining pattern and corresponding densitometry analysis revealed 
significant increase of CD11b in CA1 and DG (ML) but no changes in remaining areas analyzed (mean ± SEM). 
Statistical test: unpaired t test, two-tailed; *p < 0.05. Results of statistical analyses are depicted in table 3. 
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Supplementary Figure 2: Western blot analyses of AD-related protein expressions in the cortex, entorhinal 
cortex (EC) and olfactory bulb (OB) of mice from 1st cohort. Densitometry analyses of the corresponding protein 
bands (mean ± SEM) of the 4 AD markers performed within the different brain areas (cortex, EC and OB) are 
presented. No significant group difference was detected in any of the AD-relevant markers tested for.  
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Supplementary Figure 3: Densitometry analyses of various inflammatory markers in the 2nd cohort. Bright-
field microscopy images of immunoperoxidase-stained sections against the 3 markers analyzed are represented. For 
each marker, 1 representative image taken from the hippocampus is shown; scale bar: 400 m. Corresponding 
densitometry analyses are depicted. As in supplementary figure 1, A. CD68 staining and corresponding analyses in 
the frontal cortex, primary somatosensory cortex (S1), primary visual cortex (V1), CA1 area, molecular layer of the 
dentate gyrus (DG (ML)), thalamus (basolateral nucleus) and striatum revealed no significant differences between 
treatment groups. B. Staining pattern of COX2 and corresponding densitometry analyses revealed no significant 
main effect between treatment groups. C. Staining pattern of GFAP and corresponding densitometry analyses 
revealed no significant main effect between treatment groups in all areas analyzed.  
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Supplementary Figure 4: Western blot analyses of AD-relevant proteins in hippocampus lysates from the 2nd 
cohort. Representative Western blots (same as depicted in figure 7) for each marker is presented along with the 
densitometry analysis of the corresponding protein bands (line indicates group mean ± SEM). Relative signal 
intensities to the mean intensity of the NNN group (n = 8) are presented. Molecular weights in kDa are indicated. 
Samples were loaded as indicated above the blot. 40 g of each sample was loaded and the respective loading 
control (actin band) is shown below each blot. Blots were stripped once for pTauT205 and again for Tau. Full length 
APP detected with an N-terminal antibody (apparent molecular weight, 100 kDa). Tau, detected with a 
phosphorylation-independent antibody (apparent molecular weight between 50-60 kDa).  PTau with an antibody 
against pTauT205, expected to run at a molecular weight slightly larger than Tau. Non-specific bands at 75 and 80 
kDa were ignored. No changes were observed between the treatment groups in any of the markers analyzed. 
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Abstract 
In recent years it has become evident that exposure to prenatal inflammation can increase the risk 
to developing neuropsychiatric as well as neurodegenerative diseases in offspring. Our lab has 
recently developed a mouse model for sporadic AD by subjecting wild type animals to prenatal 
and postnatal immune-challenged induced by the viral mimic PolyI:C. In a second study, where 
mice of a different strain (C57Bl6/JOla) were subjected to both immune challenges and to 
repeated i.p. NaCl or DSP-4 injections during adulthood, the expected PolyI:C effect on immune 
activation and AD-like neuropathology could not be observed. C57Bl6/JOla mice lack -
synuclein, a protein expressed on peripheral blood cells. Therefore, this strain difference might 
be responsible for the discrepancy between the two studies. Another confounding factor might be 
the quality of PolyI:C. Here, we tested these two factors by assessing the acute inflammatory 
response to systemic PolyI:C injection in adult mice. First, we tested two batches of PolyI:C in 
female C57Bl6/N mice. Second, we compared C57Bl6/JOla and C57Bl6/N mice. Trunk blood 
was collected at different time points after i.v. PolyI:C or NaCl injection, and serum levels of 
three prototypic pro-inflammatory cytokines IL-1, IL-6 and TNF- were measured by 
multiplex electrochemiluminescent immunoassay. We observed no differences in cytokine levels 
3 hours post-administration of the two PolyI:C batches. Likewise, no genotype difference was 
detected in the cytokine profile post-PolyI:C injections, indicating that acute response towards 
immune stimulus is independent of -synuclein in adult female mice. 
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Introduction 
Inflammation-mediated neurodevelopmental animal models have gained increasing attention in 
preclinical studies of psychiatric and neurodegenerative diseases. These models typically involve 
subjecting pregnant animals to immune-activating agents with the aim to induce fetal 
inflammatory responses and subsequent neurodevelopmental defects in the offspring (Meyer, 
2014). One of the most widely used experimental approach is based on prenatal treatment with 
the viral mimetic PolyI:C, a synthetic analog of double-stranded RNA that induces a cytokine-
associated viral-like acute phase response (Meyer and Feldon, 2012). Since its initial 
establishment and application to preclinical schizophrenia research (Shi et al., 2003, Zuckerman 
et al., 2003, Meyer et al., 2005), the PolyI:C model has made a great impact in the field of 
neurodevelopmental and neuroimmunological bases of complex human brain disorders, such as 
schizophrenia and autism. As a consequence, the model now enjoys wide recognition in the 
international scientific community. More recently, prenatal PolyI:C exposure and other 
developmental immune activation models in rodents have also been applied to experimental 
investigations of brain disorders that are characterized by progressive neurodegeneration, 
including AD and PD (Harvey and Boksa, 2012a, Knuesel et al., 2014). 
We have previously shown that prenatal PolyI:C-induced maternal immune activation during late 
gestation (GD17) in mice persistently increased peripheral (IL-1) and central (IL-1, IL-1and 
IL6) levels of pro-inflammatory cytokines in the offspring (Krstic et al., 2012a). Subjecting these 
offspring to a second immune challenge during adulthood further exacerbated the central 
inflammatory phenotype resulting in increased hippocampal levels of CD68 and GFAP, which 
reflected microglia activation and astrocyte reactivity, respectively (Krstic et al., 2012a). These 
studies were conducted in wild type mice of the C57Bl/6J strain. Based on these findings, we 
concluded that prenatal immune activation during late gestation leads to a priming of both 
peripheral and central immune cells, so that exposure to a second immune challenge in postnatal 
life leads a more vigorous inflammatory response in primed versus non-primed mice. 
We have recently performed a second study using the same protocol (PolyI:C exposure at GD17 
and PolyI:C injection at 12 months of age), and in addition, 4 i.p. injections of DSP-4 or NaCl 
between the age of 3 and 12 months. This study was performed using a different wild type strain 
(C57Bl/6JOla) purchased from Harlan Laboratories (The Netherlands). This strain lacks -
synuclein due to a spontaneous mutation in the Snca gene (Specht and Schoepfer, 2001). 
Contrary to the “double hit” model (Krstic et al., 2012a), we failed to detect changes in central 
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inflammatory markers after pre- and postnatal PolyI:C exposure combined with DSP-4/NaCl. 
The lack of -synuclein, known to be expressed in peripheral immune cells (Kim et al., 2004) 
suggests, that they might develop a blunted response towards PolyI:C, and therefore, lack 
persistent inflammatory changes in the offspring following maternal stimulation. Another 
immediate possibility for the results of the second study may be that different batches of PolyI:C, 
even if provided by the same supplier, could have a differential potency to induce cytokine-
associated immune responses. Such batch effects have indeed been documented in a recent study 
in mice (Harvey and Boksa, 2012a). 
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Results and Discussion 
Here, we examined these two potential confounding factors by evaluating the influence of the 
genetic background and different PolyI:C batches on acute cytokine responses elicited in adult 
mice upon i.v. injection. In a first set of experiments, we used C57Bl6/N female mice (10 weeks 
old; Harlan Laboratories, The Netherlands) to compare the plasma levels of prototypical pro-
inflammatory cytokines (IL-1β, IL-6, and TNF-α) in response to two different batches of 
Poly(I:C) (lot#1 and lot#2; both provided by Sigma-Aldrich, Switzerland). C57Bl6/N female 
mice have been widely used in models of prenatal PolyI:C-induced immune activation (e.g., 
(Richetto et al., 2015)). Lot#1 of PolyI:C was previously used by our own group (Krstic et al., 
2012a) and (Notter et al., second study), whereas lot #2 was used by another research group 
(Richetto et al., 2015). C57Bl6/N female mice (n = 6 per group) were injected i.v. with 5 mg/kg 
of PolyI:C (lot #1 or #2) or vehicle (pyrogen-free 0.9% NaCl) as described before (Krstic et al., 
2012a) and were decapitated 3 hours (hrs) post-injection for trunk blood collection. The 
sampling time was selected based on studies reporting robust increases in plasma cytokine levels 
following PolyI:C treatment in mice (Meyer et al., 2006b, Harvey and Boksa, 2012a). Plasma 
samples were prepared as described (Giovanoli et al., 2013) and stored at -20° C until cytokine 
measurements were performed using an established multiplex electrochemiluminescent 
immunoassay (Mesoscale Discovery [MSD], Rockville, USA) for pro-inflammatory cytokines 
(Bastarache et al., 2014). The assay procedures were closely following the protocols provided by 
the supplier (Mesoscale Discovery [MSD], Rockville, USA). We found that both batches of 
PolyI:C induced a significant elevation plasma cytokines compared to vehicle treatment (figure 
1). Importantly, there were no differences between the two PolyI:C batches, as seen with the 
similar up-regulation of IL-1β (main effect by one-way ANOVA: F2,15 = 13.01), IL-6 (main 
effect by one-way ANOVA: F2,15 = 12.04, p < 0.001), and TNF-α (main effect by one-way 
ANOVA: F2,15 = 17.47, p < 0.001). Subsequent Fisher’s LSD post-hoc test comparisons 
confirmed the significant differences in the levels of the 3 cytokines (IL-1β, IL-6, TNF-α) 
between vehicle and lot #1 or lot #2 (all p’s < 0.001), but not between lot #1 and lot#2 (all p’s > 
0.5). The lack of differences between lot #1 or lot #2 is contrary to the findings reported by 
(Harvey and Boksa, 2012a), who found noticeable differences between individual PolyI:C 
batches in terms of their potency to induce plasma IL-6 responses in mice. Even though our 
results do not generally exclude the possibility of such batch differences, they clearly 
demonstrate the absence of sucheffects in the two batches of PolyI:C used in this study, which 
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included the batch previously used by our own research group (Notter et al., second study) and 
by others (e.g., (Richetto et al., 2015)). 
 
Figure 1: Acute peripheral pro-inflammatory cytokine responses 3 hrs post-PolyI:C injection into C57Bl6/N 
mice, using two different batches. Mean cytokine concentrations (± SEM) after vehicle, PolyI:C #1 and PolyI:C#2 
treatments are represented in bar plots. A significant elevation of prototypical pro-inflammatory cytokines (IL-1, 
IL-6 and TNF-) was detected 3 hrs post-PolyI:C injection. No difference between the two PolyI:C batches was 
evident. Statistical test: one-way ANOVA followed by Fisher’s LSD post-hoc test; ***p < 0.001.  
 
 
In a next series of experiments, we assessed the possible influence of the genetic background on 
the PolyI:C-induced cytokine response. We measured plasma cytokine levels of IL-1β, IL-6, and 
TNF-α following vehicle (NaCl, n = 4 per genotype) treatment at 1 h post-injection to determine 
baseline cytokine levels in handled mice and compared these baseline levels with the cytokine 
levels induced by PolyI:C (n = 6 per genotype) 1 h post injection in female C57Bl6/JOla and 
C57Bl6/N mice (9 weeks old; both strains were supplied by Harlan Laboratories, The 
Netherlands) (figure 2A). In addition, we compared the same cytokine levels at 1, 3, and 6 hrs 
after PolyI:C exposure between the two mouse strains (n = 6 per genotype and time point post-
treatment) (figure 2B).  
PolyI:C (5 mg/kg, i.v) and vehicle (pyrogen-free 0.9% NaCl, i.v.) preparation and injection, as 
well as blood collection and plasma cytokine levels measurements were performed as described 
above. We found that PolyI:C treatment led to a pronounced elevation of IL-6 and TNF-α plasma 
levels, which peaked at 1 h post-treatment and subsided afterwards (figure 2B). Even though to a 
lesser extent, PolyI:C treatment also increased plasma IL-1β levels, and this effect reached 
maximal levels at 3 hrs post-treatment (figure 2B). The initial 2 x 2 (treatment x genotype 
ANOVA at the 1 h condition revealed a highly significant main effect of treatment (IL-1β: F1,16 
= 11.19, p < 0.001; IL-6: F1,16  = 106.18, p < 0.001; TNF-α: F1,16 = 83.86, p < 0.001), but not of 
genotype for all three cytokines ( F’s1,16 ≤ 1.26, p’s ≥ 0.28). Hence, the cytokine profiles were 
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highly comparable between C57Bl6/JOla and C57Bl6/N mice, both under basal conditions and 
following PolyI:C treatment (figure 2A). 
 
Figure 2: Acute peripheral pro-inflammatory cytokine responses in two strains of mice (C57Bl6/JOla vs 
C57Bl6/N) under basal conditions (= 1 h following vehicle or PolyI:C treatment (A)) and after different time-
points (1, 3 or 6 hrs) post-PolyI:C injection (B). Mean cytokine concentrations (± SEM) after NaCl (n = 4 per 
genotype) or PolyI:C treatment (n = 6 per genotype) at different time points post-injection are depicted in bar plots 
(red = C57Bl6/JOla, blue = C57Bl6/N). A. Statistical analysis of the cytokine levels 1 h post-injection revealed a 
significant treatment effect but no genotype difference under basal conditions or after PolyI:C treatment in all three 
cytokines measured. B. A significant main effect of time-point was detected in all three cytokine levels measured 
post-PolyI:C injections. Peak levels of IL-6 and TNF-were identified 1h post injection and 3hrs post injection for 
IL-1. No differences in cytokine response profile were detected between genotypes. Statistical tests: 2x2 ANOVA 
(treatment x genotype) and 2x3 ANOVA (genotype x time points) followed by Fisher’s LSD post-hoc test; ***p < 
0.001. 
 
 
An additional 2 x 3 (genotype x time point) ANOVA was then conducted to evaluate the 
temporal cytokine profile following PolyI:C treatment. For all three cytokines, this analysis 
revealed highly significant main effect of time (IL-1β: F2,30 = 15.92, p < 0.001; IL-6: F2,30  = 
144.43, p < 0.001; TNF-α: F2,30 = 120.49, p < 0.001) (figure 2B). The main effect of genotype 
(for all cytokines F’s1,30 ≤ 2.95, p’s ≥ 0.10) or interaction between genotype and time (for all 
cytokines F’s2,30 ≤ 1.56, p’s ≥ 0.23) failed to reach statistical significance. Subsequent Fisher’s 
LSD post-hoc comparisons confirmed significant differences for IL-1β levels between 1 h and 3 
Results Study III: Results and Discussion 
116 
hrs, and between 3 hrs and 6 hrs (p’s < 0.001), but not between 1 h and 6 hrs (p > 0.83). IL-6 and 
TNF- levels significantly differed between 1h and 3hrs as well as between 1h and 6hrs (all p’s 
< 0.001), however, not between 3hrs and 6hrs (IL-6: p > 0.18; TNF-: p > 0.44). These findings 
suggest that C57Bl6/JOla and C57Bl6/N mice display comparable acute PolyI:C-induced 
cytokine responses, at least for the  prototypical pro-inflammatory cytokines such as IL-1β, IL-6, 
and TNF-α. 
Based on these results, we conclude that the differences between our initial study (Krstic et al., 
2012a) and subsequent investigations (Notter et al., second study) cannot be explained by a 
relative incapacity of C57Bl6/JOla mice to mount prototypical pro-inflammatory cytokine 
responses to PolyI:C treatment. Thus, we consider that the lack of central inflammation-related 
changes in C57Bl6/JOla offspring subjected to a single (prenatal) or combined (prenatal and 
postnatal) PolyI:C exposures is unlikely to be attributable to differences in the genetic 
background. Moreover, since the two batches of PolyI:C induced highly comparable cytokine 
responses, the maternal PolyI:C treatments in our second study have most likely been effective in 
inducing the desired immune reactions. This conclusion is further supported by our findings that 
prenatal PolyI:C exposure per se, i.e., in the absence of any other postnatal immune challenge, 
caused a mild impairment of non-spatial short-term memory in the aged offspring (Notter et al., 
second study) without being associated with signs of central inflammation. The lack of persistent 
inflammatory changes as seen in our second study would in fact be consistent with other studies 
conducted in various mouse strains, including C57Bl6/J (Pacheco-Lopez et al., 2013, Pineda et 
al., 2013, Willi et al., 2013) and Meyer, personal communication) and FVB (Meyer et al., 2008b) 
strains. However, comparisons with previous studies are limited by differences in the pregnancy 
stage at the time of treatment, which might have an impact on the long-term alterations of 
immune system function. Further investigations are required to provide a satisfactory explanation 
as to why persistent inflammatory changes were noticeable after single (prenatal) or combined 
(prenatal and postnatal) PolyI:C exposure in our initial (Krstic et al., 2012a) but not in the 
subsequent (Notter et al., second study) study. Such future investigations should test, for 
example, the role of the housing conditions, stress during transport of pregnant females, as well 
as stress induced by repeated handling and i.p. injections, which all might impact on the 
responsiveness of the immune system.  
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Materials and Methods 
Animals 
All animal experiments were carried out in accordance with Swiss law on animal 
experimentation and approved by the cantonal veterinary office of Zurich. 
10 week-old female mice of the strains C57Bl6/JOla and C57Bl6/N were purchased from Harlan 
Laboratories (Horst, the Netherlands) and were accustomed for 1 week prior to immune 
stimulation.  They were housed  in groups in a temperature- and humidity-controlled (21 ± 1 °C, 
55 ± 5%) holding facility under a reversed light–dark cycle (lights off: 8:00 A.M. to 8:00 P.M.) 
with access to food and water ad libitum.  
PolyI:C Injections 
Mice were subjected to a single i.v. of 5 mg/kg PolyI:C potassium salt (P9582, 50 mg; Sigma-
Aldrich Chemie GmbH, Buchs, Switzerland) dissolved in 0.9% sterile, pyrogen-free NaCl. 
Calculation of dose was based on the pure form. The injection volume was 5 mL/kg body weight 
or an equivalent volume of vehicle. During the injection procedure, mice were mildly restrained 
using an acrylic mouse restrainer (PlasLabs, Inc. #561-RC). After the injection, they were 
immediately returned to their home cage and left undisturbed until decapitated.  
Plasma Cytokine Measurements 
Mice were decapitated and trunk blood was collected in EDTA coated tubes. Plasma was directly 
isolated by 10 min centrifugation at 10’000 rpm at 4°C and stored at -20°C until used. Plasma 
cytokine protein concentrations were determined by multiplex electrochemiluminescent 
immunoassay (Mesoscale Discovery [MSD], Rockville, USA) for pro-inflammatory cytokines 
(Bastarache et al., 2014). The assay procedures were performed according to the manufacturer’s 
protocols (Mesoscale Discovery [MSD], Rockville, USA).  
Statistical Analysis 
Data are presented as mean ± SEM. Values were tested for Gaussian distribution using the 
Kolmogorov-Smirnov test (Prism software, GraphPad version6). Statistical analysis in the first 
experiment, comparing PolyI:C batches to vehicle control, was performed by one-way ANOVA 
followed by Fisher’s LSD post-hoc test. In the second experiment, the putative effects of 
genotype on cytokine levels were explored by 2x2 (treatment [NaCl or PolyI:C] x genotype 
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[C57Bl6/JOla or C57Bl6/N]) ANOVA at 1 h condition and a 2x3 (genotype [C57Bl6/JOla or 
C57Bl6/N] x time point [1 h, 3 hrs, or 6 hrs post-treatment) ANOVA followed by Fisher’s LSD 
post-hoc tests. Statistical significance was set at p < 0.05. All statistical analyses were conducted 
in the statistical software StatView (version 5.0). 
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IV. GENERAL DISCUSSION 
The overall objective of this study was to evaluate three particular systems and their potential 
role as a co-factor in the pathological mechanism underlying sporadic AD. We have chosen to 
focus on Reelin, neuroinflammation, and NA signaling due to their vulnerability towards ageing 
and to the exacerbation of these ageing-associated changes observed at early stages of AD. As 
noted in the introduction, GWAS have identified several polymorphisms positively correlated 
with increased risk to develop AD on genes related to the innate immune system (Harold et al., 
2009, Lambert et al., 2009, Yu et al., 2009), or encoding Reelin (Seripa et al., 2008, Kramer et 
al., 2011), DBH (dopamine -hydroxylase – the crucial enzyme in NA synthesis) (Combarros et 
al., 2010), and 2-adrenergic receptors (Yu et al., 2008) . 
The evaluation of ageing-associated Reelin aggregates in the human hippocampal formation of 
non-demented individuals in the first study revealed the strong association of Reelin 
immunoreactivity with CAm – an ageing-associated structure located in particular brain regions, 
including fiber-rich structures (figure 1, study I). In the human tissue that we analyzed, Reelin 
did not appear as granular deposits, as seen in aged mice, rats, and non-human primates. Despite 
this morphological discrepancy, we suggest CAm to represent, at least in part, neuritic 
accumulations of glucose polymers and intracellular proteins, based on the presence of axonal 
and synaptic proteins (figure 4 and 5, study I). It is not established whether they are formed 
exclusively by neurons or whether they involve other cell types – e.g., astrocytes due to the high 
glucose content. However, the high abundance of axonal proteins that we could detect by IHC 
can be taken as evidence that they might evolve through similar mechanisms as suggested for 
senile plaques (Krstic and Knuesel, 2013). The slight elevation of Reelin-associated CAm 
detected in the subiculum of AD patients compared to non-demented controls (figure 2, study I) 
is in line with a previous study (Singhrao et al., 1993) and indicates that CAm potentially result 
from impaired glucose metabolism and axonal transport deficits, which are both known to be 
exacerbated in AD patients compared to non-demented controls.  
Our second study revealed that prenatal immune activation during late gestation can alter the 
regeneration capacity of NA axons in adult offspring (figure 2, study II). The mechanisms 
underlying this effect need yet to be identified. Prenatal PolyI:C exposure further induced a long-
term effect on the innate immune system, as reflected by the increased microglia located in the 
CA1 region of the hippocampus, as well as concomitant increase in relative levels of GFAP and 
CD11b immunoreactivity, measured by densitometry analyses (figure S1, study II). However, 
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these long-term effects on innate immune system and NA axonal regeneration induced by 
prenatal PolyI:C were independent of each other. For unknown reasons, we were unable to 
induce the chronic, age-related inflammatory state required to investigate the role of impaired 
NA signaling in double immune-challenged mice in the cohort used for the second study (figure 
6 and figure S3, study II). 
Corpora Amylacea - Ageing Associated Disturbances of Basic Cell 
Functioning? 
CAm are present in normal aged CNS tissue of different species, albeit showing a different 
regional distribution and seemingly different composition (Cavanagh, 1999, Sinadinos et al., 
2014). They are detected along the walls of ventricles, the medial surface of the temporal lobe 
over the hippocampal formation, as well as in glial networks of subpial, subependymal and 
perivascular regions and in fiber-rich structures of the hippocampal formation (Chung and 
Horoupian, 1996, Cavanagh, 1999, Notter and Knuesel, 2013, Sinadinos et al., 2014). CAm are 
ill-characterized structures and, due to their apparent inert composition, have been widely 
neglected by neuroscientists. CAm mainly consist of polysaccharides. Purification studies 
revealed that CAm comprise of approximately 4% proteins (Steyaert et al., 1990) and 
approximately 2% phosphate and are devoid of both DNA and RNA despite their acidic nature 
(Sakai et al., 1969). Studies performed to resolve their origin so far remained inconclusive.  
Glycogen production in the CNS was long thought to occur exclusively in astrocytes. A recent 
study, however, has shown that neurons produce very small but detectable amounts of glycogen 
(Saez et al., 2014). In line with this finding, the co-association of axonal and dendritic proteins, 
including Reelin, APP, MAP2, -synuclein, and Tau detected in the first study, points towards a 
neuronal origin of CAm. This is in accordance with previous studies detecting CAm in terminal 
neurites and within axons in cortex (Anzil et al., 1974), striatum (Averback, 1981), ventral 
posterolateral nucleus of the thalamus (Mizutani et al., 1987), as well as the spinal cord 
(Takahashi et al., 1975), primarily in neurons associated to motor function but were never 
associated with neuronal perikarya (Cavanagh, 1999). The presence of Reelin in the core of 
CAm has led us to propose them to evolve through a similar mechanism as amyloid plaques, 
namely through aberrant accumulation of proteins transported along axons and dendrites due to 
ageing-associated deficiency in transport machinery. The detection of stress-related proteins such 
as heat shock proteins and ubiquitin in CAm further supports this possibility (Cisse et al., 1991, 
Cisse et al., 1993). In accordance, neuronal loss in amyotrophic lateral sclerosis patients was 
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correlated with a decrease in CAm number detected in the grey matter of the anterior horn of the 
spinal cord, strongly favoring a neuronal dependent development of CAm (Cavanagh, 1998).  
Intriguingly, a recent study investigating polyglucosan bodies – equivalent to CAm – in aged 
mouse hippocampus detected granular depositions highly resembling the granular Reelin 
deposits accumulating with age (Knuesel et al., 2009). In line with the first study, these deposits 
positively stained for stress-related proteins and -synuclein (Sinadinos et al., 2014). These 
authors further showed that inhibition of glycogen synthesis completely abolished the formation 
of these deposits, including the accumulation of proteins. They, therefore, concluded that the 
formation of these granular deposits is purely dependent on intraneuronal glycogen synthesis 
(Sinadinos et al., 2014). Whether some Reelin deposits detected in our previous studies might 
represent polyglucosan bodies still remains to be determined. Their ageing-associated 
appearance and localization – including the detection of polyglucosan bodies in parvalbumin 
positive interneurons (Sinadinos et al., 2014) – would favor the idea that Reelin deposits could, 
in part, represent polyglucosan bodies similar to CAm found in humans. However, Sindadinos 
did not detect a co-association of polyglucosan bodies with A whereas Reelin granular deposits 
clearly co-localize with Acontaining fragments (Doehner et al., 2010). Additional studies are 
required to determine and characterize ageing-associated murine Reelin deposits. 
Despite the strong evidence for the formation of neuronal CAm, correlation between neuronal 
loss and CAm abundance was shown to be dependent on their location (Cavanagh, 1998). These 
findings suggest the existence of different subtypes of CAm, which could be formed by different 
cell types.  
The high abundance of glucose polymers (96%) and their appearance in glial cells and 
perivascular regions suggests them to evolve within astrocytes. Astrocytes have a key role in 
local storage of glucose in the form of glycogen in order to provide additional glucose to neurons 
at times of high neuronal activity (Obel et al., 2012). Therefore, it is conceivable that ageing-
associated alterations in astrocyte function can cause aberrant glycogen polymerization. 3D 
reconstruction of brain CAm in frontal, temporal, parietal and occipital lobe tissue revealed that 
they form complex interconnected structures rather than single spherical accumulation of glucose 
polymers and proteins. This observation further supports the notion of CAm predominantly 
representing a dysfunction in glucose polymerization and, therefore, aberrant glycogen 
elongations resulting in interconnected elongated inclusions (Pirici et al., 2014). Intriguingly, in 
accordance with the first study presented here, these interconnected CAm were not co-localized 
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with but rather enwrapped by astrocytes, suggesting them to evolve in other cell types (figure 6, 
study I). Others, however, have claimed them to be detected within astrocytic processes 
(Ramsey, 1965, Anzil et al., 1974, Palmucci et al., 1982). To date, it remains unclear whether 
and how aberrant glycogenesis in astrocytes contributes to the formation of CAm.  
The role of CAm in neurological diseases remains obscure. In line with our findings, increased 
levels of CAm have been reported in AD (Singhrao et al., 1993), multiple sclerosis (Singhrao et 
al., 1995), and PD (Mizutani et al., 1987). These increases were subtle and, therefore, likely to 
reflect ageing- and disease-associated impairments rather than actively contributing to disease 
progression or onset. In line with this conclusion, CAm were detected in spinal cord and retina 
tissue from children of the age of 10 and below 10, respectively (Cavanagh, 1999). Although 
present very early, CAm did not correlate with any form of disease, further showing their 
inertness. In contrast, recent in vitro and in vivo studies in mice and Drosophila revealed that 
aberrant intraneuronal glycogen production and accumulation can induce neurodegeneration 
(Vilchez et al., 2007, Duran et al., 2012). This observation suggests that – at least in part – CAm 
might indeed contribute to neuronal loss detected in some neurodegenerative diseases including 
AD. 
Considering the recent findings in mice (Sinadinos et al., 2014), supporting our previous 
proposition on how CAm are formed, we conclude that CAm development in the human 
hippocampal formation results from both ageing-associated aberrant glycogen metabolism as 
well as impaired axonal protein transport in aged neurons (Krstic and Knuesel, 2013). These 
aberrant accumulations of glycogen polymers and proteins in neuronal processes could then 
subsequently lead to neurodegeneration. Increased cellular stress during ageing and/or 
pathological conditions may potentiate their formation, as well as neurodegeneration, as 
indicated by the subtle but significant increase in CAm in the subiculum of AD patients 
compared to non-demented controls in the first study. To what extent CAm formation correlates 
with progression of the disease and how they are linked to severe neurodegeneration detected in 
AD remains to be further examined.  
Albeit additional studies are required to substantiate and clarify the impact and origin of CAm, a 
critical role for both aberrant glucose metabolism and neuronal transport is evident. It is 
therefore conceivable that putative ageing-associated impairment in NA signaling could alter 
astrocytic regulation of glycogenesis and glycogenolysis, favoring the formation of polyglucosan 
inclusions and affecting proper axonal transport. 
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PolyI:C Effect on the Regeneration Capacity of Noradrenergic 
Axons  
Monoaminergic systems – such as the NA system – are known to retain a high level of function 
even after severe lesions (Bjorklund and Lindvall, 1979, Zigmond et al., 1990). There are two 
main mechanisms by which they can assure this compensation; adaptations in neurochemical 
components, (e.g., increased production of neurotransmitter or increased expression of receptors) 
and/or axonal regeneration of monoaminergic neurons both evidenced in AD patients 
(Hoogendijk et al., 1999, Szot et al., 2006, 2007). These compensatory mechanisms to regain NA 
signaling as fast as possible are detectable in lesion studies performed in rodents. 7 days post-
DSP-4 treatment levels of adrenergic receptors (- and ) are increased in the rat brain. One year 
post-single DSP-4 treatment, this compensation returned to baseline levels, except for -
adrenergic receptors (Wolfman et al., 1994). In parallel, independently on whether depletion was 
induced through DSP-4 or other toxins, intense regrowth and sprouting of NA axons into target 
areas starts within weeks post-lesion (Bjorklund et al., 1975, Bjorklund and Lindvall, 1979, 
Fritschy and Grzanna, 1992). The pattern and speed of reinnervation varies between areas, from 
fast and high reinnervation (thalamus, cortical areas and hippocampus) to almost complete 
absence of axons, even one 1 year post-injection (tectum and cerebellum)(Fritschy and Grzanna, 
1992). Despite the substantiated knowledge on the time-dependent induction of these 
compensatory mechanisms in rodents, we lack the identity of the particular factors involved in 
this remarkable and fast reacting system.  
Ever since the studies performed up to the early 90s, little new insights were gained on NA 
regeneration properties in the CNS. Regenerative sprouting is only observed in NA axons of LC 
and no other areas after LC depletion (Fritschy and Grzanna, 1992). This indicates that NA 
neurons require a trigger – here in the form of DSP-4 induced axon degeneration – to induce 
regeneration and sprouting of axons. 
Next to factors inducing extensive sprouting and regrowth of NA axons, the signals that guide 
NA axons to their target areas during regeneration also remain to be further determined. 
Interestingly, LC deletion studies revealed a different regeneration pattern when applied in 
neonates compared to older rats. As such, cerebellum and brainstem are mainly devoid of 
regeneration post-LC depletion in adult rats but - in contrast - are hyperinnervated when LC 
depletion occurred in neonates (Sachs et al., 1974, Kostrzewa and Garey, 1976, Bendeich et al., 
1978, Konkol et al., 1978, Schmidt and Bhatnagar, 1979, Levitt and Moore, 1980, Jonsson and 
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Hallman, 1982, Jonsson et al., 1982). This phenomenon of hyperinnervation of cerebellum and 
brainstem disappear with time and are lost when NA axon lesions are induced in rats of 5-7 days 
of age (Schmidt et al., 1980). Since the basal regeneration capacity of NA axons is not disturbed 
but only the target area of innervation changed, a shift in the expression pattern of certain trophic 
factors in target areas might be responsible for specific patterning of regeneration (Fritschy and 
Grzanna, 1992). Albeit this was proposed more than 20 years ago, to my knowledge, these 
trophic factors have never been identified. Therefore, it remains unknown whether prenatal 
PolyI:C treatment could have a long-term effect on the composition and/or concentration of such 
trophic factors.  
Intriguingly, increased electrical stimulation in the initial phase of peripheral motor axon 
regeneration of the femoral nerve revealed significantly faster and more precise regeneration, 
which is dependent on cell body signaling through BDNF and trkB pathways (Al-Majed et al., 
2000a, Al-Majed et al., 2000b). These authors have therefore suggested that an initial boost of 
regenerating neurons through electrical stimulation can activate trophic factor expression that 
induces long-term effects on regeneration mechanisms. These studies were performed in 
peripheral nerve fibers; thus, it still needs to be confirmed whether a similar stimulation 
mechanism could hold true for central axonal regeneration. If confirmed, one could speculate 
whether PolyI:C-induced changes could alter the velocity of regenerating NA axons by affecting 
levels of neurotrophic factors and activity patterns of LC neurons. In the following paragraphs, I 
will discuss this idea further and address different aspects that could – if tested and confirmed – 
explain how long-term effects induced by prenatal PolyI:C exposure during late gestation could 
alter regeneration velocity. 
Prenatal PolyI:C exposure during late gestation has long-term effects on the GABAergic system 
in the prefrontal cortex (Richetto et al., 2014) and dorsal hippocampus (Richetto et al., 2013). In 
the first, both presynaptic (GAD65/67, VGAT) and postsynaptic (GABAA receptor subunits as 
well as KCC2 levels) GABAergic markers are decreased in adult offspring. Similar changes are 
found in the dorsal hippocampus evident by decreased mRNA levels of GAD65/67 in prenatally 
PolyI:C-exposed adult offspring (Richetto et al., 2013). Furthermore, parvalbumin- and Reelin-
positive interneurons are decreased in prefrontal cortex and hippocampus of adult offspring 
exposed to PolyI:C (Meyer et al., 2006b, Meyer et al., 2008c, Knuesel et al., 2009). In general, 
these observations suggest that PolyI:C has a long-term effect on inhibitory signaling pathways.  
In the adult brain, GABA and glycine are the main inhibitory neurotransmitters. GABAA 
receptors are ionotrophic receptors selectively permeable for Cl- and HCO3-. Their function lies 
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in controlling neuronal activity of excitatory transmission through hyperpolarization (inward 
current of Cl- due to higher extracellular Cl- ([Cl]e) compared to intracellular ([Cl]i) 
concentrations) of the postsynaptic target cells. Immature neurons, however, have higher 
intracellular concentrations of Cl- due to the high expression of NKCC1 (inward Cl- transport, 
high [Cl]i) and low expression of KCC2 (outward Cl- transport, low [Cl]e) co-transporter levels 
(Hubner and Holthoff, 2013). Therefore, GABAAR activation depolarizes the target cells during 
developmental periods. Depolarization is accompanied by an increase of intracellular Ca2+, 
which was proposed to putatively serve as second messenger altering intracellular pathways 
involved in neuronal maturation. Indeed, disrupting high intracellular Cl- levels in newborn 
neurons resulted in decreased proliferation and acute truncated dendritic arborizations, which 
recovered to some extent resulting in newborn mature neurons with subtle but significant 
decreased dendritic complexity without affecting dendritic lengths (Young et al., 2012). 
Therefore, depending on the Cl- transporter composition, GABAR activation can result in de- or 
hyperpolarization of the target cells. 
Intriguingly, peripheral axonal regeneration studies performed in hypoglossal nerves revealed 
that post-nerve suturation, regeneration is associated with alterations in the GABAergic system 
including a transient decreased expression of KCC2 of large regenerating motoneurons (Tatetsu 
et al., 2012).These findings raise the question whether this temporal decreased expression of 
KCC2 in regenerating motor neurons could result in increased intracellular Cl- to an extent that 
GABAergic signaling would lead to depolarization of cells and therefore induce similar signaling 
pathways as seen after electrical stimulation of regenerating nerve fibers (Al-Majed et al., 
2000b). Thus, during initial phases of axonal regenerative processes GABAergic signaling would 
transiently switch to depolarization of target cells and thereby improve depolarization-dependent 
axonal regeneration. 
To support this highly speculative hypothesis, three important factors would need to be tested: i) 
chemical stimulation of hypoglossal motor neurons with GABA agonists in the initial phase of 
regeneration increases the velocity and precision of axonal regeneration into the target area; ii)   
LC neurons undergo a similar transient change in expression pattern as seen in regenerating 
axons of motor neurons of the hypoglossal nerve – indicating that they are responsive to 
GABAergic signaling in the initial phase; and iii) prenatal PolyI:C exposure results in long-term 
reduction of GABAergic signaling in the LC. If these three points would hold true, one could 
speculate that the PolyI:C-induced decrease in the GABAergic system impairs temporal LC 
depolarization – through GABAergic signaling – during the initial phase of regeneration, which 
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would thereby result in the subtle effect on the regeneration capacity of NA axons detected in the 
first cohort of the second study (figure 2, study II).  
Another way of how prenatal PolyI:C could affect regeneration of NA axons is through its 
property in accelerating ageing-associated changes  (Knuesel et al., 2009). Several findings in 
our lab have led to the proposal that prenatal PolyI:C could indirectly affect cytoskeleton 
integrity and thereby axonal transport mechanisms (Doehner et al., 2012a, Krstic and Knuesel, 
2013). Although, we still lack direct evidence that PolyI:C-induced changes alter microtubule 
integrity and axonal transport, it is conceivable that altered axonal transport could play a major 
role in axonal regeneration capacity.  
Although we currently do not understand how prenatal immune activation results in the changes 
observed in NA axonal regeneration, these findings suggest that prenatal PolyI:C injections did 
induce changes, which persisted throughout ageing. 
Genetic Background and -Synuclein – Reason for the Lack of 
PolyI:C-Induced Phenotype? 
To address the reasons for the lack of inflammatory response in the second experiment upon 
single or double immune challenge combined with repeated DSP-4 or NaCl injections, we 
performed the additional third study. We investigated the acute cytokine response towards 
PolyI:C in two substrains of C57Bl/6J mice, distinguished mainly by the presence or absence of 
-synuclein (see study III). In vitro studies have revealed that application of exogenous -
synuclein can induce the expression of TLR3 receptors in primary microglia cultures (Beraud et 
al., 2011). However, the effect of increased mRNA expression on the functional outcome on 
TLR3-mediated responses towards an immune challenge was not determined in this study. Our 
pilot experiment revealed that the acute effect of PolyI:C administration on 3 prototypical 
peripheral pro-inflammatory cytokine levels did not differ between C57Bl6/JOla (lack -
synuclein) and C57Bl6/N (normal -synuclein) mice (figure 2, study III). This observation 
indicates that the inflammatory response via TLR3 receptor signaling is independent on basal -
synuclein expression. Nevertheless, it is conceivable that during disease condition increased 
levels of -synuclein might affect, or perhaps prime, the immune system towards inflammatory 
insults. In line with our finding, however, a recent in vitro study focusing on the -synuclein 
priming effect on microglial cells revealed that subsequent stimulation of microglia with PolyI:C 
post--synuclein priming did not exacerbate their response, in contrast to stimulation of other 
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TLRs with synthetic bacterial lipoprotein Pam3CSK4 (Pam3), and single-stranded 
ssRNA40/LyoVec (ssRNA)(Roodveldt et al., 2013).  
Further, our pilot study revealed that the effects induced by two different batches of PolyI:C (one 
of which was used in the second study) was highly comparable in intensity and time-course for 
the 3 pro-inflammatory cytokines tested (figure 1, study III). This result indicates that the 
PolyI:C batch used in the second study was able to affect the fetuses as expected. Accordingly, 
both cohorts of the second study show some although subtle long-term PolyI:C-induced 
alterations.  
The pattern of acute response towards PolyI:C in this pilot study using young, non-pregnant 
female mice is comparable to that reported in previous studies in other strains and rats, where 
peripheral serum cytokine levels were determined after PolyI:C injections in pregnant dams 
(Meyer et al., 2006a, Meyer et al., 2006b, Connor et al., 2012, Harvey and Boksa, 2012b). 
Although we cannot completely rule out a potential role of -synuclein in the immune response 
during pregnancy, the high similarity between pregnant and non-pregnant mice towards an 
inflammatory insult induced by PolyI:C suggest a putative pregnancy effect to be rather unlikely.  
If acute PolyI:C on pregnant dams is independent of -synuclein expression, as suggested by our 
pilot experiment and other findings (see above), we have to consider other confounds that could 
have masked or prevented the development of the chronic effects. As such, further studies are 
required to evaluate the effect of central -synuclein expression on the development of long-term 
alterations, in particular on the role of -synuclein in the brain’s innate immune system. As 
shown by in vitro studies, -synuclein can affect microglia expression profile of immune 
system-related proteins (Beraud et al., 2011). Ageing-associated increased expression of -
synuclein has further been reported in nigral neurons (Chu and Kordower, 2007, Alladi et al., 
2010). Whether other brain regions show a similar age-dependent change in -synuclein remains 
to be determined. If so, it could be conceivable that -synuclein affects microglia aging (in terms 
of activation state) differently depending if they were primed by prenatal PolyI:C exposure or 
not. 
In addition to internal factors, other external influences should be assessed. These include the 
effect of stress prior to PolyI:C challenge, for example through shipment, as well as putative 
desensitization effects induced by multiple handling, as discussed in the second study.  
In conclusion, I suggest that studies conducted to address long-term effects induced by prenatal 
PolyI:C might require a parallel cohort – exclusively subjected to a single prenatal PolyI:C 
General Discussion 
128 
challenge – that can be used to regularly monitor the expected age-dependent changes in the 
status of the immune system. This approach would allow the identification of potential 
manipulation-induced masking or changing of the expected phenotype.  
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ABBREVIATIONS 
A  amyloid- 
ACh  acetylcholine 
AD  Alzheimer's disease 
AF  area fraction 
AICD  APP intracellular domain 
apoE  apolipoprotein E 
ApoER2 Apolipoprotein receptor 2 
APP  amyloid precursor protein 
AUC  area under the curve 
BBB  blood brain barrier 
BSA  bovine serum albumin 
CA1  cornu ammonis area 1 
CA3  cornu ammonis area 3 
CAm  corpora amylacea 
ChAT  Choline acetyltransferase 
COX2  cyclooxygenase 
CD11b  part of the complement receptor 3 complex 
CD45  lymphocyte common antigen 
CD68  cluster of differentiation 68 
CDK5  cyclin-dependent kinase 5 
CNS  central nervous system 
CSF  cerebrospinal fluid 
CTF  C-terminal fragment 
d  day 
DAB  3,3-diaminobenzidine 
DG  dentate gyrus 
DSP-4  N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine 
EC  entorhinal cortex 
EOAD  early-onset Alzheimer’s disease 
FA  formic acid 
FDG  Fluorodeoxyglucose 
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GABA  γ-aminobutyric acid 
GD  gestational day 
GFAP   glial fibrillary acidic protein 
GL  granule layer (of the dentate gyrus) 
GSK-3 Glycogen synthase kinase 3 
GWAS genome-wide association studies 
h (rs)  hour (s) 
Iba1  ionized calcium-binding adapter molecule 1 
IgG  Immunoglobulin G 
IHC  immunohistochemistry 
IL  interleukin 
IFN  interferon 
IRF  interferon regulatory factor 
i.p.  intraperitoneal 
i.v.  intravenous 
LC  locus coeruleus 
LSD  least significant difference 
DG (ML) molecular layer (of the dentate gyrus) 
LOAD  late-onset Alzheimer’s disease 
MAP2  microtubule-associated protein 2 
MCI  mild cognitive impairment (“pre-stage” of AD) 
MT  microtubule 
N  NaCl 
NA  noradrenaline, noradrenergic 
NAT  NA transporter 
NFT  neurofibrillary tangles 
NR2  N-terminal cleaved Reelin fragment (180kDa) 
NR6  C-terminal cleaved Reelin fragment (310 kDa) 
OB  olfactory bulb 
PBS  phosphate-buffered saline 
P  PolyI:C 
PD  Parkinson’s disease 
PET  positron emission tomography 
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PHF  paired helical filament 
PolyI:C polyriboinosinic-polyribocytidilic acid  
pTau  phosphorylated Tau  
REM  rapid eye movement 
ROI  region of interest 
SEM  standard error of the mean 
SL  stratum lucidum 
SLM  stratum lacunosum moleculare 
SNP  single nucleotide polymorphism 
SO  stratum oriens 
SP  stratum pyramidale 
SR  stratum radiatum 
ssf  optical fractionator sampling fraction 
SUV  standardized uptake value 
S1  primary somatosensory cortex 
TH  tyrosine hydroxylase 
TLR  Toll-like receptor 
TNF  tumor necrosis factor 
VLDLR very low density lipoprotein receptor 
VOI  volume of interest 
V1  primary visual cortex 
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